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Polymers such as proteins and polysaccharides, abundantly exist in nature and are major 
components of plants, animals and micro-organisms.1 Polysaccharides are polymers composed of 
monosaccharide units connected through glycosidic bonds.2, 3 The glycosidic bonds are formed by 
a condensation reaction between the anomeric carbon (C1) of one monosaccharide unit and an 
oxygen atom from a hydroxyl group on another monosaccharide unit. Since hydroxyl groups 
present on C2, C3, C4 and C6 carbons, the generated glycosidic bonds can be 1→2, 1→3, 1→4, or 
1→6 linked providing linear to highly branched chains. Polysaccharides can be categorized into two 
groups: (1) mammalian polysaccharides such as hyaluronan, chondroitin sulfate, and heparin; (2) 
non-mammalian polysaccharides such as alginate, chitin, and dextran (Scheme 1). 
 
Scheme 1. Main structures of repeating units of some polysaccharides widely investigated in biomaterials applications. Top row: 
mammalian polysaccharides; bottom row: nonmammalian polysaccharides. 
Dextran is a neutral and hydrophilic polysaccharide consisting of an α-(1→6) linked D-glucose 
main chain with a relatively low level of α-(1→3) branched linkages.4, 5 The molecular weight of 
dextran chains can vary from 1 to 2 000 kilodaltons (kDa). Although physiochemical properties of 
each dextran polymer depend on its particular structure (e.g. molecular weight and degrees of 
branching), the glycosidic bonds of dextran provide relatively high chain mobility and solubility, 
while the three pendant hydroxyl groups provide handles for its functionalization.6-8 Moreover, 
dextran is biologically inert due to the α-(1→6) glycosidic bonds making it resistant to cleavage by 
most endogenous cellular glycosidases, but it is degradable by dextranase9 which exists in 
mammalian (including human) tissues. Dextran is also non-immunogenic,10-14 making it an 
attractive polymer for the design of novel biomaterials. 
Dextran and dextran derivatives are already successfully commercialized in the biomedical field. 
Examples of dextrans used pharmaceutically include those of molecular weight 70 kDa 
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(Macrodex®) and 40 kDa (Rheomacrodex®) for plasma expansion.15-17 Furthermore fluorescent 
dye-dextran conjugates (Molecular Probes®) are widely applied in numerous biological studies.18 
Dextran can also be crosslinked by epichlorohydrin to form hydrogel beads, which are used for 
separations of molecules based on differences in molecular weight (e.g. Sephadex®).19 Dextran-
based materials are also used in wound healing (e.g. Debrisan®).20 
Due to their hydrophilicity, long shelf-life, relative stability, biocompatibility and biodegradable 
properties, dextrans have been studied as a starting material for drug delivery carriers. Cargo that 
was delivered in these studies included low molecular weight drugs, proteins/enzymes, and imaging 
agents by either direct attachment or through a linker since the 1980s.11, 21-23 Degradation of linkages 
between dextran and the conjugated drug results in the delivery of therapies. Dextran conjugation 
was also used to overcome problems such as limited solubility of the drug, short plasma half-life 
high toxicity and/or undesired interactions with tissues. For example, the solubility of paclitaxel 
increased >2000 fold upon conjugation to aminated dextran (Mw = 70 000). Furthermore, 
modification of the dextran-paclitaxel conjugates with folate increased the uptake 2-3 folds in 
human oral carcinoma KB cells.24 The in vivo biodistribution and circulation time can also be altered 
upon dextran conjugation. For example, prolonged circulation time and decreased uptake in kidney 
were observed for dextran-mouse epidermal growth factor (mEGF) conjugates, wherein mEGF 
was attached to aldehyde group functionalized dextran polymers via the formation of imine bonds 
which was further stabilized by reducing to secondary amide bonds with NaCNBH3.
25, 26 
HYDROGELS 
Hydrogels are a class of soft materials that possess a hydrophilic three-dimensional (3D) network 
hold together via chemical and/or physical bonds (i.e. crosslinks). Upon contact with water, the 
3D-network swells and the (physically) entrapped molecules diffuse out of the network and the 
kinetics of release depend on both the properties of the encapsulated molecule as well as the 
physical characteristics of the hydrogel. The viscoelastic properties are similar to soft tissues and 
combined with the water-rich environment making these hydrogels an attractive biomaterial with 
potential applications in the fields of tissue engineering and regenerative medicine.27, 28 These 
hydrogels can be synthesized from various precursors over a large molecular weight range. In this 
thesis the formation of hydrogels comprised of dextran covalently crosslinked by proteins is 
described. 
In the last two decades, in situ forming hydrogels have been extensively investigated since they can 
be delivered to patients in a minimally invasive fashion.29, 30 In situ forming hydrogels allow 
premixing of drug compounds or cells,31 followed by injection of the formulation with its non-
toxic gelation due to polymer crosslinking in the target tissues in a therapeutically relevant time 
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period. To this end, extensively applied chemoselective ligations for in situ gelation include Michael 
addition,32 azide-alkyne Click reactions,33, 34 Schiff base formation35 and disulfide exchange.36 
Moreover, physical crosslinking methods with suitable gelation kinetics can also be used to form 
in situ hydrogels.37 The physical crosslinks can consist of hydrogen bonds, hydrophobic interactions, 
π-π interactions or host-guest inclusion, to endow the hydrogels with dynamic, reversible and self-
healing properties.38 
Hydrogels have been studied as a biomaterial for the localized and sustained release of therapeutic 
agents in order to decrease the number of drug administrations, to prevent rapid drug degradation 
or to prolong therapeutic drug concentrations.39 Typical drug release mechanisms applied in drug 
delivery systems include diffusion controlled drug release40, degradation controlled drug release,41 
stimuli triggered drug release,42 and affinity-based drug release. The affinity-based drug release 
mechanism uses non-covalent interactions between the therapeutic agents and hydrogel platform, 
such as electrostatic, hydrophilic-hydrophobic, hydrogen bonding, or van der Waals interactions, 
to control the release of the therapeutic.43 These materials can improve drug loading, stability and 
release. Affinity-based carriers include specific host molecules such as cyclodextrin,44-48 serum 
albumin49-52 and heparin53-55, or cavities formed within the solid polymer material by the molecular 
imprinting technique.56, 57 
DEXTRAN GELS 
Since the 1990s, hydrogels composed of dextran have been developed for macroscale therapeutics 
delivery and 3D cell culture.58, 59 Chemically crosslinked dextran hydrogels can be prepared from a 
functionalized dextran precursor. For example, Hennink and co-workers prepared degradable 
dextran hydrogels by free radical polymerization of aqueous solutions of glycidyl methacrylated 
dextran or hydroxyethyl methacrylated dextran for the delivery of proteins.9, 60-62 Liu et al. used UV-
light exposure to initiate the crosslinking between dextran functionalized with both methacrylate 
and lysine groups and methacrylamide modified gelatin in presence of a photoinitiator and cells to 
obtain a 3D smooth muscle cell culture.63 
To improve the biocompatibility of the gelation process and the obtained hydrogels, crosslinked 
dextran hydrogels can be prepared from a pair of polymeric precursors that can react with each 
other under physiological condition. Hiemstra et al. synthesized thiol modified dextrans and vinyl-
sulfone modified dextrans to induce hydrogel formation via a Michael type addition reaction.64 Wei 
et al. synthesized fulvene modified dextran and dichloromaleic-acid modified poly(ethylene glycol) 
to develop self-healing dextran hydrogel via reversible Diels–Alder reaction.65 Supramolecular 
dextran hydrogels have also be developed via specific non-covalent interactions. For example, Huh 
et al. established a thermo-reversible hydrogel system with poly(ethylene glycol) grafted dextrans 
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and α-cyclodextrins which was crosslinked by the inclusion complex formation between 
poly(ethylene glycol) and α-cyclodextrins.66 De Jong et al. established another thermo-reversible 
hydrogel system with L-oligo(lactic acid) grafted dextran and D-oligo(lactic acid) grafted dextran 
which was crosslinked by the stereocomplex formation between enantiomers.67  
Besides macroscopic dextran hydrogels, various emulsification approaches were applied to obtain 
chemically crosslinked dextran microgels (also called as microspheres or microcapsules) and 
nanogels. Using a cyclohexane inverse miniemulsion, crosslinked nanogels with an averaged 
diameter below 100 nm were prepared starting from alkyne-dextran and azide-dextran.68 To avoid 
the use of organic solvents, “water-in-water” emulsions were used to synthesize microgels. 
Aqueous mixtures of dextran and polymers such as polyethylene glycol (PEG) or poly(vinyl alcohol) 
(PVA) can form an aqueous two-phase system at elevated concentrations, which can be emulsified 
to obtain a water-in-water emulsion. De Geest et al. emulsified an aqueous solution containing 
dextran azide and dextran alkyne in an external aqueous PEG phase. CuSO4 and sodium ascorbate 
were added afterward to obtain dextran microgels via Huisgen click reaction.69 Similarly, Ghugare 
et al. prepared dextran microgels with an averaged diameter around 1000 nm using ultrasound 
assisted “water-in-water” emulsification. The emulsion contained dextran methacrylate, 
photoinitiator and PVA was crosslinked under UV-light afterwards.70  
Additionally, charged dextrans, such as dextran sulfate, dextran phosphate and dextran amine, have 
been used to prepare polyelectrolyte complex. For example, positively or negatively charged 
colloids were obtained from non-stoichiometric polyelectrolyte complexes of dextran sulfate and 
chitosan.71 Dextran sulfate and protamine were constructed to microcapsules for enzyme delivery 
by a layer-by-layer approach using a removable melamine formaldehyde template.72 Complexes 
formed by cationized dextran amine and plasmid DNA enhanced gene expression in vitro, showing 
its potentials for gene delivery.73 
GENERAL OUTLINE OF THE THESIS 
In the present thesis, several dextran-based hydrogel systems are synthesized and characterized for 
biomedical applications. To prepare dextran polymers for crosslinking, the backbone is initially 
functionalized with maleimides or vinyl sulfones, which are able to form covalent bonds with 
nucleophilic thiols via a thiol-Michael addition reaction. These reactive groups (i.e. maleimides or 
vinyl sulfones) were coupled to the hydroxyl groups of dextran via an ester or an ether linkage. The 
stability of linkages strongly affected the properties and applications of the prepared hydrogel 
systems as described in the following chapters. 
Human serum albumin (HSA), the most abundant protein in human plasma, strongly binds various 
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types of (hydrophobic) low molecular weight molecules. Inspired by this natural carrier, a 
covalently crosslinked dextran-albumin hydrogel system was developed in Chapter 2 to explore 
the potential of HSA as a hydrophobic-drug cavity and crosslinker for affinity-based drug delivery. 
Native HSA was modified with 2-iminothiolane (2-IT) to introduce thiol groups at the lysine 
residues. Circular dichroism spectroscopy revealed that the conformation of thiolated HSA (sHSA) 
is mostly maintained showing that sHSA was capable of simultaneously being a drug carrier and 
the crosslinker in the hydrogel system. The hydroxyl groups of dextran were modified with 
maleimide groups through the formation of ester linkages resulting in functionalized dextran (i.e. 
Dex-Mal). Next, sHSA was added to Dex-Mal resulting in gelation of the mixture under 
physiological conditions in a relatively fast manner. The resulting dextran-albumin (Dex-Mal-
sHSA) hydrogel was characterized by oscillatory rheology experiments. In vitro release profiles of 
three hydrophobic drugs (i.e., ibuprofen, paclitaxel and dexamethasone) from the dextran-albumin 
hydrogel were recorded, showing high drug loading efficiency and demonstrating sustained release 
of the corresponding guest molecule. 
To improve the stability and to gain control over the properties of the abovementioned dextran-
albumin hydrogel system (Dex-Mal-sHSA), two new affinity-based drug delivery hydrogel systems 
were developed in Chapter 3. Firstly, a fraction of the dextran hydroxyl groups were modified with 
vinyl sulfone. The effect of reaction temperature, reaction time and dextran molecular weight was 
studied to control degree of vinyl sulfone modification of dextran (i.e. Dex-VS). In comparison to 
the Dex-Mal polymer in Dex-Mal-sHSA hydrogels used in Chapter 2, the obtained vinyl sulfone 
functionalized dextran polymers (Dex-VS) showed to be more stable against hydrolysis. Next, a 
new dextran-albumin hydrogel system (Dex(VS)-sHSA) with improved stability was developed by 
reacting Dex-VS with sHSA. However, the vinyl sulfone groups show relatively slower reaction 
kinetics towards thiol groups than the maleimide groups. To accelerate the gelation process while 
maintaining the concentration of albumin constant, a third macromolecular precursor, 
poly(ethylene glycol) dithiol (PEG-DT), was introduced into the dextran-albumin hydrogel. By 
balancing the number of reactive vinyl sulfone groups from Dex-VS and thiol groups from both 
sHSA and PEG-DT for the thiol-Michael addition reaction, the covalently dual-crosslinked 
Dex(VS)-sHSA-PEG hydrogel system was prepared where sHSA acts both as a drug carrier and 
crosslinker. Three Dex-sHSA-PEG hydrogels with different weight concentrations were studied 
by oscillatory rheology experiments and swelling tests and compared to the corresponding 
Dex(VS)-sHSA and Dex-VS-PEG hydrogels. By introducing the PEG crosslinker the gelation 
kinetics and the mechanical properties of the resulting three-component Dex-sHSA-PEG 
hydrogels could be more easily controlled in comparison to the other two dextran-albumin 
hydrogels. The capacity of the network to release a drug molecule, Doxorubicin, in a sustained 
manner was validated through in vitro studies using MCF-7 breast cancer cells. 
Chapter 1 
12 
Cyclodextrins are able to form a reversible host-guest complex with suitable hydrophobic 
molecules. In Chapter 4 the potential of cyclodextrin-modified dextran based drug carriers in a 
zebrafish embryo toxicity assay was explored. Zebrafish embryos have become a promising model 
organism for developmental and reproductive toxicity screening studies.17, 19, 74 However, ineffective 
uptake of certain compounds by zebrafish embryos was reported raising concerns of the predictive 
capacity of zebrafish embryo based toxicity assays.75 It was reported that zebrafish embryos show 
a weaker than expected sensitivity for neurotoxic compounds with respect to acute toxicity.76 Here, 
a previously reported -cyclodextrin decorated dextran-poly(ethylene glycol) Dex-CD/PEG drug 
carrier system45 was used to enhance the uptake of the model drug valproate in the zebrafish 
embryo toxicity assay. The polymeric drug carrier was synthesized by crosslinking maleimide 
modified dextran with poly(ethylene glycol) dithiol, wherein cyclodextrins were conjugated to the 
dextran backbone to ensure binding of valproate through the formation of a non-covalent host-
guest complex. The uptake of fluorescent labelled Dex-CD/PEG drug carriers into the 
gastrointestinal tract of zebrafish embryos was observed by fluorescent microscopy. Comparison 
of zebrafish embryos exposed to valproate or valproate loaded Dex-CD/PEG carrier showed that 
the Dex-CD/PEG carrier improves the valproate uptake via the gastrointestinal tract. Correlations 
between the composition of Dex-CD/PEG carriers and the viability of 4-dpf zebrafish embryos 
after 48-hour exposure to valproate loaded Dex-CD/PEG carrier were also studied to investigate 
the role of Dex-CD/PEG carriers in the toxicity assay. 
In Chapter 5, the capacity of hydrogels to guide the formation of giant unilamellar vesicles is 
explored. Giant unilamellar vesicles (GUVs) are widely used cell membrane model systems for 
biophysical measurements.77-79 Recently, it was reported that GUVs can be prepared through 
hydration of a lipid film on a hydrogel consisting of agarose, which was more straightforward and 
rapid to generate GUVs in solutions of physiologic ionic strength.80 However, using agarose for 
the hydrogel film results in contamination of the vesicles due to its dissolution during the hydration 
process. To address this issue, the chemically crosslinked polymer system Dex-Mal-PEG was 
covalently anchored to a glass slide as a substrate for GUV formation. Using this method, polymer 
and additive-free GUVs can be prepared rapidly in high yield under physiological ionic strength 
conditions. Moreover, by varying physiochemical properties of Dex-Mal-PEG hydrogels through 
controlling the molar ratio of the maleimide and thiol groups, the molecular weight of PEG-DT 
and the degrees of substitution of Dex-Mal and PEG-DT, the effect of the network on the yield 
and size distribution of the prepared GUVs was investigated. 
In Chapter 6, an attempt was made to direct the assembly of dextran polymers via specific coiled-
coil interactions. The coiled-coil motif is one of the basic folding motifs in natural proteins, which 
is a left-handed superhelix formed through the winding of two or more right-handed α-helical 
peptides around each other.81, 82 Peptide E (amino acid sequence: (EIAALEK)3) and peptide K 
(amino acid sequence: (KIAALKE)3), able to assemble into heterodimeric coiled coils, were grafted 
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to dextran-vinyl sulfone polymers to obtain multivalent peptide-dextran conjugates. Two pairs of 
dextran-peptide E and dextran-peptide K bioconjugates were synthesized, wherein the dextran 
polymer was attached at either the N- or C-terminus of the peptides. The effect of conjugation on 
peptide conformation and the interaction between complementary dextran-peptide conjugates was 
studied by circular dichroism spectroscopy, fluorescence spectroscopy and dynamic light scattering 
measurements. 
Finally in Chapter 7, the findings and conclusions of this thesis are summarized and possibilities 
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CHAPTER 2  
 
THIOLATED HUMAN SERUM ALBUMIN 
CROSSLINKED DEXTRAN HYDROGEL AS 




Hydrogels play an important role in macroscale delivery systems by enabling the transport of cells 
and molecules. Here we present a facile and benign method to prepare a dextran-based hydrogel 
(Dex-sHSA) using human serum albumin (HSA) as a simultaneous drug carrier and covalent 
crosslinker. Drug binding affinity of the albumin protein was conserved in the thiolation step using 
2-iminothiolane and subsequently, in the in situ gelation step. Oscillation rheometry studies 
confirmed the formation of a three-dimensional viscoelastic network upon reaction of dextran and 
the HSA protein. The mechanical properties of Dex-sHSA hydrogel can be tuned by the protein 
concentration, and the degree of thiolation of sHSA. Sustained release of hydrophobic drugs, such 
as ibuprofen, paclitaxel and dexamethasone, from the Dex-sHSA network was shown over one 
week. Hence, this albumin-based dextran hydrogel system demonstrates its potential as a 















Hydrogels are composed of crosslinked hydrophilic polymer networks, resulting in porous, 
macroscopic materials of high water content. Their unique physicochemical properties enable them 
to perform as macroscale delivery systems of bioactive agents ranging from cells to molecules.1, 2 
Within such systems, methods to gain spatiotemporal control over release of therapeutic payloads 
have involved diffusion,3-7 swelling,8-10 degradation,11-13 light14-19 or drug-carrier affinity 
interactions.20 More specifically, the latter mechanism facilitates controlled release through the 
strong and reversible association of the drug molecules using non-covalent interactions such as 
hydrogen bonding, ionic, van der Waals, and hydrophobic interactions within the macroscale 
material scaffold. In the context of lipophilic drug delivery, the problem of encapsulating a 
lipophilic drug within a water-rich environment is resolved through the inclusion of hydrophobic 
side chains,21, 22 hydrophobic drug carriers,23 such as cyclodextrin,24-29 within the polymer or using a 
molecular imprinting approach30, 31 to prepare the polymeric scaffold. Since it is estimated that 40% 
of new active chemical entities discovered by pharmaceutical companies are poorly water soluble 
(aqueous solubility less than 10 µM),32 macroscale drug delivery systems capable of transporting 
hydrophobic therapeutics are highly relevant. 
Inspired by nature, human serum albumin (HSA) is emerging as an attractive drug carrier in 
biomedical materials.33 HSA is the most abundant plasma protein in human (35-50 g L-1) with a 
molecular weight of 66.5 kDa and has been shown to be biocompatible, biodegradable, non-
immunogenic and non-toxic through its in vivo metabolism by proteases into innocuous degradation 
products. Naturally, HSA acts as a transport vehicle in the blood for a variety of molecules, ranging 
from metal ions, fatty acids, amino acids to numerous drug compounds. Furthermore, HSA has 6 
potential binding sites including two major hydrophobic cavities34 resulting in numerous 
possibilities for specific non-covalent interactions with drug compounds. Thus far, various 
approaches have been explored to develop albumin-based hydrogels for drug delivery, involving 
albumin crosslinking by coupling agents,35-37 free radical polymerization,38 UV39, 40 or γ-ray 
irradiation.41 Despite successful implementation of albumin in these drug delivery systems, the 
biocompatibility of the reported gelation procedures and their effect on the albumin protein 
remains unclear. 
We here report, a facile method to simultaneously use HSA as a crosslinker and drug carrier within 
a dextran polymeric hydrogel system (Figure 1). Dextran is a highly water-soluble and 
biocompatible natural polymer. Native HSA was modified with thiol groups at lysine residues of 
the protein under physiological conditions. Finally, a covalently crosslinked hydrogel network was 
prepared using a Michael addition reaction between maleimide functionalized dextran (Dex-Mal) 
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and thiolated albumin (sHSA) in aqueous solution. The conformation of albumin was observed to 
be retained in circular dichroism (CD) experiments after thiolation and conjugation steps. 
Oscillatory rheometry confirmed the formation of Dex-sHSA viscoelastic network and revealed 
that the mechanical properties can be tuned by varying the degrees of thiolation of sHSA and its 
concentration relative to Dex-Mal. In vitro drug release profiles were evaluated with ibuprofen, 
paclitaxel and dexamethasone demonstrating sustained release over one week. 
 
Figure 1. Preparation of the Dex-sHSA macroscale delivery system. (a) HSA thiolation. (b) Drug loading. (c) Gelation via maleimide-
thiol Michael addition. 
RESULTS AND DISCUSSION 
SYNTHESIS OF SHSA 
The native HSA protein contains 35 cysteine residues, one free thiol (Cys-34) and 17 disulfide 
bridges. The disulfide double loops of HSA play an important role in the formation of the two 
main hydrophobic cavities within the protein, that can be used for ligand binding.34 Since the goal 
was to use sHSA as a simultaneous crosslinker and drug carrier, a gentle thiolation agent that helps 
to retain the native conformation and binding capacity of albumin was required. To this end, 
Traut’s reagent, 2-IT, was selected due to its inherent water-solubility and ability to react with 
primary amines quantitatively in the pH range (7-10) of biological solutions. In comparison to 
reducing reagents such as dithiothreitol (DTT), 2-mercaptoethanol and tris(2-
carboxyethyl)phosphine (TCEP) 2-IT retains intramolecular disulfide bridges and lysine residues’ 
charge upon thiolation, thus aiding protein’s stability and solubility in water.42, 43 Using Ellman’s 
test prior to thiolation with the native HSA, 0.24 free thiol groups per protein were detected (Table 
1), indicating a majority of Cys-34 residues of the obtained native HSA was oxided. It was found 
that commercially available HSA contained a significant amount of oxidized Cys-34 and the 
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amount of oxidized Cys-34 increased with the storage time even being stored at -80˚C.44 This value 
increased to 3.16 free thiol groups per protein when thiolated with 20-fold of 2-IT. As shown in 
Table 1, the degree of thiolation (DT) can be easily varied by the molar ratio between HSA and 2-
IT, thus providing a handle to control the mechanical properties of the final Dex-sHSA hydrogel 
(vide infra). 
Table 1. Controlling the degree of thiolation of sHSA by tuning the molar ratio between HSA and 2-IT. 






CONFORMATION OF HSA, SHSA, AND DEX-SHSA 
CD spectroscopy is a convenient technique to study the structure of proteins in aqueous solution.45 
More specifically, absorption signatures in the far-UV region (below 240 nm) provide insight into 
protein’s secondary structure while absorption in the near-UV region (260-320 nm) is often 
correlated with protein’s tertiary structure. Hence, to investigate the effects of the thiolation by 2-
IT and the conjugation of the dextran polymer on the conformation of HSA, CD spectra of a series 
of samples containing native HSA were collected. 
A comparison of CD spectra of HSA and sHSA suggests that albumin’s secondary and tertiary 
structure is largely retained post-thiolation by 2-IT (Figure 2). Generally, the CD spectrum of native 
HSA in the far-UV has two major minima of a similar ratio around 208 and 222 nm arising from 
the degree of protein α-helical character. The mean residue molar ellipticity [θ] of thiolated sHSA 
at both 222 and 208 nm was found to decrease post-thiolation. relative to the native form by 13%, 
thus indicating a slight loss of α-helicity. Additionally, the near-UV CD spectrum shows a subtle 
decrease in the intensity of [θ] for the thiolated form. This decrease may be correlated with 
structural rearrangements occurring nearby HSA’s disulfide bridges and tryptophan residues.46, 47 
Subsequently, we examined the CD signature of the HSA protein upon reacting an equivalent 
molar ratio of maleimide functionalized dextran polymer and thiolated sHSA. To prevent gelation 
from occurring during conjugate formation in the CD cuvette, the concentration of sHSA was kept 
at 0.5 mg mL-1. The CD spectrum of HSA recorded after formation of the Dex-sHSA conjugate is 
nearly identical to the far-UV CD curve of sHSA and is suggestive of α-helical character retention. 
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More specifically, in the near-UV region, the intensity of [θ] increased slightly after conjugation, on 
par with the native protein. A similar result was previously reported by Antonov,48 whom suggested 
that hydrogen bond formation between the hydroxyl groups of dextran with the tryptophan 
residues located on bovine serum albumin leads to the observed increase in CD signal. Gratifyingly, 
a negligible effect on HSA conformation is observed upon reaction with 2-IT and subsequently, 
with the dextran polymer by CD spectroscopy. 
 
Figure 2. Far-UV CD (a) and near-UV CD (b) spectra of HSA, sHSA and Dex-sHSA (1:1 maleimide:thiol) in sodium phosphate 
buffer (50 mM, pH 7). 
FORMATION OF DEX-SHSA HYDROGELS 
Dex-sHSA hydrogels were formed via maleimide-thiol Michael addition, a rapid, widely used click 
reaction in biological applications. Since this reaction does not require any initiator, catalyst or 
crosslinking agent, cell viability can be retained after in situ hydrogel formation.2, 49 
The gelation process of Dex-sHSA hydrogels was monitored by an oscillatory time sweep. After 
loading and mixing of the Dex-Mal and sHSA solutions on the rheometer plate, the hydrogel was 
formed on the order of seconds (Figure 3a). Values of storage modulus (G’) were observed above 
the loss modulus (G”) from the start of the experiment due to the rapid gelation of the sample. 
Hence, the cross-over point of G’ and G” (generally considered as the gel point) could not be 
observed. In less than half an hour, G’ reached a plateau indicating that the bulk of the gelation 
process occurred. Moreover, the gelation time was found to be dependent on the initial 
concentrations of Dex-Mal and sHSA. In comparison with the 4 wt% Dex-sHSA hydrogel, 6 wt% 
samples were found undergo a more rapid gelation process, resulting in a greater storage modulus 
on the initial reading.  
The resulting hydrogels were further examined by amplitude and angular frequency sweep 




Figure 3. Oscillatory rheometry of Dex-sHSA hydrogels at 37 °C. (a) Time sweep of 4 wt% and 6 wt% hydrogels at 1 rad s-1 and 5% 
strain. (b) Amplitude sweep from 0.5% to 100% at 1 rad s-1. (c) Angular frequency sweep from 100 rad s-1 to 0.1 rad s-1 and 5% strain. 
Effect of (d) the relative concentration of sHSA (DT=3.16) to Dex-Mal, and (e) the degree of thiolation of sHSA on the storage and loss 
modulus (G’ and G”) of 5 wt% Dex-sHSA hydrogels.  
linear viscoelastic region of the Dex-sHSA hydrogel, which was found to be in the range of 0.1% 
to 100%. Angular frequency sweep measurements (Figure 3c) showed that G’ was at least an order 
of magnitude greater than G” over the range of 0.1-100 rad s-1; in agreement with the formation of 
a three-dimensional crosslinked network.  
Since sHSA acts as a crosslinker in the dextran polymeric network, both the relative concentrations 
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and the degrees of thiolation (DT) of sHSA can influence the mechanical properties of Dex-sHSA 
hydrogels. For the former method, the concentration of Dex-Mal was held constant while the 
concentration of sHSA was varied corresponding to the molar ratio of between thiols and 
maleimide. As shown in Figure 3d, the storage modulus (G’) of Dex-sHSA gels increased from 25 
Pa to 52 Pa when sHSA concentration doubled from 2.5 wt% to 5 wt%. By further increasing the 
concentration to 6 wt%, G’ of the gels went up to 62 Pa. In the latter method, increasing degrees 
of thiolation of the sHSA protein also yielded a concomitant increase in the mechanical properties 
of the resulting Dex-sHSA conjugates. 
In Figure 3e, at low DT, sHSA can be covalently ligated to Dex-Mal, but a limited number of thiol 
groups on the albumin surface prevents the formation of hydrogels. For these samples, G” was 
greater than G’ in all oscillation measurements exhibiting predominant viscous-behavior. When the 
DT increased to 1.7 and over, G’ was found to be greater than G” in angular frequency sweep 
measurements and a viscoelastic material was formed. Hence, both methods, either increasing 
protein concentration or DT of the protein, provide a facile handle to tune mechanical properties 
of the macroscale delivery scaffold. 
IN VITRO DRUG RELEASE 
Drug release kinetics from HSA binding pockets within the Dex-sHSA hydrogels were evaluated 
using ibuprofen (IBU), paclitaxel (PTX) and dexamethasone (DXM). IBU is a typical non-steroidal 
anti-inflammatory drug. PTX is an antimicrotubule chemotherapeutic agent currently used in the 
treatment of solid tumour malignancies. Both IBU and PTX have been shown to be highly bound 
to plasma proteins (above 95%).50, 51 DXM is a synthetic corticosteroid widely used as anti-
inflammatory and immunosuppressant in clinical treatments, which is moderately bound to plasma 
proteins (70-80% depending on the test procedure).52 Despite the lipophilic and poor water-soluble 
character of the three drugs tested (See supporting information Table S1), the drugs were co-
dissolved with the HSA drug carrier to form water-soluble drug-HSA complexes and reacted with 
the hydrogel material. High drug loading efficiencies of IBU, PTX and DXM within the Dex-sHSA 
material were obtained (91.3%, 87.7% and 92.1%, respectively). By this method, organic solvents 
such as DMSO become unnecessary for the dispersion of various therapeutics, and further ligation 
to the hydrogel scaffold enables their prolonged delivery.  
In vitro drug release of Dex-sHSA hydrogels were performed under physiological conditions (PBS, 
pH 7.4) at 37 °C. As shown in Figure 4, the release of all three drugs from the hydrogels occurred 
in two stages: a fast release in the initial 10 hours, followed by a second stage of slower and 
sustained release up to 140 hours. In the first stage, hydrophobic drug release was driven by 
diffusion and swelling (See supporting information, Figure S2) of the hydrogel matrix. In the 
second stage, the erosion of the hydrogel plays an important role in release kinetics. The release 
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curve of DXM exhibited a faster release rate than IBU and PTX, which may arise from differences 
in hydrophobic character and binding interactions with HSA. However, it is anticipated that these 
release profiles will change when these networks are presented with proteases due to the 
enzymatically sensitive HSA crosslinks. Overall, this assay shows that Dex-sHSA hydrogels can be 
easily loaded with hydrophobic therapeutics and show sustained release. 
 
Figure 4. In vitro drug release profiles of IBU, PTX and DXM from Dex-sHSA hydrogels (4.5 wt%, DT=3.16) in PBS (150 mM, 
pH 7.4) at 37 °C. 
CONCLUSION 
In this work, we have demonstrated a facile and benign method to simultaneously use HSA as a 
drug carrier and hydrogel crosslinker in a macroscale drug delivery system. Thiol groups were 
introduced to HSA by a mild thiolation agent 2-IT, which assisted in the preservation of the native 
protein conformation as observed by CD spectroscopy. Mixing of sHSA and Dex-Mal resulted in 
rapid in situ gelation with the potential to tune mechanical properties by modulating protein 
concentration and the degrees of thiolation of sHSA. Moreover, the incorporation of HSA into 
these networks provided access to sustained delivery of hydrophobic therapeutics on the order of 
one week. This hydrogel based macroscale delivery system combines the advantage of the versatile 
drug-binding capability of HSA and the biocompatible, highly hydrophilic nature of dextran 
polymers. Beyond therapeutic delivery applications in an in vivo context, such scaffolds can also be 





Dextran (70 kDa), human serum albumin (HSA), N,N'-diisopropylcarbodiimide (DIC), 2-
iminothiolane (2-IT), 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB), dimethyl sulfoxide (DMSO), 
ethylenediaminetetraacetic acid (EDTA), ibuprofen (IBU), paclitaxel (PTX) and dexamethasone 
(DXM) were purchased from Sigma-Aldrich. Dextran was dried in a vacuum oven (30 °C) and 
DMSO was dried over 4Å molecular sieves before use. 3-maleimidopropionic acid and 4-
(dimethylamino)pyridinium 4-toluenesulfonate (DPTS) were synthesized as previously 
reported.53,54 Dialysis membranes (MWCO 3,500-5,000 Da) were obtained from Spectrum 
Laboratories, Inc. 
SYNTHESIS OF DEX-MAL 
Dextran (1 g, 6.17 mmol), 3-maleimidopropionic acid (417 mg, 2.47 mmol), and DPTS (115.7 mg, 
0.247 mmol) were dissolved in DMSO (33 mL) followed by the addition of DIC (580 μL, 3.7 
mmol). After stirring overnight at room temperature, N, N’-dialkylurea was removed by filtration 
and the crude product was obtained by precipitation in cold isopropanol. The precipitate was 
dialyzed against Milli-Q water using a 3500-5000 MWCO cut-off membrane and subsequently 
lyophilized. 1H NMR (400 MHz, D2O): δ 3.3-4.0 (m, dextran glucopyranosyl ring protons), 4.9 (s, 
dextran anomeric proton), 6.9 (s, maleimide). 
The degree of substitution of the dextran polymer (DS[Mal]) is defined as the number of maleimide 
groups per 100 glucopyranose residues. The DS[Mal] is calculated using the ratio: (100x)/(2y), in 
which x is the integral of the maleimide protons (δ 6.9) and y is the integral of the anomeric proton 
of dextran (δ 4.9) from the 1H NMR spectra measured by a Bruker AV-400 spectrometer.55 The 
DS[Mal] of the dextran polymer (Dex-Mal) synthesized in this work was 4.6. 
SYNTHESIS OF THE THIOLATED HUMAN SERUM ALBUMIN (SHSA) 
HSA was dissolved in 50 mM sodium phosphate buffer (pH 8, including 5 mM EDTA) and stirred 
gently at 0 °C on ice. Subsequently, an aqueous solution of 2-IT (20 mg mL-1) was added drop-wise 
to the HSA solution. After 2 hours, the mixture was brought back to room temperature. The 
product was first dialyzed against 10 mM HEPES buffer (pH 7) three times over 24 hours and 
then, against Milli-Q water three times over 2 days at 4 °C. Finally, sHSA was lyophilized and stored 
at -20 °C. 
The degrees of thiolation (DT) of sHSA were quantified by the Ellman’s test.56, 57 Briefly, 100 μL 2 
mM DTNB, 200 μL 10 mg mL-1 sHSA and 700 μL 0.1 M sodium phosphate buffer (pH 8) were 
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mixed and incubated for one hour at room temperature. During this reaction, the formation of the 
2-nitro-5-thiobenzoate anion (TNB2-) resulted in an intense yellow colour with an absorbance at 
412 nm by UV-vis spectroscopy (Agilent, Cary-300). The molar extinction coefficient of TNB2- at 
412 nm, εTNB2
- = 14150 M-1 cm-1, was used to calculated the concentration of free thiol groups in 
the tested sHSA solution. The concentration of albumin in a control group (200 μL 10 mg mL-1 
sHSA and 800 μL 0.1 M sodium phosphate buffer) was determined with the absorbance at 279 nm 
by UV-vis spectroscopy (εalbumin = 0.531 M
−1 cm−1). The DT of sHSA was then calculated by 
dividing the concentration of free thiol groups by the concentration of albumin. 
CIRCULAR DICHROISM (CD) 
Circular dichroism spectra were obtained on a Jasco J-815 spectrometer. All spectra were collected 
with a scan speed of 50 nm min-1 and a response time of 1 second at 20 °C. Each spectrum was 
averaged over 5 scans. Samples of native HSA, sHSA (DT=3.2), Dex-sHSA conjugate (molar ratio 
of thiol to maleimide 1:1) were prepared in sodium phosphate buffer (50 mM, pH 7). Native HSA 
and sHSA solutions were filtered through 0.2 μm syringe filters before CD measurements. For 
near-UV measurements (250-330 nm), a 1 cm path length quartz cuvette was used for 0.5 mg mL-
1 protein samples. For far-UV measurements (200-250 nm), a 0.1 cm path length quartz cuvette 
was applied for 0.1 mg mL-1 protein samples. 
CD data were presented in terms of ellipticity [θ] (degrees) and converted to the mean residue 
molar ellipticity [θ] in deg cm2 dmol-1 by equation 1, where n is the number of amino acid residues 
(585), l is the path length of the cuvette, and Cp is the mole fraction. 
[𝜃]  =  
𝜃(𝑚𝑑𝑒𝑔)
𝐶𝑝 ×𝑛×𝑙×10
       (1) 
α-helix content was calculated from the value of [θ] at 222 nm58 by equation 2. 
𝛼 − ℎ𝑒𝑙𝑖𝑥 % = (
[𝜃] −2430
30300
) × 100     (2) 
DEX-SHSA HYDROGELS 
Dex-Mal and sHSA were dissolved in phosphate buffered saline (PBS, 150 mM, pH 7.4) 
individually and then mixed together using a pipette to prepare the hydrogel samples (1:1 molar 
ratio of maleimide to thiol). 
An AR-G2 rheometer (TA Instruments) was used to measure the mechanical properties of Dex-
sHSA hydrogels in oscillatory mode at 37 °C using the parallel plate geometry (40 mm diameter). 
Solutions of Dex-Mal and sHSA were loaded at 300 µL of each component onto the bottom plate 
and the geometry was lowered to a gap of 0.40 mm for all experiments. Time sweep measurements 
Chapter 2 
30 
were performed to follow gel curing at 1 rad s-1 with 5% strain. The linear viscoelastic regime was 
determined using an amplitude sweep measurement at 1 rad s-1 from 0.1% to 100% strain. 
Frequency sweep measurements were performed from 100 to 0.1 rad s-1 with 5% strain in the linear 
viscoelastic regime. 
IN VITRO DRUG RELEASE 
Lipophilic drugs (IBU, PTX or DXM) and sHSA were co-dissolved in PBS (150 mM, pH 7.4, 0.02% 
NaN3) and incubated for 2 hours at 37 °C prior to gelation. The molar ratio of sHSA and drug was 
kept at 1:1 in all samples. The drug-sHSA solution was subsequently crosslinked with the Dex-Mal 
polymer solution to form the drug-loaded hydrogels for in vitro drug release.  
To examine the drug loading efficiency, 1 mL 0.25% trypsin solution (25 mM HEPES buffer, pH 
7) was added on top of 200 µL drug loaded Dex-sHSA gel (4.5 wt%) and incubated at 37 °C. 2 mL 
acetonitrile was added to the mixture and the precipitates were removed by ultracentrifuge at 13 
000 rpm for 10 minutes. The amount of drug was subsequently quantified by reversed-phase high 
performance liquid chromatography (RP-HPLC) analysis using two LC-8A pumps, SPD-10AVP 
UV-VIS and ELSD-LTII detectors from Shimadzu. The separation was performed on a Gemini 
C18 column at a flow rate of 1 mL min-1 with a linear gradient from 90% B to 10% B, where A 
was acetonitrile with 0.1 vol% TFA and B was H2O with 0.1 vol% TFA. The eluate was monitored 
at both 220 and 254 nm. The drug loading efficiency was calculated from the amount of drug 
recovered from the gel divided by the amount of drug loaded expressed in percent. 
For in vitro drug release study, the drug loaded Dex-sHSA gel was immersed in PBS at 37 °C. At 
predetermined time intervals, the supernatant buffer solution was collected and replaced with fresh 
PBS. The collected buffer solutions at each time point were analysed by RP-HPLC. All drug release 
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SWELLING PROPERTIES OF DEX-SHSA HYDROGEL 
A Dex-sHSA hydrogel sample (4.5 wt%) was immersed in 150 mM phosphate buffered saline (PBS, 
pH 7.4, 0.02% sodium azide) at 37 °C. At predetermined time intervals, the entire buffer weight 
was weighed and fresh buffer was refilled afterwards. The normalized hydrogel weight (NWh) was 





Where Wt is the hydrated mass at time t and Wo the initial mass of the hydrogel after gelation. 
 
Figure S2. Swelling properties of Dex-sHSA hydrogels. 
 
IN VITRO DRUG RELEASE  
Table S1. Physicochemical properties of applied drugs. 
Drugs Mw Water solubility (25 °C)* logP* 
ibuprofen 206.28 21 mg/L 3.97 
paclitaxel 853.91 insoluble 3 
dexamethasone 392.46 89 mg/L 1.83 




In order to quantify the amount of drugs released from the Dex-sHSA gels, calibration curves 
between drug’s concentration and its peak intensity from RP-HPLC analysis were determined prior 
to the in vitro drug release study. 
 






DUAL-CROSSLINKED HUMAN SERUM 
ALBUMIN-POLYMER HYDROGELS FOR 




A dual-crosslinked in situ gelling drug delivery scaffold based on dextran, thiolated serum albumin 
and poly(ethylene glycol) is presented. Dextran-vinyl sulfone conjugates with varied molecular 
weight and degrees of substitution were synthesized by controlling the reaction time and 
temperature with divinyl sulfone. Dextran-human serum albumin hydrogels were prepared using a 
thiol-vinyl sulfone Michael addition reaction with thiolated albumin as the crosslinker. 
Poly(ethylene glycol) dithiol was added as a third component to the crosslinked dextran-human 
serum albumin hydrogel to facilitate additional crosslinking; simultaneously reducing the gelation 
time and increasing the tunability of the physicochemical properties of the Dex-sHSA-PEG 
network. The onset of gelation of the modular three-component dual-crosslinked hydrogel 
network ranged from 45 minutes to 1.5 hours depending on both gel constituent concentrations 
and the gelation temperature (25 °C or 37 °C). All gels remained stable for over a 25-day period 
under physiological conditions. In vitro drug release assays showed that dual-crosslinked Dex-
sHSA-PEG hydrogels can deliver Doxorubicin in a sustained manner over 7 days. Finally, an MTT 
assay showed the biocompatible nature of the Dex-sHSA-PEG hydrogels and capacity to deliver 











Macroscale drug delivery systems have garnered much attention in pharmaceutical research because 
of their potential to exert control over drug release spatiotemporally.1, 2 Rather than conventional 
oral or intravenous drug administrations, novel macroscale drug delivery systems are usually 
implanted at a site of need for use in long-term or drug delivery. By releasing therapeutics locally 
at a desired site, side effects and toxicity can be diminished due to lower dosing quantities. Typical 
drug release mechanisms applied in drug delivery systems include diffusion-controlled drug 
release,3 degradation-controlled drug release4 and stimuli-triggered drug release,5 each with its own 
inherent advantages and disadvantages in a therapeutic setting. 
Affinity-based drug release systems have emerged to be an attractive platform for their delivery 
due to the capacity to exploit interactions between the delivery system and the therapeutic drug 
using a combination of non-covalent interactions to control drug release such as hydrophobicity, 
hydrogen bonding, electrostatics or van der Waals forces.6 Advantages of affinity-based drug 
delivery systems include improved drug loading, prolonged drug stability and sustained release. 
Drug-binding hosts can be introduced into the polymeric scaffolds using (macro)molecules such 
as cyclodextrin,7-11 serum albumin12-15 and heparin,16-18 or by generation of cavities within the bulk 
polymer material by molecular imprinting.19, 20 A particularly attractive carrier is the most abundant 
plasma protein (35-50 g L-1) human serum albumin (HSA). HSA has been shown to be 
biocompatible, biodegradable, non-immunogenic and non-toxic, and is known to bind and 
transport numerous molecules in the blood circulation, such as fatty acids, bilirubin, hormones, 
and metal ions.13, 21 Several therapeutic drugs have also been shown to bind various locations of the 
albumin protein by several non-covalent interactions with high affinity. Consequently, HSA has 
been exploited for use as a drug depot in a broad range of particulate carriers,22-24 but fewer 
examples of its use in macroscale hydrogel systems have been reported.12, 25-30 Until now, the 
synthesis of human serum albumin-based hydrogel materials involves the use of various coupling 
agents,25-27 free radical polymerization,12 UV29, 30 and γ-ray irradiation28 in order to facilitate gelation 
of HSA with varying degrees of biocompatibility. However, in order to apply these HSA-based 
materials in the biomedical domain, benign gelation strategies that enable control over the resultant 
hydrogel physicochemical properties are still very much needed. 
Injectable, in situ gelling hydrogels are practical clinically for deploying macroscale drug delivery 
systems because of their potential for administration in a minimally invasive manner, reducing 
patient discomfort, recovery time and treatment workload.31, 32 The thiol-Michael addition “click” 
reaction, involving nucleophilic thiols and electron-deficient carbon-carbon double bonds, is highly 
attractive to form in situ gelling hydrogel scaffolds because of its ability to operate selectively under 
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physiological conditions and with high efficiency.33, 34 Acrylates, methacrylates, vinyl sulfones and 
maleimides are typical Michael acceptors ranging in reactivity towards thiols,35 opening the door 
for modulating the kinetics of polymer network formation. Generally, the more electron-deficient 
the C=C bond, the more likely it is to engage in a Michael addition reaction. Although vinyl 
sulfones present relatively slower reaction kinetics as Michael acceptors with thiols in comparison 
to maleimides,34, 36-38 they can form very stable thioether sulfone bonds under mild reaction 
conditions.39-47 Moreover, the resulting thioether sulfone bonds are more resistant to hydrolytic 
degradation over succinimide thioether bonds,48 which can even undergo competitive exchange 
with excess thiols or disulfides present in solution.49 
Previously, we reported a covalently crosslinked dextran hydrogel system50 that is rapidly formed 
by a thiol-maleimide Michael addition reaction between the thiol groups of thiolated human serum 
albumin (sHSA) and maleimide groups of a maleimide-modified dextran (Dex(Mal)). The dextran 
polymer was selected for its biocompatible character. In this Dex(Mal)-sHSA hydrogel system, 
sHSA acts as both crosslinker and drug carrier facilitating the sustained release of several drug 
molecules. However, an issue that limits their broad application is that they were found to degrade 
after one week at 37 ˚C in phosphate buffer. This result can be either due to the hydrolysis of the 
ester bonds connecting the reactive maleimide group to dextran, or the back reaction of the 
succinimide thioether in presence of excess thiols.49 To increase the stability of Dex-sHSA 
hydrogels for long-term release applications, we simultaneously replaced the ester linkage and the 
succinimide thioether by reacting dextran with divinyl sulfone to provide an ether-linked reactive 
group for Michael addition. The hydrogel physicochemical properties were tuned by modifying the 
degrees of substitution of the Dex(VS) polymer. Moreover, the addition of poly(ethylene glycol) 
dithiol (PEG), a biocompatible and FDA approved polymer, to the Dex-sHSA hydrogel as a 
second crosslinker was explored, while maintaining the sHSA concentration constant, to increase 
gelation kinetics while simultaneously modifying mechanical stiffness under physiological 
conditions. Finally, the capacity of the improved and biocompatible dual-crosslinked Dex-sHSA-
PEG hydrogel to deliver a therapeutic payload in a sustained manner was tested using Doxorubicin 
in vitro and in the presence of MCF-7 breast cancer cells (Figure 1). 
RESULTS AND DISCUSSION 
SYNTHESIS OF DEXTRAN-VINYL SULFONE CONJUGATES 
The vinyl sulfone substituted dextran polymer was prepared according to the method outlined by 
Yu et al.51 because of its potential for zero-length conjugation and synthetic facility in contrast to 
earlier approaches for polysaccharides.52, 53 In their approach, dextran polymers were dissolved in 
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various concentrations of sodium hydroxide (NaOH) solutions (e.g. 0.01 M, 0.1 M, 0.2 M, etc.) to 
generate alkoxides, followed by their reaction with divinyl sulfone (DVS) to form stable ether 
linkages on the order of minutes. The degree of substitution was modulated as a function of pH, 
ratio of DVS to OH, and reaction time. The most optimal reaction conditions, enabling control 
over the reaction rate and product formation, were found when applying 0.1 M NaOH solution 
(pH = 13) and using a DVS to –OH molar ratio of 1.25 equivalents. We therefore applied these 
conditions to prepare vinyl sulfone-substituted dextran polymers of various molecular weights (Mn 
= 20, 70, 150, and 250 kDa) (Table 1) and we examined the reaction time and temperature to 
control the degree of substitution. 
 
Figure 1. Schematic representation of the polymers, proteins and resulting hydrogels in this study: (A) Dex(VS), (B) Dex(VS)-sHSA 
hydrogels, and (C) Dex(VS)-sHSA-PEG hydrogels. 
We first examined the effect of reaction time of reacting divinyl sulfones on the dextran polymers 
(Mn = 20 and 70 kDa) at room temperature for 5 minutes as previously described.
51 Precipitation 
occurred for both dextran polymers (Mn = 20 and 70 kDa) before the reaction was halted, 
suggesting a high degree of substitution of vinyl sulfone and putative crosslinking of the dextran 
polymers. The precipitated Dex20k(VS) and Dex70k(VS) were examined by 1H NMR spectra in 
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deuterated DMSO. The degree of substitution of both dextran polymers (Mn = 20 and 70 kDa) 
were higher than 80 indicating that at least one vinyl sulfone group can be found per 
anhydroglucose unit of the dextran polymer. Because soluble polymers are required to facilitate in 
situ crosslinking to form hydrogels, we decreased the reaction time to reduce the degree of 
substitution of the substituted Dex(VS) polymer. In the case of functionalizing of a dextran 
polymer with a molecular weight of 20 kDa in 0.1 M NaOH solution at room temperature, when 
the reaction time was reduced to 2, 1 and 0.5 minutes the degree of substitution of obtained 
Dex20k(VS) conjugates were 31.4, 17.5 and 8.4 % respectively (Table 1). These results show that 
the reaction time correlates positively with the degree of substitution of Dex(VS), but the relatively 
rapid reaction time can make the degree of substitution difficult to control. 






Degree of substitution 
[%] 
Dex20k 5 RT 86 
Dex20k 2 RT 31 
Dex20k 1 RT 17 
Dex20k 0.5 RT 8 
Dex70k 5 RT 83 
Dex20k 1 0 5 
Dex70k 2 0 6 
Dex70k 1 0 4 
Dex150k 1 0 3 
Dex250k 1 0 3 
 
To further control the functionalization of the dextran polymer, we turned to using the reaction 
temperature to modulate the reaction kinetics. We decreased the reaction temperature to 0 °C while 
retaining the other reaction conditions including the stoichiometry of the reagents. In the case of 
dextran (Mn = 20 kDa) with a reaction time of one minute, the degree of substitution was 
successfully decreased from 17.5 to 5.3 % when the reaction temperature was lowered from room 
temperature to 0 °C (Table 1) demonstrating increased control over the reaction. This positive 
result with Dex20k(VS) encouraged us to use both reaction time and temperature to control the 
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degree of substitution for a broader range of dextran polymers from 20 – 250 kDa. Dextrans with 
higher molecular weights such as 70, 150 and 250 kDa, showed decreased degrees of substitution 
in comparison to the 20 kDa polymer. Most likely, the accessibility of the generated alkoxide ions 
on dextran are sterically hindered by the increased polymer length precluding reaction with the 
electrophilic double bonds of DVS. Additionally, the solubility of the substituted Dex150k(VS3) 
and Dex250k(VS3) conjugates was limited. At a concentration of 2 w/v%, neither of the 
Dex150k(VS3) and Dex250k(VS3) resulted in clear solutions when dissolved in water, while the 
corresponding unfunctionalized dextran polymers are soluble in water at 2 w/v% (Table 1). Since 
the vinyl sulfone substituents can increase the hydrophobic character of the dextran polymer 
affecting its water solubility, both the degree of substitution and the molecular weight of the 
dextran polymer become important factors to take into consideration for their applications in in 
situ forming hydrogels. 
HYDROGEL FORMATION AND MICROSTRUCTURE 
The variably substituted Dex(VS) polymers were then evaluated for their capacity to form affinity-
based hydrogels by the Michael addition click reaction with the thiolated human serum albumin 
protein (sHSA). sHSA, prepared with 2-iminothiolane (2-IT) prior to dextran conjugation, was 
used simultaneously as a therapeutic depot and crosslinker. All hydrogels were prepared by mixing 
an equimolar ratio of thiols on the sHSA protein to vinyl sulfone groups on the dextran polymer 
in phosphate buffered saline at pH 7.4 at room temperature. The concentration of sHSA was kept 
at 5 % (w/v) in resulting hydrogels as previously observed in our Dex(Mal)-sHSA hydrogel 
systems.50 Consequently, the amount of Dex(VS) polymer used to prepare Dex(VS)-sHSA 
hydrogels was varied accordingly to maintain an equimolar ratio with the number of thiol groups 
on sHSA. 
The vial tilting method was used to evaluate the gelation time of the Dex(VS)-sHSA hydrogels at 
room temperature. The effect of Dex(VS) polymer chain length on the gelation time of Dex(VS)-
sHSA hydrogel samples was also evaluated with Dex20k(VS5), Dex70k(VS4), and Dex150k(VS3) 
by controlling the molar concentration of functional groups (-VS and -SH) at a fixed concentration 
of 4 mM (Figure 2). Hydrogels were formed under all conditions tested. An increased gelation time 
for the higher molecular weight polymer was found, which may be due to the reduced accessibility 
of vinyl sulfone groups resulting in a decreased rate of thiol-Michael addition with the sHSA. 
To increase the applicability of this affinity-based hydrogel system for drug delivery, we sought to 
further tune the rate of hydrogel formation by increasing the concentration of functional groups, 
and thus crosslinks within the network. Since the amount of sHSA in the hydrogel was kept on par 
with the concentration reported in plasma, 35-50 g/L, an additional synthetic polymer was required 




Figure 2. Gel inversion tests of Dex(VS)-sHSA hydrogels prepared from 5.6 w/v% Dex20k(VS5)-sHSA (left), 5.9 w/v% 
Dex70k(VS4)-sHSA (middle), 6 w/v% Dex150k(VS3)-sHSA (right) at room temperature, showing the gelation mixtures (top) and 
their resulting hydrogels (bottom). 
Mn = 3400) was selected to be added to the dextran-sHSA network to provide polymeric bulk and 
an increased number of crosslinks. PEG was first mixed sHSA (5 w/v%) prior to addition of the 
corresponding Dex(VS) solution. The dual-crosslinked Dex70k(VS6)-sHSA-PEG hydrogels were 
prepared at various polymeric crosslinker concentrations (7.5, 10, 11.5 and 13 w/v%) keeping the 
concertation of sHSA constant and only linearly increasing the concentrations of Dex70(VS6) and 
PEG (the exact molar ratios of all polymer concentrations are presented in Table 2 at room 
temperature. All Dex70k(VS6)-sHSA-PEG samples turned from sols to gels upon inversion in 6 
hours (Figure 3A). Faster gelation rates were achieved in presence of PEG upon maintaining the 
final concentration of sHSA at 5 w/v%. By such an approach, the gelation time of the Dex(VS)-
sHSA-PEG hydrogels can be tuned without modifying the sHSA concentration, providing the 
flexibility to independently vary the amount of crosslinks and drug binding sites. 
Whereas the dual-crosslinked Dex70k(VS6)-sHSA-PEG hydrogels showed faster gelation kinetics 
over Dex70k(VS6)-sHSA gels by vial inversion tests, we additionally quantified their onset of 
gelation and mechanical properties by oscillatory rheology. An amplitude sweep was conducted 
from 0.01 to 100 % strain in order to determine the linear viscoelastic regime of a 10 w/v% 
Dex70k(VS6)-sHSA-PEG hydrogel (Figure 3C). The gelation process was followed by growth of 
the storage modulus (G’) of the freshly mixed polymer solutions of Dex(VS) and PEG and sHSA 
with respect to time (Figure 3B) at 25 ºC. As shown in Figure 2b, G’ started to increase dramatically 
after 45 minutes and reached a plateau after two and a half hours at 2900 Pa for the 13 w/v% 
Dex70k(VS6)-sHSA-PEG hydrogel sample at 25 ºC. For 10 and 11.5 w/v% Dex70k(VS6)-sHSA-
PEG hydrogel samples took a longer time to reach a plateau during measurement, and the absolute 
value of G’ decreased significantly with crosslinking density. In the 7.5 w/v% Dex70k(VS6)-sHSA-
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PEG hydrogel sample, the time for gelation to occur was greater than 3 hours and drying of the 
sample was found to be significant during the oscillatory rheology experiment and is therefore not 
represented here. Once the rate of gelation and storage moduli were examined for all samples, the 
mechanical properties of the Dex(VS)-sHSA-PEG hydrogels were further probed by angular 
frequency sweeps. Frequency sweep measurements showed the formation of a viscoelastic network 
with G’ being greater than G” by two orders of magnitude from 0.1 to 12.56 rad/s (Figure 3D). 
Interestingly, gelation kinetics could be increased by elevating the reaction temperature from 25 °C 
to 37 °C, resulting in both faster gelation (from 1.5 hours to 45 minutes, respectively) and increased 
mechanical properties of the hydrogels (from 180 Pa to 716 Pa) (Figure 3E) for the 5 w/v% sample. 
Furthermore, it is anticipated that the gelation kinetics can be further increased by raising their 
concentration or their degree of functionalization opening the door for their use as practical and 
tunable hydrogel scaffolds in the biomedical domain. Cryo-scanning electron microscopy (cryo-
SEM) images of 7.5 w/v% Dex70k(VS6)-sHSA-PEG hydrogels support the measured rheology 
data depicting a continuous and porous hydrogel microstructure consistent with other covalent 
hydrogel systems with pore diameters in the range of 2 - 10 µm (Figure 4).  
The effect of sHSA on the gelation behavior of the dual-crosslinked Dex(VS)-sHSA-PEG 
hydrogels was then examined by comparing time sweep measurements of hydrogels with and 
without sHSA on hydrogel formation. The rheological properties of 10 w/v% Dex70k(VS6)- 





-VS on Dex 
[mM] 
-SH on HSA 
[mM] 
-SH on PEG 
[mM] 
Dex20k(VS5)-sHSA 5.6 4 4 - 
Dex70k(VS4)-sHSA 5.9 4 4 - 
Dex150k(VS3)-sHSA 6 4 4 - 
Dex70k(VS6)-sHSA 5.4 4 4 - 
Dex70k(VS6)-sHSA-PEG 7.5 8 4 4 
Dex70k(VS6)-sHSA-PEG 10 15 4 11 
Dex70k(VS6)-sHSA-PEG 11.5 20 4 16 
Dex70k(VS6)-sHSA-PEG 13 25 4 21 





Figure 3. (A) Gel inversion of 7.5, 10, 11.5 and 13 w/v% Dex70k(VS6)-sHSA-PEG hydrogels. Oscillatory rheology measurements 
of Dex70k(VS6)-sHSA-PEG hydrogels at 25 °C (25 mm plate-plate geometry); (B) time sweep measurement of 10, 11.5 and 13 w/v% 
Dex70k(VS6)-sHSA-PEG hydrogels at 6.28 rad/s with 0.05 % strain at 25 ºC; (C) amplitude sweep measurement of 10 w/v% 
Dex70k(VS6)-sHSA-PEG hydrogels from 0.1 to 12.56 rad/s with 0.05 % strain at 25 ºC; (D) angular frequency sweep measurement 
of 10 w/v% Dex70k(VS6)-sHSA-PEG hydrogels from 0.01 to 100 % strain at 6.28 rad/s at 25 ºC; (E) comparison of gelation of 
10 w/v% Dex70k(VS6)-sHSA-PEG hydrogels at 25 °C and 37 °C. 
 
 
Figure 4. Cryo-SEM images of 8 mM Dex70k-VS6-sHSA-PEG hydrogel prepared in phosphate buffer saline (pH=7.4). Scale bars: 




sHSA-PEG showed both slower gelation kinetics and lower mechanical stiffness and 5 w/v% 
Dex70k(VS6)-PEG hydrogels were compared, in which for the latter sample to maintain an 
equimolar ratio of thiol and vinyl sulfone groups the molar equivalents of sHSA were replaced by 
additional PEG (Table 2). Interestingly, the Dex70k(VS6)-sHSA-PEG hydrogels after 2.5 hours 
than the Dex70k(VS6)-PEG hydrogels (Figure S2). Most likely, the higher molecular weight and 
more compact conformation of albumin reduce the accessibility of thiol groups of sHSA to 
Dex(VS) polymers resulting in slower reaction and gelation kinetics of Dex(VS)-sHSA-PEG 
hydrogels relative to the Dex-PEG hydrogels and overall lower mechanical properties. However, 
our previous work using Dex-sHSA hydrogels does show that sHSA can act as a crosslinker so the 
sHSA has a combined role in both to some extent contributing to crosslinking within the 
hydrophilic Dex-sHSA-PEG network in addition to its envisioned role as a drug carrier, albeit at 
the cost of network stiffness compared to native Dex-PEG hydrogels. 
HYDROGEL SWELLING AND DEGRADATION 
Equilibrium swelling measurements were performed to evaluate hydrogel network swelling and 
stability.54 Previously, we demonstrated that Dex(Mal)-sHSA gels (5 w/v%), prepared from sHSA 
and a maleimide-functionalized by an ester bond to dextran (Dex(Mal)), were observed to maintain 
their integrity in PBS for more than three weeks at room temperature in swelling experiments. 
However, on performing the same experiment at 37 °C complete degradation of the Dex(Mal)-
sHSA gels was observed in one week. Consequently, we sought to increase the stability of the 
hydrogel network under physiological conditions by changing the ester-linked maleimides to vinyl 
sulfone groups in the Michael addition reaction.  
Hydrogels composed of Dex70k(VS6)-sHSA-PEG (10, 11.5, and 13 w/v%) and Dex70k(VS6)-
sHSA (5.9 w/v%) were probed every day at 37 ˚C for a total of 24 days with all hydrogels being 
stable over the measuring period (Figure 5A). Both the Dex70k(VS6)-sHSA-PEG and 
Dex70k(VS6)-sHSA hydrogels displayed slight swelling in the first 48 hours and a subsequent 
decrease over the remaining time period. This decrease in swelling is consistent with the diffusion 
of unreacted polymer or protein components from the network; consistent with other covalent 
polymer hydrogel systems.55 After 3 to 4 days, the swelling ratio eventually became constant 
reaching equilibrium. The Dex70k(VS6)-sHSA-PEG hydrogels showed a lower degree of swelling 
compared to the Dex70k(VS6)-sHSA hydrogels, which is on par with a polymer network that 
possesses a higher crosslinking degree due to the added poly(ethylene glycol). 
The release of albumin from the hydrogel network during the swelling process was quantified over 
time to better understand the extent of sHSA coupling and to evaluate the effect of PEG addition 
to the hydrogel network. Hydrogels consisting of thiolated (sHSA) and native (HSA) albumin were 
compared for their release. In all cases the amount of albumin loaded was kept constant at 5 w/v%. 
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The native albumin protein, lacking additional free thiol groups and unable to act as a crosslinker, 
was physically encapsulated to form a 10 w/v% Dex70k(VS6)-PEG hydrogel, and its release was 
compared to hydrogels containing thiolated albumin, 5.4 w/v% Dex70k(VS6)-sHSA, 7.5, 10, 11.5 
and 13 w/v% Dex70k(VS6)-sHSA-PEG hydrogels. After 48 hours, nearly 80 % of the loaded 
native albumin was released from 10 w/v% Dex70k(VS6)-PEG hydrogel network (Figure 5B, 
presented as star symbols). On the other hand, 35 % of sHSA was released from the 5.4 w/v% 
Dex70k(VS6)-sHSA hydrogels to the surrounding buffer solutions after 48-hour incubation 
(Figure 5B, presented in cross symbols). This result demonstrates that a fraction of the added sHSA 
protein remains unconjugated to the Dex(VS) polymer despite having reactive groups and that 
crosslinking retards its diffusion from the network. All 10, 11.5 and 13 w/v% Dex70k(VS6)-sHSA-
PEG hydrogels (Figure 5B, presented in square, circle and triangle symbols respectively), retained 
the thiolated albumin protein to an even greater extent with less than 20 w/v% of sHSA being 
released up to 6 days, putatively due to the increased crosslinking of the network from the addition 
of the PEG. 
 
Figure 5. (A) Equilibrium swelling study of 10 (○), 11.5 (Δ) and 13 (+) wt% Dex70k(VS6)-sHSA-PEG and 5.9 w/v% 
Dex70k(VS6)-sHSA (□) hydrogels at 37 °C over 24 days. (B) Albumin release studies from 10 (○), 11.5 (Δ) and 13 (+) w/v% 
Dex70k(VS6)-sHSA-PEG, and 5.9 w/v% Dex70k(VS6)-sHSA (□) hydrogels with thiolated sHSA and 5 w/v% Dex70k(VS6)-
PEG () hydrogel with native HSA, respectively. 
In comparison to the earlier reported Dex(Mal)-sHSA hydrogels, the Dex(VS)-sHSA and dual-
crosslinked Dex(VS)-sHSA-PEG hydrogels with the new thioether linkages showed increased 
stability for use under physiological conditions at 37 ºC. Moreover, the addition of PEG as a 
crosslinker can modulate the gelation time, mechanical stiffness and the equilibrium swelling of the 
network providing access to a highly tuneable platform for drug delivery. 
DRUG DELIVERY FROM DEX(VS)-SHSA-PEG HYDROGELS 
Once the physicochemical properties of the dual-crosslinked Dex(VS)-sHSA-PEG hydrogel 
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network were examined, we then sought to evaluate its potential as an affinity-based drug scaffold 
by using the bound sHSA to bind a chemotherapeutic drug Doxorubicin (DOX). DOX is well-
known to intercalate within the DNA base pairs and to interact with DNA-associated proteins, 
such as topoisomerase enzymes I and II, to produce cytotoxic effects through DNA damage.56 
Because of the notorious cardiotoxicity of DOX, delivery systems that enable its sustained release 
are of interest in the medical field. Slow release of DOX from the network is anticipated due to 
the known binding of DOX to HSA (Kd= 1.1*10
4 L mol-1).57 As a first approach, an in vitro release 
DOX release assay was performed by incubation of 0.5 mg/mL DOX with sHSA to facilitate its 
encapsulation prior to crosslinking with PEG to form the 10 w/v% Dex70k(VS6)-sHSA-PEG 
hydrogel at 25 °C to benchmark the release properties of the hydrogel, resulting in a sustained 
release over 7 days. Subsequently, two different concentrations (0.5 and 1.0 mg/mL) were probed 
at 37 °C to better understand the kinetics of DOX release from the network under physiological 
conditions. The continuous release of DOX was observed over 7 days where 1.0 mg/mL DOX 
loaded gels expectedly released the therapeutic cargo faster than their 0.5 mg/mL loaded 
counterparts (Figure 6). Interestingly, the hydrogels prepared at 37 °C showed decreased release 
kinetics most likely due to the formation of more crosslinked materials as observed by oscillatory 
rheology. 
 
Figure 6. In vitro drug release profile of Doxorubicin (0.5 and 1.0 mg/mL) from 10 w/v% Dex70k(VS6)-sHSA-PEG hydrogels at 
25 °C and 37 °C measured over 7 days. 
Overall, the albumin drug carrier can effectively aid in the solubility and binding of the drug in the 
hydrogel while reducing its diffusivity and retarding its release as a function of DOX concentration. 
Therefore, Dex(VS)-sHSA-PEG hydrogels demonstrate their potential for use as materials for 
sustained drug delivery under physiological conditions. 
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Subsequently, the toxicity of the Dex(VS)-sHSA-PEG hydrogel network and its capacity to deliver 
therapeutics to MCF-7 breast cancer cells was probed (Figure 7). Native hydrogels, DOX-loaded 
hydrogels (0.5 mg/mL) and as a negative control a 1 µM DOX solution were incubated with MCF-
7 cells for up to three days and cell viability was monitored using an MTT assay. The native hydrogel 
showed a negligible decrease (~10 %) of cell viability compared to the untreated MCF-7 cells, 
indicating that the material by itself shows no cytotoxic effects towards MCF-7 cells over this 
period. The negative control containing free DOX showed a reduction in cell viability of ~ 86% 
after three days. The cells incubated with DOX-loaded hydrogels showed a drastic reduction in cell 
viability, 80% after 3 days, demonstrating the potency of the drug against cancerous cells when 
released from the gel network. 
 
Figure 7. In vitro MTT cytotoxicity assay on the effects of Doxorubicin drug-release from 10 w/v% Dex70k(VS6)-sHSA-PEG 
hydrogels on MCF-7 breast cancer cells. Conditions: untreated MCF-7 cells (white), treated with native hydrogel (diagonal stripes), treated 
with Doxorubicin containing hydrogel (check pattern), treated with free DOX (horizontal stripes). 
CONCLUSION 
A novel and stable dual-crosslinked affinity-based drug delivery system based on dextran, human 
serum albumin and poly (ethylene glycol) was successfully prepared using thiol-vinyl sulfone 
Michael addition. Vinyl sulfone modified dextran polymers with various degrees of substitution 
and molecular weights were synthesized in a controllable manner by using time and decreasing the 
reaction temperature of the dextran reaction with divinyl sulfone. Through tethering vinyl sulfone 
reactive groups by an ether linkage to the dextran polymer, stable hydrogel systems were prepared 
that can be used at 37 ºC for several weeks. Moreover, the addition of PEG as a secondary 
crosslinker and modulation of the reaction temperature resulted in the formation mechanically 
tunable networks with a more rapid gelation time and the stable incorporation of albumin. Finally, 
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we validated Dex(VS)-sHSA-PEG hydrogels as a sustained drug delivery system and showed 
efficient doxorubicin-mediated cytotoxicity. These results highlight that by using human serum 
albumin as a drug carrier in such materials, a broad range of therapeutics can be loaded efficiently 
within them enabling their sustained release. Moreover, the biocompatible nature of all three 
hydrogel components and the tunability of the hydrogels with respect to their gelation times and 
properties open the door for their future widespread application in the biomedical domain. 
EXPERIMENTAL 
MATERIALS 
Dextran (Mn = 70 kDa), divinyl sulfone, human serum albumin (HSA) (fatty acid free), 2-
iminothiolane (2-IT), 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB), sodium hydroxide, sodium azide, 
hydrochloric acid (37%), poly(ethylene glycol) dithiol (PEG, Mw = 3.4 kDa), dimethyl sulfoxide 
(DMSO), and doxorubicin hydrochloride (DOX) were obtained from Sigma-Aldrich. Dextrans 
(Mn = 20 kDa, 150 kDa and 250 kDa) were purchased from Pharmacosmos. Dialysis membranes 
(MWCO = 3.5 - 5 kDa) were obtained from Spectrum Laboratories Inc. Dextran was dried in a 
vacuum oven (30 °C) before use. Phosphate buffered saline stock (1x) was obtained from the Cell 
Observatory of Leiden University. 24-well Corning® Transwell® polyester membrane cell culture 
inserts plate were purchased from Sigma. 
SYNTHESIS OF DEXTRAN-VINYL SULFONE CONJUGATES 
Dex(VS) was synthesized according to the method reported by Yu et al.51 In general, a 2 % (w/v) 
dextran solution (MW = 20, 70, 150 or 250 kDa, synthesis is described for 70 kDa as an example) 
was prepared by dissolving dextran (1 g, 14.3 µmol) in 0.1 M NaOH (50 mL). Divinyl sulfone (DVS) 
(0.778 mL, 7.75 mmol) was added to a vigorously stirred dextran solution at either 0 °C or room 
temperature for a specific time ranging from 0.5 - 5 min. The reaction was quenched using 5 M 
HCl adjusting the pH to 5 and the product was dialyzed against Milli-Q water 5 times over 3 days 
and lyophilized. 1H NMR recorded on a Bruker AV-400 (D2O, 400 MHz): δ 3.3–4.1 (m, dextran 
glucosidic protons), 4.97 (s, dextran anomeric proton), 6.3-6.5 ppm (m, -SO2CH=CH2), 6.9-7.0 (m, 
-SO2CH=CH2). The obtained Dex(VS)-polymers were further confirmed by 
1H NMR and 1H-13C 
HSQC 2D spectra spectra measured by a Bruker AV-400 spectrometer (Figure S1). 
The degree of substitution of the vinyl sulfone functionalized dextran polymer (Dex(VS)) is defined 
as the number of vinyl sulfone groups per 100 glucopyranose residues. The degree of substitution 
is calculated from the 1H NMR spectrum of Dex(VS) using the ratio: (100x)/(2y), in which x is the 
integral of vinyl sulfone protons (δ 6.3-6.5) and y is the integral of the anomeric proton of dextran 
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(δ 4.9). Therefore, the nomenclature of the various polymers consists of the molecular weight of 
the dextran used (e.g. Dex70k(VS6))and the degree of substitution of vinyl sulfone on the particular 
polymer (e.g. Dex70k(VS6)). A complete overview of the polymers synthesized in this work is 
shown below in Table 1. 
SYNTHESIS OF THIOLATED HUMAN SERUM ALBUMIN (SHSA) 
HSA (1 g) was dissolved in 50 mM sodium phosphate buffer (45 mL, pH 8, including 5 mM EDTA) 
and stirred at 0 °C in ice bath. To this an aqueous solution of 2-IT (104 mg, 5.2 mL) was added in 
a drop-wise manner. After 2 hours, the reaction mixture was dialyzed against 10 mM HEPES buffer 
(pH 7) three times over 24 hours and then against Milli-Q water three times over 2 days at 4 °C. 
Finally, sHSA was lyophilized and stored at -20 °C. 
The degree of thiolation of sHSA was quantified using an Ellman’s test.58, 59 In short, DTNB (2 
mM, 100 µL) and sHSA (2 mg, 200 µL) were mixed with sodium phosphate buffer (700 µL, 0.1M 
pH8) and incubated at room temperature for one hour. The formation of the yellow 2-nitro-5-
thiobenzoate anion (TNB2-) due to the presence of free thiols was quantified using UV-Vis 
spectroscopy at 412 nm using the molar extinction coefficient ε = 14150 M-1 and used to calculate 
the concentration of free thiol groups on the sHSA, which was found to be 2.7. 
GELATION PROTOCOL 
Dex(VS)-sHSA and Dex(VS)-sHSA-PEG hydrogels were prepared from independent solutions of 
Dex(VS), sHSA and PEG-dithiol dissolved in phosphate buffer saline. An example of the 
preparation of a Dex(VS)-sHSA-PEG hydrogel is described below. The same protocol applies to 
Dex(VS)-sHSA hydrogels only omitting the addition PEG. Molar ratios of the various constituents 
of the hydrogels used in this work are listed in Table 2. 
Generally, a sHSA solution (300 µL) was first mixed with a PEG solution (300 µL) at room 
temperature in a nitrogen atmosphere. When a clear solution was obtained, the Dex(VS) solution 
(300 µL) was added to the mixture at an equimolar ratio of the combined thiols to the vinyl sulfone 
groups and vortexed for 10 s, prior to standing at room temperature for gelation to occur. 
The vial tilting method was used to evaluate the gelation of the Dex(VS)-sHSA hydrogels by gently 
inverting the gelation mixtures every half hour. When the sample showed a lack of flow upon tilting 
the vial 180˚ for one minute, it was regarded as a gel and the time was recorded. 
OSCILLATORY RHEOLOGY 
A DHR-2 rheometer (TA Instruments) was used to measure the mechanical properties of 
hydrogels in oscillatory mode using a parallel plate geometry (25 mm diameter) at 25 °C or 37 °C. 
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The axial force was kept constant at 0.1 N and a water trap was applied to prevent sample 
evaporation during measurement. The precursor solutions of Dex(VS), sHSA and PEG were 
mixed thoroughly in an Eppendorf tube (gel samples shown in Table 2) in a 300 µL volume and 
loaded immediately onto the lower plate of the rheometer. The upper plate was lowered until the 
sample filled the gap (500 µm). Time sweep measurements were performed at an angular frequency 
of 6.28 rad s-1 and 0.05 % strain. The linear viscoelastic regime (LVR) for each material was 
determined by an amplitude sweep measurement from 0.01 to 100 % strain at an angular frequency 
of 6.28 rad s-1. Frequency sweep measurements were collected within the LVR from 12.56 to 0.1 
rad s-1 with 0.05 % strain. All experiments were performed in duplicate. 
SCANNING ELECTRON MICROSCOPY 
The morphologies of the hydrogels in the swollen state were observed by a JEOL 6330 Cryo Field 
Emission Scanning Electron Microscope from the General Instrumentation Facility at Radboud 
University (Nijmegen, The Netherlands). 5 µL of 7.5 w/v% Dex70k(VS6)-sHSA-PEG hydrogel 
was taken and injected into a hollow cylindrical sample holder and immediately flash frozen in 
liquid nitrogen. The sample was then inserted in the cold-stage of the SEM cyro-preparation 
chamber and cleaved to make a horizontal fracture plane. The water was sublimated during 15 
minutes and the fracture plane was coated with a thin gold-palladium layer and subsequently the 
sample is transferred into the SEM chamber, where it remained frozen during the imaging process. 
EQUILIBRIUM SWELLING 
Hydrogel samples (5.4 w/v% Dex70k(VS6)-sHSA, 10, 11.5 and 13 w/v% Dex70k(VS6)-sHSA-
PEG hydrogels) were prepared in phosphate buffer saline in a glass vial at room temperature and 
left standing overnight to gelate. Phosphate buffer saline (pH = 7.4) supplemented by 0.02 % NaN3 
(2 mL) was added on top of the formed hydrogel at 37 ˚C. At specific time points, the buffer was 
removed from the swollen hydrogel, weighed and fresh buffer was layered on top afterwards. When 
the weight of swollen hydrogel reached a plateau, the equilibrium swelling ratio (ESR) was 
calculated using equation 1. Where Ws is the swollen weight at equilibrium and Wd the dry weight 




   (1) 
GEL DEGRADATION 
Erosion of hydrogel samples (5.4 w/v% Dex70k(VS6)-sHSA, 10, 11.5 and 13 w/v% Dex70k(VS6)-
sHSA-PEG hydrogels) over time was assayed by quantifying the amount of albumin released from 
the network over a period of ~ 6 days. Hydrogel samples (200 µL) were made in phosphate buffer 
saline in a glass vial at room temperature and left to stand overnight. The hydrogels were layered 
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with phosphate buffer saline (containing 0.02% NaN3, pH = 7.4, 2 mL) and placed in an incubator 
at 37 ˚C. The buffer solution was removed after 24 hours for analysis and replenished with fresh 
buffer. Each withdrawn buffer solution was analyzed by fluorescence spectroscopy to determine 
the released albumin concentration. The excitation wavelength was set to 295 nm to prevent 
overlapping excitation of tyrosine residues and the emission spectrum was recorded in the range 
of 305 - 450 nm on a Tecan infinite M1000 fluorescence plate reader. The excitation and emission 
bandwidths were both 5 nm. Black Greiner 96-well plates were used. 5 w/v% Dex70k(VS6)-PEG 
hydrogels were also prepared with HSA lacking chemical modification (5 w/v%) at the same 
concentration as a control. 
CHEMOTHERAPEUTIC DRUG DELIVERY FROM DEX(VS)-SHSA-PEG 
HYDROGELS 
The ability of Dex(VS)-sHSA-PEG hydrogels to deliver therapeutic cargo was evaluated using 
doxorubicin hydrochloride (DOX) as a model drug. To prepare the drug loaded hydrogels, DOX 
(either 75 µg, 130 nmol or 150 µg, 260 nmol) was pre-mixed with 100 µL of a sHSA solution (15 
mg, 225 nmol) and incubated for 1 hour at 25 °C or 37 °C. Subsequently, 100 µL of a PEG (5.1 
mg, 1.5 µmol) solution was added, and the mixture was combined with 100 µL of a Dex(VS) 
polymer solution (10.8 mg, 154 nmol) to form a 0.5 or 1 mg/mL DOX-loaded 10 w/v% 
Dex70k(VS6)-sHSA-PEG gelation solution of which 200 µL was left to gelate overnight in an 
appropriate vessel. 
First, a drug release assay was performed. The DOX-loaded Dex(VS)-sHSA-PEG gels (200 µL) 
were layered with phosphate buffer saline (1 mL) and incubated at either 25 °C or 37 °C for 24 
hours. The supernatant buffer solution (800 µL) was collected and replaced with fresh phosphate 
buffer saline (800 µL) every 24 hours. The collected buffer solutions were analyzed by UV-Vis at 
480 nm to determine the concentration of DOX released by its molar extinction coefficient (ε = 
11 500 M-1 cm-1). All drug release experiments were performed in triplicate. 
MCF-7 cells were seeded in a 24-well plate at a concentration of 25 000 cells / well in full growth 
medium (500 µL). The cells were allowed to grow for 24 hours (37 °C, 5% CO2) before hydrogels 
(200 µL) prepared in Transwell® inserts with and without Doxorubicin (0.5 mg/mL) to assess cell 
death due to drug release and native gel toxicity. As a negative control cells were incubated for 
three days with a 1 µM solution of free Doxorubicin. The viability of the cells was assessed daily 
using an MTT assay in triplicate. The Transwell® inserts containing gels were removed and an 
MTT solution prepared in phosphate buffer saline (5 mg/mL, 20 µL) was added directly to the 
wells to be assayed. The cells were incubated for 4 hours with MTT to allow for the formation of 
formazan crystals. Subsequently, the medium was removed and the formazan crystals were 
dissolved in DMSO (500 µL) by gentle agitation. The amount of formazan formation was 
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quantified by UV-Vis spectroscopy using the absorbance at 570 nm. Cell viability was expressed 
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Figure S1. 1H NMR spectra in D2O: (a) unfunctionalized dextran, 20 kDa, (b) Dex20k-VS (DS=31.4) and (c) Dex20k-VS 





Figure S2. Oscillatory rheology time sweeps of the gelation processes of 10 w/v% Dex70k(VS6)-sHSA-PEG hydrogels (dash line) and 






ZEBRAFISH EMBRYO TOXICITY ASSAY USING A 
CYCLODEXTRIN-MODIFIED DEXTRAN-PEG 




High-throughput screening assays based on zebrafish embryos have been applied in toxicology and 
drug discovery studies. However, concerns over the predictive capacity for specific compounds, 
such as neurotoxic compounds, conducted by the zebrafish embryo toxicity assay have been raised 
because the uptake of compounds through the membranes of zebrafish embryos varies thereby 
affecting the observed toxicity. In this chapter, a drug carrier mediated zebrafish embryo toxicity 
assay was developed, which improves the uptake of the model drug valproate through the 
gastrointestinal tract. The polymeric drug carrier used in this study is obtained by crosslinking 
maleimide modified dextran with poly(ethylene glycol) dithiol, wherein cyclodextrins were 
conjugated to the dextran backbone to provide drug binding cavities. By applying this 
macromolecular drug carrier the sensitivity of the zebrafish embryo toxicity assay toward the model 









Comprehensive safety data is essential for industrial chemicals, biocides, food additives, 
pharmaceuticals and other commercial chemicals, thus a wide variety of toxicity assays have been 
developed over years, varying from in vitro cell-based assays to in vivo assessments in whole animal 
models.1 Typically, in vitro cell-based assays enable automated high-throughput screening of toxicity 
and are relatively cost-effective. However, in vitro cell-based models lack relevant whole-animal 
physiology thereby failing to fully resemble the complexities of in vivo models. To provide a better 
assessment, it would be optimal to evaluate results obtained from in vitro assays together with results 
obtained from in vivo assays in whole animal models such as rodents, dogs or monkeys. Considering 
the great number of compounds that need to be tested, ethical issues have been raised regarding 
the use of vertebrate animals in research and testing.2, 3 Therefore, alternative toxicity assays that 
can bridge the gap in this field between cell assays and whole animal assays are required.4-6 
To date, zebrafish (Danio rerio) embryos have been used predominantly in the fields of 
developmental biology, molecular genetics, toxicology and drug discovery.7-10 The zebrafish model 
provides several remarkable advantages including their small size, high fecundity, fast development 
and transparent body in early stage embryos, which allows high-throughput screening based for 
various applications.11-15 Moreover, zebrafish are sensitive to chemical exposure especially during 
early development.7, 16, 17 Exposure of zebrafish embryos to chemical compounds can be achieved 
by addition of the chemical of interest at a physiological dose to the embryos’ aquarium. Since 
embryonic development of zebrafish has been well characterized 18, 19 and the optically transparent 
embryos enable live observation under a light microscope, zebrafish embryos have become a 
promising model for developmental and reproductive toxicity screening,20, 21 bridging the gap 
between simple cell-based assays and biological validation in whole animals such as rodents. For 
example, zebrafish have been used as a model to screen the acute toxicity of organic compounds,22-
24 nanoparticles,25-28 various biomaterials29 and heavy metals.30-33 
However, regarding zebrafish embryo based toxicity assays concerns have been raised in their 
predictive capacity for specific compounds. Considering that organs of zebrafish embryos are not 
fully developed, ineffective uptake of certain molecules may result in false negative and/or 
unreliable results. It has been observed that fish embryos are relatively insensitive to neurotoxic 
compounds thereby failing to predict acute toxicity.34-35 For example, valproate (i.e. 2-n-
propylpentanoic acid) is an anti-epileptic drug traditionally used for the treatment of certain types 
of seizures. Although studies indicate that more adverse effects are observed in pregnancies with 
valproate exposure than other antiepileptic drugs, including fetal death and malformations26, the 
zebrafish embryo toxicity assay is rather non-sensitive to assess the toxicity of valproate. Zebrafish 
embryos exposed to valproate from 6 hpf (hours post-fertilization) to 5 dpf (days post-fertilization) 
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showed only moderate malformations when exposed to 1 mM valproate.24 In contrast, zebrafish 
embryos exposed to 0.4 mM valproate from 6 hpf to 4 dpf with daily solution changes followed 
by growth in the absence of valproate showed full mortality of the embryos.36, 37 Recent studies 
indicated that the ineffective uptake of valproate into zebrafish embryos may be due to the poor 
membrane permeability as well as metabolism of valproate, resulting in the observed weak toxicity 
of zebrafish embryos toward this drug.38 To improve the uptake efficiency of a variety of drugs, 
hydrophobic drug-hydrophilic polymer conjugates were tested in a toxicity assay using 7-dpf 
zebrafish embryos. This study showed a higher toxicity as compared to free drug.39 
Previously, injectable hydrogel systems were developed based on mono-thiolated β-cyclodextrins 
(MSCD) conjugated to maleimide-bearing dextran crosslinked with linear poly(ethylene glycol) 
dithiols (PEG-DT) resulting in macromolecular networks (Figure 1).40, 41 No severe phenotype 
abnormalities were observed upon injection of these Dex-CD/PEG drug carriers in zebrafish 
embryos. These drug loaded Dex-CD/PEG drug carriers are able to release the drugs in a sustained 
manner due to the reversible nature of the inclusion complexes between β-CD and drug molecules. 
In this work, the ability of Dex-CD/PEG polymeric drug carriers to mediate valproate uptake in 
zebrafish embryos was assessed. 
 
Figure 1. Schematic representation of the preparation of the Dex-CD/PEG drug carrier. 
RESULTS AND DISCUSSION 
INTERACTIONS BETWEEN VALPROATE AND Β-CYCLODEXTRIN 
Cyclodextrins have been studied and applied for drug delivery for decades due to their ability to 
form inclusion complexes with specific guest molecules.42 Cyclodextrins have a relatively 
hydrophilic, truncated cone-shaped exterior and a hydrophobic hollow tapered cavity, permitting 
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the formation of an inclusion complex with specific hydrophobic guest molecules enhancing their 
solubility, stability and bioavailability. First, the interaction between β-CD and valproate was 
studied to evaluate its ability to bind valproate. 
An equimolar mixture of β-CD and valproate was prepared by mixing β-CD and valproate in D2O 
and studied by 1H-NMR spectroscopy. Figure 2 shows the assignment of proton signals of the β-
CD/valproate mixture. Formation of the valproate/β-CD inclusion complex was shown by 2D 
NOESY NMR, cross-peaks revealed the interaction between H4, H4’ of valproate molecules and 
H3, H5 of β-CD (Figure 2C). Cross-peaks also revealed interaction between H2, H2’ of valproate 
molecules and H5 of β-CD. These correlations revealed that valproate indeed is bound inside the 
cavity of β-CD.43 
EXPOSURE OF DEXTRAN DERIVATIVES TO ZEBRAFISH EMBRYOS 
Fluorescent labelled dextrans are membrane impermeable and often used to study membrane 
fusion and endocytosis processes.44-46 Here, zebrafish embryos were exposed to rhodamine B 
labelled dextrans (dex-RhoB) in order to study the biodistribution and uptake of these soluble 
macromolecules. Fluorescent dex-RhoB was synthesized by esterification of some of the hydroxyl 
groups of dextran (Mw = 20 000 Da) with rhodamine B carboxylic acid. The obtained conjugate 
was purified using a Sephadex G-25 column to remove unreacted dye. Figure 3A shows the UV-
Vis spectra of dextran (1 mg/mL), rhodamine B (4 µM) and dex-RhoB (1 mg/mL) conjugates, 
respectively. The absorption maximum of rhodamine B redshifted 9 nm upon conjugation to 
dextran, in accordance with Zhang et al. who showed a similar shift upon esterification of the 
carboxyl acid group on the phenyl ring of rhodamine B.47 
Zebrafish embryo develops rapidly in the initial 100 hours post fertilization. At 72-hpf (i.e. 3-dpf) 
zebrafish embryo development is at a protruding-mouth stage.19 At this stage, the mouth of the 
embryo opens and protrudes anteriorly. Also, the liver and bile cells become visible at this time 
point. Thus, it becomes probable that zebrafish embryos are able to take up soluble 
(macro)molecules through the oral route from 3 dpf onwards. 
To evaluate the uptake of dextran derivatives, solutions of dextran (1 mg/mL) and dex-RhoB (1 
mg/mL) were prepared in egg water, and added to 3-dpf zebrafish embryos, while egg water 
without dextran was used as a control group. Twelve embryos were used in each group and the 
zebrafish were observed for 48 hours. The viability of zebrafish embryos was determined every 24 
hours and fluorescent microscopy images of zebrafish embryos of the dex-RhoB group were taken. 
During this 48-hour exposure period, no toxicity was observed and dex-RhoB was observed in the 
gut of zebrafish embryos. Dex-RhoB fluorescence appeared in the mouth region of embryos after 







Figure 2. (A) Molecular structure of β-CD and valproate. (B) Protons of the 1H NMR spectrum of the mixture of β-CD and valproate 
in D2O. (C) Cross-peaks between protons of the valproate and the β-CD moieties shown in the NOESY NMR spectrum of the 
valproate/β-CD complex in D2O.  
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(Figure 4B). This reveals that dextran and dextran derivatives are taken up by 3-dpf zebrafish 
embryos into the gastrointestinal tract via the oral route. However, 50% of the embryos showed 
no uptake of dex-RhoB after a 24-hour exposure period, which may be due to differences among 
the exact hatching time of each embryo in the testing group. Therefore, instead of 3-dpf zebrafish 
embryos, 4-dpf zebrafish embryos were used in the following studies in order to minimize the 
developmental differences among embryos and to facilitate oral uptake. 
 
Figure 3. (A) UV-vis spectra of dextran, rhodamine B and dex-RhoB conjugate in PBS buffer (pH 7.4). (B) Fluorescence excitation 
and emission spectra of 0.2 mg/mL dextran-RhoB in PBS buffer (pH 7.4) (λex = 563 nm, λem=580 nm). 
 
Figure 4. Optical and fluorescent images of 3-dpf zebrafish embryos exposed to 1 mg/mL dex-RhoB after (A) 24-hour exposure and 
(B) 48-hour exposure. 
EXPOSURE OF ZEBRAFISH EMBRYOS TO DEX-CD/PEG 
To utilize the valproate binding properties of β-CD and the oral uptake of dextran derivatives by 
zebrafish embryos, a previously reported Dex-CD/PEG polymeric drug carrier was applied to 
deliver valproate as a new zebrafish embryos toxicity assay.40 The synthesis of Dex-CD/PEG 
includes the following steps: (1) functionalization of dextran (Mw = 20 kDa) with maleimide 
sidegroups to obtain dextran-maleimides (Dex-Mal); (2) conjugation of mono-thiolated β-
cyclodextrins (MSCD) to 10% of the maleimide groups yielding dextran-cyclodextrin (Dex-CD); 
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and (3) mixing Dex-CD and linear PEG dithiols (PEG-DT, Mw = 3400 Da) aqueous solutions at 
an equimolar ratio of maleimide/thiol groups to obtain crosslinked Dex-CD/PEG polymeric drug 
carriers. Moreover, polymeric fluid could be obtained by decreasing the concentration of Dex-
CD/PEG below the gelling point,40 enabling their use in zebrafish toxicity assays. 
Dex-CD/PEG (DS[Mal]=7, 7 maleimide groups per 100 glucopyranose residues) showed to be 
viscoelastic fluid at 2.5 wt%. No linear viscoelastic region was found in a range of 0.1-100% strain 
in the oscillatory amplitude sweep of the 2.5 wt% Dex-CD/PEG sample (Figure 5). By increasing 
the oscillatory strain, the storage modulus of the 2.5 wt% Dex-CD/PEG sample dropped to be 
lower than its loss modulus, showing a cross-over point at 6% strain. No valid data was obtained 
from dynamic light scattering (DLS) measurements due to very high polydispersity, suggestive of 
the presence of large particles or aggregates in the sample. 
To investigate whether Dex-CD/PEG could be administered to 4-dpf zebrafish embryos via the 
oral route, N-(5-Fluoresceinyl)maleimide was conjugated to some of the thiols of PEG-DT (0.03 
mol%) prior to the addition of Dex-CD yielding fluorescein labelled Dex-CD/PEG (2.5 wt%). 
 
Figure 5. Oscillatory amplitude sweep of 2.5 wt% Dex-CD/PEG carriers from 0.1 to 100 rad/s with 1% strain at 25˚C. 
The fluorescent polymeric drug carrier was diluted with Danieau buffer (pH 7.2) and added a 96-
well plate containing one zebrafish embryo per well. Next zebrafish viability and malformation 
were studied using light microscopy. After a 24-hour exposure period, fluorescein labelled Dex-
CD/PEG was observed in the gut of all tested zebrafish embryos (Figure 6), indicating the efficient 
uptake of Dex-CD/PEG. Furthermore, by using 4-dpf embryos instead of 3-dpf embryos, the 
uptake of dextran-based carriers occurred already in the initial 24 hours of the exposure. After a 




Figure 6. Images of zebrafish embryos (5-dpf) taken by fluorescent microscopy after 24-hour exposure to egg water control group (left) and 
fluorescein labelled 2.5 wt% Dex-CD/PEG carriers group (right). 
presence of the Dex-CD/PEG revealing that this polymeric drug carrier is non-toxic to 4-dpf 
zebrafish embryos, which is in agreement with previous work.40 
Zebrafish embryo at the early stage of development (i.e. 0 - 120 hpf) mainly relies on endogenous 
feeding, thus the uptake of test compounds in a toxicity assay can only occur via diffusion through 
the surface of the zebrafish embryo.38, 48 However, after 3-dpf the larvae has completed most of its 
morphogenesis and mouths of 3-dpf zebrafish embryos have protruded.19, 49 The 4-dpf zebrafish 
embryos continue growing rapidly and the gut tube drops more ventrally which can be easily 
observed.19, 50 Belanger et al. reported that fluorescence appeared in the gut of 5-dpf zebrafish 
embryos after feeding the embryos with fluorescent protozoa which is indicative of exogenous 
feeding.51 The ability of exogenous feeding is considered as the transition from the eleuthero 
embryo to larva interval in fish development. Moreover, these zebrafish studies were conducted at 
25˚C and it is likely that at a warmer temperature the development of the zebrafish embryo will be 
accelerated.51 In this study fertilization and hatching of embryos was performed at 28.5 C, thus it 
is likely that 4-dpf zebrafish embryos already developed faster enabling uptake via the oral route. 
The location of the fluorescence in zebrafish embryos proves that the oral uptake of soluble 
polymers can occur during the transition from the eleuthero embryo to larva interval in zebrafish 
development (see Figure 4 and 6). 
DRUG CARRIER MEDIATED ZEBRAFISH EMBRYO TOXICITY ASSAY 
The uptake of relatively polar compounds such as valproate by diffusion through membranes is 
inefficient and malformations of zebrafish embryos (e.g. oedema, brain deformities, bent tail) were 
observed only when the zebrafish embryos were exposed to valproate at a concentration of 1 mM.36, 
38 Thus, to have a comparable toxicity evaluation, zebrafish embryo viability upon a 48-hour 
exposure to various concentrations of valproate (from 10 µM to 1 mM) was tested. When 4-dpf 
zebrafish embryos were exposed to 100 μM valproate, no obvious signs of toxicity were observed, 
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while at 500 μM malformations became apparent However, no mortality was observed at this high 
concentration. 
Next Dex-CD/PEG (2.5 wt%) loaded with valproate was prepared for the zebrafish embryo 
toxicity assay. For this, valproate (final concentration = 100 uM) was added in the Dex-CD solution 
prior to the addition of PEG-DT and kept overnight. Surprisingly, zebrafish embryo viabilty 
dropped to only 8 percent after a 48-hour exposure period and pericardial edema in zebrafish larvae 
were observed revealing valproate’s toxicity (see Figure 7B-E). 
 
Figure 7. Zebrafish embryos upon exposure to 100 μM valproate loaded 2.5% Dex-CD/PEG carriers: (A) normal zebrafish embryo; 
(B-E) zebrafish embryos with pericardial edema. 
In contrast, no death or malformation of embryos was observed in either the egg water control 
group, the 100 μM valproate group, or the 100 µM valproate mixed with 2.5 wt% Dex-CD/PEG 
group (Figure 8). Furthermore, no death or malformation of embryos was observed in 2.5 wt% 
Dex-CD/PEG carriers. Thus, the observed toxicity of 100 μM valproate encapsulated in Dex-
CD/PEG can only be attributed to the interaction between the 2.5 wt% Dex-CD/PEG carriers 
and valproate. This data strongly suggests that the valproate/CD host-guest complex within Dex-
CD/PEG plays a pivotal role, as evidenced by the efficient uptake and concomitant toxicity in this 
zebrafish embryo toxicity assay through the oral route. Most likely Dex-CD/PEG increases the 
internal concentration of the valproate compound, thereby changing the toxicokinetic profile of 
the valproate compound to zebrafish embryos. 
INFLUENCE OF DEX-CD/PEG COMPOSITIONS 
To study whether the composition of Dex-CD/PEG carriers influences the toxicity of the carriers 




Figure 8. Viability of zebrafish embryos after 48-hour exposure to the egg water (control group), 100 µM valproate, 100 µM valproate 
mixed with 2.5 wt% Dex-CD/PEG carriers, and 100 µM valproate loaded 2.5 wt% Dex-CD/PEG carriers respectively. 
carriers was varied. A library of Dex-CD/PEG carriers was synthesized in which the degrees of 
substitution of the applied Dex-Mal polymers (DS[Mal]) was varied. Table 1 provides an overview 
of compositions of prepared Dex-CD/PEG carriers. For the zebrafish embryos toxicity assay, the 
valproate concentration was kept constant and loaded into each drug carrier group prior to the 
crosslinking reaction between Dex-Mal and PEG-DT. The final concentration of valproate was 
100 μM. For each Dex-CD/PEG carrier, a control group without valproate was also exposed to 
4-dpf zebrafish embryos for 48 hours. The viability of zebrafish embryos was examined after a 48-
hour exposure period, providing information about the uptake efficiency of valproate by the 
zebrafish embryos. The viscosity of each Dex-CD/PEG carriers was measured by a U-tube 
viscometer to obtain its dynamic viscosity which is related to valproate delivery properties of the 
drug carrier. 
For Dex-CD/PEG carriers prepared with Dex-Mal4 (DS[Mal] of 4), no toxicity was observed after 
48 hours when the concentration was below 2 wt% (Figure 9). However, the viscosity of Dex-
CD/PEG carriers increased as a function of Dex-CD/PEG carriers concentration going from 0.5 
wt% to 2 wt%. At 3 wt%, the viability of zebrafish embryos dropped from 100% to 50% after a 
48-hour exposure period. At this concentration the liquid became too viscous to be measured with 
a U-tube viscometer. 
Similar trends were also observed in the group of Dex-CD/PEG carriers prepared with Dex-Mal7 
(DS[Mal] of 7) (Figure 9). After exposure for 48 hours the viability of zebrafish embryos maintained 
to be 100% for Dex-CD/PEG carriers having a concentration below 2 wt%, while the viscosity of 
Dex-CD/PEG carriers doubled when the concentration of Dex-CD/PEG carriers increased from  
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0.5 wt% 4 5 0.17 2.2 1 1.0990 100% 
1.0 wt% 4 10 0.33 4.4 1 1.4974 100% 
1.5 wt% 4 15 0.50 6.7 1 2.6666 100% 
2.0 wt% 4 20 0.67 8.9 1 6.2535 100% 
2.5 wt% 4 25 0.83 11.1 1 - 83.3% 
3.0 wt% 4 30 1.00 13.3 1 - 50% 
0.5 wt% 7 5 0.25 3.3 1 1.2376 100% 
0.75 wt% 7 7.5 0.37 5.0 1 1.2376 100% 
1.0 wt% 7 10 0.50 6.6 1 1.9683 100% 
1.5 wt% 7 15 0.75 9.9 1 2.6953 100% 
2.0 wt% 7 20 0.99 13.2 1 - 58.3% 
2.5 wt% 7 25 1.24 16.5 1 - 8% 
0.5 wt% 11 5 0.40 5.3 1 1.4829 100% 
0.75 wt% 11 7.5 0.60 8.0 1 2.4804 75% 
1.0 wt% 11 10 0.80 10.7 1 3.8541 66.7% 
 
0.5 wt% to 1.5 wt%. Upon increasing the concentration of Dex-CD/PEG carriers to 2 wt%, the 
viability of zebrafish embryos dropped from 100% to 58%. Analysis of the dynamic viscosity at 
these concentrations could not be determined. 
The group of Dex-CD/PEG carriers prepared with Dex-Mal11 (DS[Mal] of 11) showed a similar 
trend ) (Figure 9). When the concentration of Dex-CD/PEG carriers increased from 0.5 wt% to 
1.5 wt%, the viability of zebrafish embryos decreased from 100% to 67% after exposure for 48 




Figure 9. Viability of 4-dpf zebrafish embryos after 48-hour exposure to 100 µM valproate encapsulated in Dex-CD/PEG carriers 
prepared by Dex-Mal with (A) DS[Mal] of 5, (C) DS[Mal] of 7, and (E) DS[Mal] of 11. Dynamic viscosities of Dex-CD/PEG 
carriers prepared by Dex-Mal with (B) DS[Mal] of 5, (D) DS[Mal] of 7, and (F) DS[Mal] of 11.  
carriers in each group. For the control groups of each Dex-CD/PEG carrier without loading 
valproate, no death of the tested zebrafish embryos was observed. 
From these experiments, it became apparent that there is a correlation between the observed 
valproate toxicity and the viscosity of the Dex-CD/PEG carrier. Although the measured viscosity 
is not obtained for every Dex-CD/PEG carrier, it is well accepted that higher concentrations of 
functional groups from the precusors (such as Dex-Mal and PEG-DT) generate crosslinked 
systems with higher viscosity. When the viscosity of the applied Dex-CD/PEG carrier was too low, 
the loaded valproate rapidly released into the culture medium thus limited amount of valproate 
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could be taken up by zebrafish embryos together with the Dex-CD/PEG carriers. 
Regarding the influence of the DS[Mal], it was found that Dex-CD/PEG carriers prepared with 
higher DS[Mal] (such as DS[Mal]=11) were capable of affecting the valbility of tested zebrafish 
embryos at a lower viscosity. Since mono-thiolated β-CD molecules were conjugated to the Dex-
Mal polymers at 0.1 equivalent to the maleimide groups, Dex-CD/PEG carriers prepared with 
higher DS[Mal] have more β-CD moieties attached for valproate binding. As mentioned above, 
the same amount of valproate was loaded in each Dex-CD/PEG carriers to maintain a final 
concentration of 100 μM valproate, thus more β-CD moieties in the Dex-CD/PEG carriers may 
improve the drug delivery effiency during the toxicity assay. In other words, for Dex-CD/PEG 
carriers prepared at the same concentration, a higher DS[Mal] of applied Dex-Mal provides more 
binding sites for valproate delivery, thereby improving the uptake efficiency of valproate into the 
zebrafish embryos.  
Therefore, the composition of Dex-CD/PEG carrier affects the viability of zebrafish embryos 
exposed to the corresponding 100 μM valproate encapsulated in Dex-CD/PEG. Hence the uptake 
efficiency of valproate in the zebrafish embryo toxicity assay depends on the viscosity and the 
density of drug binding sites of Dex-CD/PEG carriers. 
CONCLUSIONS AND PERSPECTIVES 
In this work, we explored the potential of dextran based crosslinked drug carriers to control the 
observed toxicity of valproate in a zebrafish embryo toxicity assay. We showed that the Dex-
CD/PEG carriers can be internalized by 4-dpf zebrafish embryos into the gastrointestinal tract. 
Zebrafish embryos exposed to valproate encapsulated in Dex-CD/PEG became more sensitive 
toward the drug. Thus Dex-CD/PEG significantly improves the uptake of valproate in zebrafish 
embryos and should be applicable to any other drug that is able to form an inclusion complex with 
cyclodextrin. 
Furthermore the observed toxicity of valproate depends on the composition of the applied Dex-
CD/PEG carrier. It was shown that only polymeric carriers with sufficient viscosity and valproate 
binding sites can effectively improve oral uptake in a zebrafish embryo toxicity assay. However, 






Dextran (Mw = 20 000 Da) was purchased from Pharmacia (Upsala, Sweden) and stored in a 
vacuum oven at 30 ˚C. Maleimide modified dextrans (Dex-Mal) with different degree of 
substitutions were synthesized as described previously.52 Poly(ethylene glycol) dithiol (Mw = 3 400 
Da, PEG-SH), sodium valproate, N-(5-Fluoresceinyl)maleimide, Rhodamine B (RhoB), 1,1’-
carbonyldiimidazole (CDI), dimethylaminopyridine (DMAP), dimethyl sulfoxide (DMSO) were 
purchased from Sigma-Aldrich. Mono-thiolated β-cyclodextrin (MSCD) was provided by Ke 
Peng.40 Danieau buffer (pH=7.2) was obtained from the Biology department. 1H and 2D NOESY 
spectra were obtained in D2O using a Bruker DRX-400 (400 MHz) spectrometer. 
PREPARATION OF DRUG CARRIERS 
Dex-CD/PEG carriers were prepared following a previously published protocol.40 For example, 
to prepare 1 mL 2.5 wt% Dex-CD/PEG carriers (DS[Mal]=7), 1.3 mg MSCD (0.1 eq with respect 
to the maleimide groups) was added into 0.5 mL PBS buffer solution of Dex-Mal (25 mg, Mw = 20 
000 Da, DS[Mal]=7) and the resulted Dex-CD solution was vortexed for 5 minutes. Then 0.5 mL 
PBS buffer solution of PEG-DT (16.5 mg, 0.9 eq to the maleimide groups) was mixed with the 
Dex-CD solution by vortexing and kept at room temperature overnight. The final concentration 
of Dex-Mal in the resulting Dex-CD/PEG carriers was about 2.5 wt%. 
To prepare FITC labelled Dex-CD/PEG carriers, a 10 mg/mL stock solution of FITC was firstly 
prepared in DMSO. Taking the FITC labelled 2.5 wt% Dex-CD/PEG carriers for example, 12.5 
µL FITC stock solution (0.03 eq with respect to the thiol groups) was added into the 0.5 mL PBS 
buffer solution of PEG-DT (16.5 mg) prior to the crosslinking reaction. 
To prepare valproate loaded Dex-CD/PEG carriers, 100 mM valproate stock solution was 
prepared in Danieau buffer (pH 7.2). Droplets of 100 mM valproate stock solution were added to 
Dex-CD solution and incubated for 2 hours before the preparation of Dex-CD/PEG carriers. 
Taking the 100 µM valproate encapsulated 2.5 wt% Dex-CD/PEG carriers for example, 10 µL of 
the 100 mM valproate stock solution was added into 0.5 mL PBS buffer solution of Dex-Mal (25 
mg). The resulted valproate loaded Dex-CD solution was vortexed for 5 minutes and incubated 
for 2 hours. Then 0.5 mL PBS buffer solution of PEG-DT (16.5 mg, 0.9 eq to the maleimide 
groups) was mixed with the valproate loaded Dex-CD solution by vortexing and kept at room 





The mechanical properties of 2.5 wt% Dex-CD/PEG carriers (DS[Mal]=7) were measured on a 
DHR-2 rheometer (TA Instruments) at 25 °C using a parallel plate-plate geometry (40 mm 
diameter). 900 µL Dex-CD/PEG carriers were loaded on the bottom plate and the geometry was 
lowered to the gap distance of 700 µm. Time sweep measurements were performed to follow 
gelation process at a frequency of 1 rad s-1 with 1% strain. The linear viscoelastic regime (LVE) 
was determined for each sample using an amplitude sweep measurement at 1 rad s-1 from 0.1% to 
100% strain. Frequency sweep measurements were conducted from 100 to 0.1 rad s-1 with 1% 
strain in the linear viscoelastic regime. The mechanical properties of other Dex-CD/PEG carriers 
listed in Table 1 were measured by a U-tube viscometer to calculate the dynamic viscosity of each 
carrier. 
ZEBRAFISH EMBRYO TOXICITY ASSAY 
All zebrafish were handled in compliance with the local animal welfare regulations and maintained 
according to standard protocols (zfin.org). Larvae were raised in egg water (60 g/ml Instant Ocean 
sea salts) at 28.5 °C. All protocols adhered to the international guidelines specified by the EU 
Animal Protection Directive 2010/63/EU. 
96-well plates were applied for housing zebrafish embryos during the toxicity assay. In each well, 
one zebrafish embryo and 250 μL egg water containing the testing dose of valproate alone or 
encapsulated in the Dex-CD/PEG carriers were added. To prevent sample bias, embryos from 
collected clutches were pooled, then individual 4-dpf embryos were randomly assigned to 
individual wells of 96-well plates. Therefore, for each experiment, all embryos were taken from the 
same mating pairs. Both exposure methods used a total of 12 embryos per dose. Control embryos 
(exposed to egg water only) were included as references of normal embryonic development. These 
96-well plates were kept in the incubator at 28 ˚C and the mortality of treated and control embryos 
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CHEMICALLY CROSSLINKED POLYMER 





Giant Unilamellar Vesicles (GUVs) have become popular as cell membrane model systems for 
biophysical studies. However, preparation of GUVs is not trivial. The quality, size and yield 
strongly depends on their preparation method. Here we present a novel method for GUV growth 
using gentle hydration of a lipid film from a chemically crosslinked dextran–poly(ethylene glycol) 
hydrogel substrate, wherein the hydrogel was formed by the thiol-Michael addition reaction. 
Polymer and additive-free GUVs were prepared rapidly under physiological ionic strength 
conditions in high yield without the need of special equipment. By modulating the physicochemical 
properties of the hydrogels, the GUV growth can be controlled in terms of yield, size and size 
distribution. The influence of the molar ratio of thiols and maleimides functional groups, the 
molecular weight and structure of thiolated poly(ethylene glycol) and the degree of substitution of 
maleimide modified dextran on GUV formation was studied. Chemical reagents and/or 
biomacromolecules can be encapsulated during formations and the obtained GUVs can be used 
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Cell membranes, as the frontier between the cell and its environment, play an important role in 
cellular phenomena such as mass transfer, energy transformation and signal transduction.1, 2 Cell 
membranes are comprised of self-assembled lipid bilayers, hosting a variety of membrane proteins 
and multi-subunit assemblies. Due to their high degree of sophistication and functionality, cell 
membranes have long fascinated researchers in Physics, Chemistry and Biology. To study the 
properties of cell membranes, various simplified biomimetic models of cell membranes have been 
developed over the past one hundred years.2, 3 
Giant unilamellar vesicles (GUVs) are widely used model systems for investigating various 
properties of cell membranes,4-6 because they approximate the size and membrane curvature of 
living cells and offer the flexibility to visualize and probe biophysical phenomenon of one single 
vesicle under an optical microscope. GUVs are typically prepared by gentle hydration7 or the 
electroformation methods.8 The gentle hydration method usually involves evaporation of a lipid-
containing organic solvent on a glass substrate and subsequent exposure to a buffer solution results 
in vesicle formation. In order to form vesicles at a moderate ionic strength (200 mOsm/kg), there 
must be 10-20% negatively charged lipids in the lipid composition and a heating step is required to 
bring the lipid solution above its phase transition temperature. In some cases, it is also necessary 
to add monosaccharaides in the dry lipid film to promote lamellar repulsion.9 The main 
disadvantage of the gentle hydration method is the variable size and relatively low yield of produced 
vesicles and the gentle hydration method is not suitable for all lipid compositions. On the other 
hand, the electroformation method is the most widely used vesicle formation method and can 
provide a high GUV yield with a narrow size distribution.10 Lipid mixtures are able to swell and 
grow in non-electrolytic solutions when an electric field is applied. However, to prepare GUVs 
under high ionic strength conditions, higher electric field frequencies and longer hydration times 
are required leading to potential lipid hydrolysis and peroxidation.11, 12 
Recently, researchers have found that the traditional gentle hydration method can be significantly 
improved using a hydrogel film. Horger et al. demonstrated that by applying an agarose gel film on 
a glass slide, GUVs were formed when a lipid film was hydrated on this substrate under 
physiological conditions.13 However, GUV contamination occurred due to dissolution of agarose 
in the hydration process. Traces of agarose were found both inside and spanning the GUV 
membrane, which modified the mechanical properties and membrane permeability.14 Poly(vinyl 
alcohol) hydrogels were used as an alternative to prevent GUV contamination by the gel 
components, but a high yield of GUVs was only obtained in presence of sucrose.15 
To enable GUV formation under physiological conditions, we developed a chemically crosslinked 
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hydrogel matrix to be used as a substrate covalently anchored to a glass surface. The hydrogel 
network consists of dextran and poly(ethylene glycol) (PEG) polymers crosslinked via a thiol-
Michael addition reaction and anchored to a thiolated glass surface. Using this method, GUVs can 
be formed from various lipid compositions under additive-free, physiological ionic strength 
conditions. Moreover, we studied the influence of the physiochemical properties of the hydrogel 
with respect to the molar ratio of the thiol and maleimide functional groups, the molecular weight 
of thiolated PEG and the degree of substitution of both thiolated PEG and Dex-Mal on GUV 
formation. Dex-PEG hydrogels were characterized by oscillatory rheology, swelling experiments 
and cryo-SEM imaging. The yield and size distribution of formed GUVs were analyzed by the 
fluorescence microscopy and fluorescence activated cell sorting (FACS). Based on these results, we 
developed a chemically crosslinked hydrogel system for GUV growth under physiological 
conditions without artifacts intercalated or encapsulated within the membrane. Additionally, we 
found that modulation of the physicochemical properties of the Dex-PEG hydrogel resulted in the 
potential for control over GUV growth in terms of yield and size. 
RESULTS AND DISCUSSION 
HYDROGEL SYNTHESIS 
Dex-PEG hydrogels were prepared by reacting aqueous solutions of Dex-Mal and thiolated PEG 
(PEG-SH) using the thiol-Michael addition reaction (Scheme 1). Since no initiator or catalyst is 
required to facilitate the reaction, contamination of the GUVs or biomolecule-encapsulated GUVs 
formed using these hydrogel films is prevented. 
Oscillatory time sweeps were used to probe the rate of network formation and its final mechanical 
properties, while amplitude and frequency sweeps were used to confirm the formation of a 
chemically crosslinked network. Typically, solutions of 3.5% (w/v) Dex70k-Mal5.5 (Mw=70 kDa, 
DS[Mal]=5.5) and PEG2k-2SH (Mw=2 kDa, 2 thiol end groups) were loaded on the rheometer 
plate and the storage modulus (G’) and the loss modulus (G”) were followed as a function of time. 
Within a few seconds, G’ increased dramatically and became higher than G”, indicative of the 
formation of a viscoelastic material. Once a plateau in G’ was attained, amplitude and angular 
frequency sweeps were conducted. G’ and G” remained nearly constant with G’ being two orders 
of magnitude greater than G” in both amplitude and frequency sweeps, consistent with the 
formation of a chemically crosslinked network (Figure 1). 
In order to grow GUVs from these hydrogel films, a solution of Dex70k-Mal and thiolated PEG 
was drop-casted on a thiolated glass slide at 40 °C until a thin hydrogel layer was formed through 




Scheme 1. Molecular structures of (A) Dex-Mal and (B) PEG-SH (linear, 4 arms and 8 arms). (C) Formation of the Dex-PEG 
hydrogel by crosslinking Dex-Mal and PEG-SH. 
different combinations of polymer precursors resulted in distinct appearances of hydrogel films 
formed on the glass slides. Dex-PEG gels prepared from Dex70k-Mal with DS[Mal] of 2~4 
resulted in transparent and homogeneous layers on glass surfaces. In contrast, Dex70k-Mal with a 
DS[Mal] greater than 5 led to the formation of a inhomogeneous film. We found that the surface 
roughness affected the GUV yield and size (vide infra). Moreover, the hydrogel coated glass slides 
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were examined for their capacity to swell upon rehydration by their immersion in PBS buffer at 
room temperature. The swollen weight of hydrogels prepared by various DS[Mal] of Dex70k-Mal 
attached onto glass slides was measured over time. The weight of all swollen samples reached a 
plateau within an hour, suggestive of rapid swelling kinetics (Figure S1). 
 
Figure 1. Oscillatory rheology measurements of Dex-PEG hydrogels composed of 3.5% (w/v) Dex70k-Mal5.5 crosslinked with 
PEG2k-2SH at 25 ˚C. (A) Time sweep using 1% strain at 1 rad/s. (B) Amplitude sweep from 0.1 to 100 rad/s with 1% strain. 
(C) Angular frequency measurement from 0.1% to 100% strain at 1 rad/s. 
GIANT VESICLE PREPARATION USING CROSSLINKED DEX-PEG FILMS 
To evaluate the potential of the chemically crosslinked hydrogel for assisting GUV growth, several 
buffers and lipid compositions were tested for this purpose. 1% (w/v) Dex70k-Mal4 (Mw=70 kDa, 
DS[Mal]=4) and PEG3.4k-2SH (Mw=3.4 kDa, 2 thiol end groups) were mixed together to produce 
the gel layer for the following studies. 
Vesicle production in buffer systems of physiological ionic strength was first examined. The 
osmolality of phosphate buffered saline (PBS) and HEPES buffered saline (HBS) was 310 
mOsm/kg and 320 mOsm/kg, respectively, which are on par with buffers found and used in 
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biology and physiological fluids (300 mOsm/kg). For both buffers, free floating vesicles were 
obtained in high yield without any extra reagents or special requirements regarding the lipid 
composition. 
The capacity of Dex-PEG gel to promote GUV formation with various lipid compositions was 
subsequently assayed. Lipid compositions with different percentages of cholesterol (CH), 
negatively charged lipids (POPG and DOPS) and liquid ordered lipid phases (DPPC) were 
deposited on gel-coated glass slide (See Table 1) to yield vesicles as described earlier. In presence 
of CH (Table 1: a, b and h), free floating GUVs with a spherical morphology (Figure 2: A, B and 
F) were prepared in good yields in contrast to previous reports17 where the use of the gentle 
hydration method showed exclusive formation of tubular morphologies (POPC with 5–30% CH 
in HEPES). The content of anionic lipids was increased up to 50% using the Dex-PEG hydrogel 
method, which is in contrast to the gentle hydration methods where this value is kept below 10% 
to promote growth (Table 1: c, d and e). More specifically, in presence of relatively high percentage 
of POPG or DOPS, spherical vesicles were successfully formed in high yield by our method 
(Figure2: C, D and E). When using lipids that form liquid ordered lipid phases, it is known that 
 
Figure 2. Formation of GUVs from Dex-PEG hydrogel coated glass slides with various lipid compositions (scale bar: 10 µm). (A) 
90% POPC : 10% CH, (B) 80% POPC : 20% CH, (C) 90% POPC : 10% POPG, (D) 50% POPC : 50% POPG, (E) 90% 
POPC : 10% DOPS and (F) 50% DOPC : 25% DOPE : 25% CH. Reproduced from ref. [16].  
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lipid mixtures can undergo phase separation through phase coexistence of liquid ordered (Lo) and 
liquid disordered (Ld) phases.
18 Thus far, phase separated GUVs have only been formed under non-
physiological conditions (KCl, 50 mM).19 On our hydrogel matrices, phase-separated GUVs 
consisting of 30-50% DPPC were easily grown at 50 °C (Figure S2). Hence, we demonstrated that 
the Dex-PEG gel-assisted hydration method can successfully produce GUVs from different types 
of lipids showing its potential to enable their facile growth. 
Table 1. Lipid compositions examined for GUV growth on Dex-PEG at physiological ionic strength conditions (>300 mOsm/kg). 
No. Lipid composition (% mol) 
Buffer system 
PBS HBS 
a 90% POPC / 10% CH √ √ 
b 80% POPC / 20% CH √ √ 
c 90% POPC / 10% POPG √ √ 
d 50% POPC / 50% POPG √ √ 
e 90% POPC / 10% DOPS √ √ 
f 50% DOPC / 25% DOPE / 25% CH √ √ 
g 50% DOPC / 50% DPPC √ √ 
h 33.3% DOPC / 33.3% DPPC / 33.3% CH √ √ 
i 50% DOPC / 20% DOPE / 5% PEG2000-PE / 25% CH √ √ 
 
INFLUENCE OF THE HYDROGEL PHYSICOCHEMICAL PROPERTIES ON 
GUV PRODUCTION 
Since the pioneering work by Horger et al. on the gel-assisted hydration method for GUV growth,13 
few research groups have studied and improved this advanced technique with various types of 
gels.14, 15 The mechanism of giant vesicle formation via this method, especially the role of the 
hydrogel films, is however still unclear. According to Horger et al., the swelling of the hydrogel film 
is a key step in the formation of the lipid lamellae, the growth of liposomes and their fusion.13 
Because the degree of hydrogel swelling strongly depend on the crosslinking density (ρx) of the 
network,20 we hypothesized that the production of GUVs could be controlled by the polymeric 
structure of Dex-PEG hydrogels. Starting from the initially developed Dex-PEG gel film 
composition for GUV formation (hydrogel prepared from 1% Dex70k-Mal4 and PEG3.4k-2SH 
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at equimolar thiol to maleimide), we modulated the physicochemical properties of Dex-PEG 
hydrogels using three parameters: the molar ratio of thiol to maleimide (MR[SH:Mal]), the 
molecular weight and architecture of thiolated PEG, and the degree of substitution of the 
maleimide modified dextran (DS[Mal]). The obtained GUVs were analyzed by fluorescence 
microscopy and the fluorescence-activated cell sorting (FACS). To gain insight into the effect of 
these three factors on GUV production, we further examined the difference in the network 
properties of the hydrogels using oscillatory rheology, swelling experiments and cryo-SEM imaging. 
THIOL-MALEIMIDE MOLAR RATIO 
To study the effect of the molar ratio of thiol to maleimide groups (MR[SH:Mal]), Dex70k-Mal4 
was crosslinked with PEG2k-2SH at a molar ratio of thiol to maleimide of 0.5, 0.75, 1 and 1.25. In 
these experiments, the molar concentration of maleimides was kept at 8 mM while the molar 
concentration of thiols was varied. 
The gelation kinetics of Dex-PEG hydrogels (3.5%, w/v) with 4 different SH:Mal ratios were 
followed by oscillatory rheology using time sweep measurements. Significant differences in gel 
formation kinetics and plateau moduli were observed (Figure 3A). When the molar ratio of SH:Mal 
was decreased from 1 to 0.75, the Dex-PEG hydrogel formed more slowly reaching a lower plateau 
modulus (260 Pa). When the molar ratio of SH:Mal was further decreased to 0.5, the gelation time 
of Dex-PEG hydrogels was two times slower in comparison to the 1:1 sample with final storage 
modulus one order of magnitude lower (20 Pa). When the molar ratio of SH:Mal was increased to 
1.25, the gelation of Dex-PEG hydrogels proceeded faster than other three samples, however the 
final storage modulus did not exceed samples prepared with MR[SH:Mal] of 1. The formation of 
viscoelastic materials by all samples was confirmed by amplitude and angular frequency sweeps. 
The equilibrium mass swelling ratio (q) of different hydrogel systems with different molar ratios of 
thiol to maleimide were compared. As shown in Figure 3B, the value of q increased when the 
hydrogel formulation departed from a 1:1 stoichiometry. For Dex-PEG hydrogels prepared with a 
large excess of maleimide groups (0.5 molar ratio) the greatest amount of swelling is observed with 
a two-fold increase in q. 
Combining the results of the rheological and swelling measurements, modulation of the molar ratio 
of thiol to maleimide groups can result in significant changes in hydrogel physicochemical 
properties in terms of mechanical strength and swelling behavior. These properties are influenced 
by the crosslinking density (ρx) of the network. When one of the functional groups is in excess a 
network with fewer crosslinks is obtained, resulting in lower storage moduli and higher equilibrium 
swelling ratios. This trend is on par with a previously reported polymeric hydrogel system 
synthesized by the azide-alkyne click reaction.21 The stoichiometric imbalance of functional groups 
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in the Dex-PEG system may promote the formation of closed loops, which is formed by thiols on 
the same PEG chain of the PEG-SH crosslinker reacted to maleimides on the same Dex-Mal chain. 
These closed loops, called primary cycles, do not connect to the crosslinked network but only 
dangle within it, decreasing the hydrogel crosslinking density resulting in spatial inhomogeneity of 
hydrogel networks.22 
 
Figure 3. The effect of the thiol to maleimide molar ratio in the Dex-PEG hydrogel composed of 3.5% (w/v) Dex70k-Mal4 and 
PEG2k-2SH on (A) the gelation kinetics and mechanical strength, (B) the equilibrium swelling ratio. (C) The size distribution of 
generated GUVs (lipid composition: 50% DOPC : 25% DOPE : 25% CH, wherein Dex-PEG hydrogel films for the hydration 
process were prepared by 1% (w/v) Dex70k-Mal4 and PEG2k-2SH with a molar ratio of thiol to maleimide at 0.75, 0.5, 1 and 
1.25). Reproduced from ref. [16, 23]. 
Hydrogel films were prepared from 1% (w/v) Dex70k-Mal4 and PEG2k-2SH with a molar ratio 
of thiol to maleimide of 0.5, 0.75 and 1 and were attached to glass slides for GUV formation. With 
a molar ratio of thiol to maleimide of 1, a very narrow size distribution of GUVs were obtained 
with an average size of 15 µm. When the hydrogel film departed from a 1:1 stoichiometry, the 
GUV size distribution broadened (Figure 3C) and the value of the average peak size turned greater. 
This observation confirms that the size distribution and the diameter of obtained GUVs by gel-
assisted hydration method is related to the polymeric structure of Dex-PEG hydrogels. On the 
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other hand, decreasing the molar ratio of thiol to maleimide of the gel network led to the formation 
of a more inhomogeneous network with the formation of GUVs (50 – 100 µm) that were larger 
and more polydisperse in size. 
PEG MOLECULAR WEIGHT AND ARCHITECTURE 
To study the effect of crosslinker architecture and size, five different thiolated PEG (PEG-SH) 
crosslinkers (Scheme 1B and Table 2) were reacted with 3.5% (w/v) Dex70k-Mal4 at a 1:1 molar 
ratio of thiol to maleimide in PBS buffer. By oscillatory rheology, more rapid gelation kinetics and 
a higher mechanical strength were observed for hydrogels prepared from thiolated PEG with a 
higher molecular weight (Figure 4A). By increasing the Mw of the linear PEG-dithiols from 2 kDa 
to 10 kDa (i.e. PEG2k-2SH and PEG10k-2SH), the storage modulus of the Dex-PEG hydrogels 
increased one order of magnitude. Hydrogels prepared from PEG10k-SH (Mw=10 kDa) with a 
non-linear architecture and an increased number of functional groups provided a more complicated 
trend. Compared to PEG10k-2SH (Mw=10 kDa, 2 thiol-ending groups), PEG10k-4SH (Mw=10 
kDa, 4 thiol ending groups) increased the gelation rate and improved the mechanical strength of 
the obtained Dex-PEG hydrogel. However, the use of PEG10k-8SH (Mw=10 kDa, 8 thiol-ending 
groups) resulted in a lower storage modulus in comparison to PEG10k-4SH. 
Table 2. Thiol functionalized PEGs used to prepare Dex-PEG hydrogels. 
Sample Molecular weight SH per molecule 
PEG2k-2SH 2 kDa 2 
PEG3.4k-2SH 3.4 kDa 2 
PEG10k-2SH 10 kDa 2 
PEG10k-4SH 10 kDa 4 
PEG10k-8SH 10 kDa 8 
 
This observation was in accordance with results of the viscosity measurement performed on 
mixtures composed of 0.5% (w/v) Dex70k-Mal2.5 and various thiolated PEG (Figure S3). 
Crosslinked polymer samples containing the 4-arm PEG10k-4SH showed the highest dynamic 
viscosity, while similar values were obtained from the 8-arm PEG10k-8SH and the linear PEG-
2SH. Equilibrium swelling measurements displayed a similar trend to the oscillatory rheology data 
after reaction of Dex70k-Mal4 with various thiolated PEG (Figure 4B). By increasing the molecular 
weight of the linear PEG-2SH molecules (i.e. PEG2k-2SH, PEG3.4k-2SH and PEG10k-2SH), the 
equilibrium mass swelling ratio (q) of obtained hydrogels decreased. When the molecular weight of 
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the linear PEG-2SH polymer increased four-fold, q decreased 54%. Conversely, when the 
molecular weight of PEG-SH was maintained at 10 kDa, q increased with its modulation of its 
architecture. In the case of the 8-arm PEG10k-8SH, a 68% increase of q was recorded in 
comparison to the linear PEG variant (PEG10k-2SH). 
 
Figure 4. Effect of molecular weight and architecture of various thiolated PEGs on (A) the gelation process and the mechanical strength 
and (B) the equilibrium swelling ratio of Dex-PEG hydrogels. Hydrogels were prepared by reacting 3.5% (w/v) Dex70k-Mal4 with 
various thiolated PEG at a MR[SH:Mal] of 1 in PBS. Thiolated PEGs used to prepare Dex-PEG hydrogels: PEG2k-2SH (black), 
PEG3.4k-2SH (red), PEG10k-2SH (blue), PEG10k-4SH (yellow) and PEG10k-8SH (purple). Reproduced from ref. [23]. 
Cryo-SEM images of the Dex-PEG hydrogel films prepared using the various types of PEG-SH 
crosslinkers provided insight into their microstructure (Figure 5). For linear PEG-2SH with the 
lowest molecular weight (PEG2k-2SH), the porous structure was discontinuous. On the other hand, 
hydrogels prepared with PEG3.4k-2SH, PEG10k-4SH or PEG10k-8SH presented a more 
homogeneous microstructure having interconnected pores similar to honeycombs. 
The experimental results described above show the molecular weight and the architecture of the 
thiolated PEG precursor also strongly influence the effective crosslinking density of the network. 
As mentioned earlier, the formation of inhomogeneities in the network is strongly related to the 
presence of primary cycles and other non-idealities formed during the gelation process precluding 
effective crosslinks from forming. Moreover, according to a study by Elliott, the formation of 
primary cycles in the polymeric network can be lessened by increasing the size of the crosslinking 
agent and the precursor concentration.24 Similarly, Metters reported that decreasing the crosslinker 
concentration and functionality generated more non-idealities in the network.22 It became evident 
that we also encountered a similar phenomenon at low concentrations of precursors when 
preparing the thin hydrogel films for GUV formation. The steric accessibility of the functional 
groups and kinetics of the thiol-maleimide addition reaction play a significant role in formation of 
the network. After one end of the linear PEG-2SH is chemically ligated to Dex-Mal, the other 




Figure 5. Cryo-SEM images of Dex-PEG hydrogels prepared by 1% (w/v) Dex70k-Mal4 crosslinked to various PEG-SH. (A) 
PEG2k-2SH, (B) PEG3.4k-2SH, (C) PEG10k-4SH and (D) PEG10k-8SH. Scale bar: 1 µm. Reproduced from ref. [23]. 
molecular weight, such as PEG2k-2SH, the second thiol group is more likely to react with a 
maleimide group on the same Dex-Mal chain or remain unreacted due to its short chain length, 
thus generating primary cycles and other inhomogeneities in the network. The effect of the 
polymeric architecture of thiolated PEG on hydrogel properties can be explained by the same 
hypothesis. In comparison to the linear PEG10k-2SH and the 4-arm PEG10k-4SH, the size of 
PEG10k-8SH is more compact, thus the accessibility of reactive thiols is restricted. Therefore, it is 
reasonable that hydrogels prepared with PEG10k-8SH display lower crosslinking density and, thus 
weaker mechanical properties and higher equilibrium swelling ratios than that of hydrogels 
prepared with PEG10k-2SH and PEG10k-4SH. In summary, polymeric networks of Dex-PEG 
hydrogels show strong dependence on the molecular weight and the architecture of the reactive 
PEG-SH polymers and, therefore the design of the hydrogel system is important in order to 
maximize GUV growth. Based on the effect of the molecular weight and architecture of PEG-SH 
on the formation of the hydrogel networks, films of various samples were prepared to study their 
influence on GUV formation. Two different lipid compositions, 75 mol% POPC : 20 mol% 
cholesterol : 5 mol% PEG2000-PE and 80 mol% POPC : 20 mol% cholesterol, were used to 
prepare GUVs and the yields of GUVs were quantified by FACS (Figure 6A). It was found that 
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hydrogel films made from 1% Dex70Mal4 and PEG10k-4SH resulted in the lowest yield of GUVs 
for both lipid compositions. Considering PEG10k-4SH preformed a much lower equilibrium mass 
swelling ratio than other types of thiolated PEG, this result indicates that the swelling of Dex-PEG 
hydrogel film is crucial to the formation of GUVs during the hydration of the lipid and hydrogel 
film. In contrast, although hydrogels made weak mechanical property, relatively high yields of 
GUVs were obtained. Thus a higher equilibrium mass swelling ratio facilitates GUV production. 
 
Figure 6. Yields of GUVs produced on Dex-PEG hydrogel films composed of (A) 1% (w/v) Dex70k-Mal4 and various thiolated 
PEG (PEG2k-2SH, PEG3.4k-2SH, PEG10k-4SH and PEG10k-8SH) at an equimolar ratio of thiol to maleimide; (B) 1% 
(w/v) Dex70k-Mal with different DS[Mal] (Dex70k-Mal2.5, Dex70k-Mal4, Dex70k-Mal5.5 and Dex70k-Mal13) and 
PEG3.4k-2SH at an equimolar ratio of thiol to maleimide. Line patterned bars represent GUVs with a lipid composition of 75 mol% 
POPC : 20 mol% cholesterol : 5 mol% PEG2000-PE. Cross-hatched bars represent GUVs with a lipid composition of 80 mol% 
POPC : 20 mol% cholesterol. Reproduced from ref. [16, 23]. 
MODULATION OF THE DEGREE OF SUBSTITUTION OF THE DEX-MAL POLYMER 
The effect of the degree of substitution of maleimide (DS[Mal]) of the Dex-Mal polymer on the 
physiochemical properties of Dex-PEG gels was examined using PEG2k-2SH crosslinked to 
Dex70k-Mal with various degree of substitution (DS[Mal]=4, 5.5 and 9) at a stoichiometric ratio 
of thiols to maleimides in PBS. It should be noticed that the set-up of hydrogel systems prepared 
from Dex-Mal with different DS[Mal] is crucial to the resulting trend, which will be discussed 
below in detail. 
3.5% (w/v) Dex70k-Mal4, Dex70k-Mal5.5 and Dex70k-Mal9 were crosslinked to PEG2k-2SH 
respectively and measured by oscillatory rheology. Dex70k-Mal with higher DS[Mal] displayed 
faster gelation process and resulted in stronger hydrogels (Figure 7A). The oscillation time sweep 




Figure 7. Oscillatory rheology time sweep profiles of Dex-PEG hydrogels prepared by (A) 3.5% (w/v) Dex70k-Mal crosslinked to 
PEG2k-2SH wherein Dex70k-Mal4, Dex70k-Mal5.5 and Dex70k-Mal9 were used respectively; (B) 1% and 3.5% (w/v) 
Dex70k-Mal9 crosslinked to PEG2k-2SH; (C) 1.1% (w/v) PEG2k-2SH crosslinked to Dex70k-Mal wherein Dex70k-Mal4, 
Dex70k-Mal5.5 and Dex70k-Mal9 were used respectively; (D) The equilibrium swelling ratio of hydrogels prepared using 1.1% (w/v) 
PEG2k-2SH and Dex70k-Mal wherein Dex70k-Mal4, Dex70k-Mal5.5 and Dex70k-Mal9 were used respectively. The molar 
ratio of thiol to maleimide was kept at 1 in all samples. 
of the corresponding hydrogel. However, the influence of the DS[Mal] of Dex-Mal polymers 
cannot be assessed due to different functional group concentrations of these hydrogel systems. In 
fact, when the concentration of Dex-Mal in all three hydrogel systems (DS[Mal]=4, 5.5 and 9) was 
kept at 3.5% (w/v), different numbers of maleimide groups per dextran chain led to various 
concentrations of maleimide groups in each system. The observed trend (Figure 7A) is probable 
caused by the functional group concentration instead of the architecture of the Dex-Mal polymer. 
To verify this, hydrogels composed of 2% (w/v) Dex70k-Mal9 crosslinked to PEG2k-2SH were 
prepared and measured by oscillatory rheology (Figure 7B). As shown in Figure 7B, the gelation 
was slowed down and the final storage modulus of 2% gels was one order of magnitude smaller 
than that of 3.5% gels. Also, high similarity in oscillation time sweep curves was observed between 
the Dex-PEG gel prepared from 2% Dex70k-Mal9 and the Dex-PEG gel prepared from 3.5% 
Dex70k-Mal4. These results showed that the observed trend in Figure 7A may be dominated by 
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the concentration of maleimide, making it difficult to assess the influence of DS[Mal] on the 
resulting hydrogel properties. 
Therefore the concentration of PEG2k-2SH was maintained to 1.2% for the preparation of 
1%Dex-PEG hydrogels using Dex70k-Mal4, Dex70k-Mal5.5 and Dex70k-Mal9 respectively at an 
equimolar ratio of thiol to maleimide. The concentration of Dex-Mal in each hydrogel system was 
not the same, Dex70k-Mal4 (5.1%), Dex70k-Mal5.5 (3.5%) and Dex70k-Mal9 (1%). Figure 7C 
shows that hydrogels prepared from Dex70k-Mal with a higher DS[Mal] displayed a slower gelation 
process resulting in a weaker hydrogel. When the DS[Mal] of Dex-Mal increased from 4 to 9, the 
gelation process was retarded and the final storage modulus of resulting hydrogels decreased by 
one order of magnitude. The swelling experiments also revealed that the equilibrium mass swelling 
ratio (q) of hydrogels doubled when the DS[Mal] of Dex-Mal increased from 4 to 9 (Figure 7D). 
As the viscoelastic property of dextran solution is nearly independent of dextran concentration at 
such a low concentration of dextran (below 5%), any obvious change in the oscillatory rheology 
and swelling experiments is due to the DS[Mal] rather than the concentration of Dex-Mal. Thus 
these results indicate that hydrogels prepared from Dex-Mal with higher DS[Mal] have a lower 
effective crosslinking density. 
Cryo-SEM images of Dex-PEG hydrogels prepared by 1% Dex70k-Mal with various DS[Mal] 
(from 4 to 13) and PEG3.4k-2SH displayed differences in the hydrogel microstructure (Figure 8). 
For the sample prepared from Dex70k-Mal4 and Dex70k-Mal5.5, multiple layers of continuous 
pores were observed. The pore size seemed to increase with the DS[Mal] of the applied Dex-Mal. 
For the sample prepared from Dex70k-Mal4 an average pore size around 200 nm was observed. 
For the sample prepared from Dex70k-Mal5.5, an average pore size around 1 µm was observed. 
However, a further increase of the DS[Mal] to 9 led to the formation of inhomogeneous network 
(Figure 8C). When Dex70k-Mal13 was used, the sample presented a poorly connected structure 
lacking well defined pores (Figure 8D).  
Taken together, too high DS[Mal] of Dex-Mal may reduce the effective crosslinking density of 
prepared hydrogels. For example, when the DS[Mal] of Dex-Mal increases from 4 to 9, the amount 
of maleimide groups on each dextran polymer chain increases from 17 to 39 (Table 3), thus too 
many maleimide functional groups are substituted on the same polymer chain. In the case of 
applying Dex70k-Mal9 (DS[Mal]=9), once one of these maleimide groups on the dextran chain 
reacts to one thiol group of the thiolated PEG, the accessibility of other maleimide groups on the 
same dextran chain decreases. For each maleimide group on the same dextran chain, the probability 
to be reacted to different thiolated PEG also decreases. Thus using Dex-Mal with a higher DS[Mal] 
for Dex-PEG hydrogel preparation may lead to a drop of the number of effective crosslinks. 




Figure 8. Cryo-SEM images of Dex-PEG hydrogels prepared from 1% (w/v) (A) Dex70k-Mal4, (B) Dex70k-Mal5.5, (C) 
Dex70k-Mal9 and (D) Dex70k-Mal13 crosslinked to PEG3.4k-2SH. An equimolar ratio of thiol to maleimide was maintained in 
all samples. Scale bar: 1 µm. Reproduced from ref. [23]. 
Table 3. List of prepared Dex-Mal polymers with increasing degree of substitution. 
Number of maleimide groups on dextran 
Sample per 100 glucopyranose units (DS[Mal]) per dextran chain 
Dex70k-Mal2.5 2.5 10.8 
Dex70k-Mal4 4 17.3 
Dex70k-Mal5.5 5.5 23.8 
Dex70k-Mal9 9 38.9 
Dex70k-Mal13 13 54.9 
 
compact conformation of the Dex-Mal polymer in the solution. Such compact conformation may 
hinder part of the maleimide groups to react with the thiolated PEG. 
The influence of the DS[Mal] of Dex-Mal on the yield of GUV production was investigated using 
Dex-PEG hydrogel films prepared from various Dex70k-Mal (Dex70k-Mal2.5, Dex70k-Mal4, 
Dex70k-Mal5.5 and Dex70k-Mal13) and PEG3.4k-2SH at an equimolar ratio of thiol to maleimide. 
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It was found that the hydrogel films prepared from Dex70Mal4 resulted in the lowest yield of 
GUVs while the hydrogel films prepared from Dex70Mal13 resulted in the highest yield of GUVs. 
Such results are similar to the observation discussed in the above section related to the type of 
thiolated PEG. It seems that hydrogel films having relatively high equilibrium mass swelling ratios 
assist the formation of GUVs more efficiently during the hydration. 
In summary, the generation of GUVs depends on the physicochemical properties of the hydrogel 
films in the gel-assisted hydration method. Swelling properties of the hydrogel film, such as the 
equilibrium swelling ratio, influence on the yield of GUVs. As the swelling process of the hydrogel 
film influences the hydration of the lipid, interactions between lipids and the hydrophilic 
environment of the hydrogel film is also important for the GUV formation. 
CONCLUSION 
We developed a chemically crosslinked Dex-PEG hydrogel to improve the GUV growth method 
using gentle hydration. Polymer and additive-free GUVs can be made rapidly under physiological 
ionic strength conditions in high yield without any special equipment. This approach makes it 
possible to prepare GUVs in PBS from various lipid compositions showing important advantages 
for certain lipid compositions that are otherwise difficult for vesicle formation. 
Dex-PEG hydrogels are prepared by mixing two functionalized hydrophilic polymers in aqueous 
buffer. Compared to physical gels, the gelation of the covalent Dex-PEG hydrogel system proceeds 
rapidly to form stable hydrogels with a controllable structure. The GUVs production was 
systematically investigated by controlling the molar ratio of the thiol and maleimide functional 
groups, the molecular weight of thiolated PEG and the architecture of both thiolated PEG and 
Dex-Mal. We found that to produce GUVs in high yield, it is essential for Dex-PEG gel films to 
have a relatively high equilibrium swelling ratio. These hydrogel films may promote the interaction 
between the lipid components and hydrophilic polymeric network, which is likely the key factor 
for successful GUV formation. 
We have explored the Dex-PEG hydrogel film-assisted hydration method for encapsulation of 
chemical reagents, biomacromolecules and even polymersomes.23 This simple and versatile 
approach has facilitated the visualization and quantification of transmembrane activities25 and the 
study of membrane proteins. We anticipate that this method can be useful to research areas such 





Cholesterol (CH), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-
palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) (POPG), 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) 
(PEG2000-PE), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B 
sulfonyl) (ammonium salt) (PE-LR) were purchased from Avanti Polar Lipids. 1,2-Dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC), maleic anhydride, p-toluene sulfonic acid monohydrate (PTSA) 
4-nitrophenyl disulfide, 4-(dimethylamino) pyridine (DMAP), dextran (70 kDa), N,N'-
diisopropylcarbodiimide (DIC), dimethyl sulfoxide (DMSO), poly(ethylene glycol) dithiols (Mw=3.4 
kDa) were purchased from Sigma-Aldrich. Poly(ethylene glycol) dithiols (Mw=2 kDa, Mw=10 kDa) 
were purchased from NANOCS (USA), 4-arm poly(ethylene glycol) thiols and 8-arm poly(ethylene 
glycol) thiols (Mw=10 kDa) were purchased from Jenkem Technology (USA). Phosphate buffered 
saline (PBS) was composed of 150 mM NaCl, 15 mM K2HPO4 and 5 mM KH2PO4. HEPES 
buffered saline (HBS) was composed of 150 mM KCl and 20 mM HEPES. 
Dextran was dried in a vacuum oven (30 °C) and DMSO was dried over 4Å molecular sieves before 
use. 3-maleimidopropionic acid and 4-(dimethylamino)pyridinium 4-toluenesulfonate (DPTS) were 
synthesized as previously reported.26, 27 Dialysis membranes (MWCO 3.5-5 kDa) were obtained 
from Spectrum Laboratories Inc. 
SYNTHESIS OF DEX-MAL  
Dex-Mal was synthesized by DIC mediated esterification of the hydroxyl groups of dextran with 
N-maleoyl-β-alanine. Briefly, N-maleoyl-β-alanine (313 mg, 1 eq.), DPTS (86.8 mg, 0.15 eq.) and 
DIC (434.9 µL, 1.5 eq.) were dissolved in anhydrous DMSO (15 mL). The mixture was stirred at 
room temperature for two hours, followed by the addition of a dextran solution in DMSO (15 mL). 
After stirring overnight at room temperature, the formed N, N’-dialkylurea was removed by 
filtration and the crude product was obtained by precipitation in cold isopropanol. The precipitate 
was dissolved in water and dialyzed against Milli-Q water five times over two days and subsequently 
lyophilized. 1H NMR (400 MHz, D2O): δ 3.3-4.0 (m, dextran glucopyranosyl ring protons), 4.9 (s, 
dextran anomeric proton), 6.8 (s, maleimide). 
The degree of substitution of Dex-Mal (DS[Mal]) is defined as the number of maleimide groups 
per 100 glucopyranose residues of dextran, which was calculated from the 1H NMR spectra based 
on the protons of the maleimides (δ 6.8) and the anomeric proton (δ 4.9). The DS[Mal] of Dex-
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Mal was controlled by the molar ratio between dextran and N-Maleoyl-β-alanine. 
DEX-PEG HYDROGELS PREPARATION 
Dex-Mal and thiolated PEG were dissolved in PBS individually and then mixed together using a 
pipette to prepare the hydrogel samples. Compositions of the Dex-PEG hydrogel are shown below 
(Table 4). 
Table 4. Composition of Dex-PEG hydrogels. 
Gel conc. 
(w/v) 











SH:Mal Volume (mL) 
1.0% 4 10.0 linear 3400 3.9 1 1 
        
3.5% 4 35.6 linear 2000 8.2 1 1 
3.5% 4 35.6 linear 2000 6.2 0.75 1 
3.5% 4 35.6 linear 2000 4.1 0.5 1 
3.5% 4 35.6 linear 2000 10.3 1.25 1 
        
3.5% 4 35.6 linear 2000 8.2 1 1 
3.5% 4 35.6 linear 3400 13.9 1 1 
3.5% 4 35.6 linear 10000 20.5 1 1 
3.5% 4 35.6 4-arm 10000 10.3 1 1 
3.5% 4 35.6 8-arm 10000 45.8 1 1 
        
3.5% 5.5 35.6 linear 2000 12.0 1 1 
2.0% 9 21.1 linear 2000 12.0 1 1 
5.0% 4 52.0 linear 2000 12.0 1 1 
 
GEL-ASSISTED GUV FORMATION 
The surface of a microscope glass slide was functionalized with 3-mercaptopropyl trimethoxysilane 
according to a previously reported method28 (Figure 9, step 1) and sequentially drop-casted by a 
mixture of the Dex-Mal solution and thiolated PEG at 40 °C (Figure 9, step 2) until a homogeneous 
hydrogel film was formed and anchored to the glass surface. The molar ratio of maleimides to 
thiols was 1:1 in all samples unless otherwise stated. After the hydrogel layer was fully gelated, a 
lipid solution (14 mM, 10 µL) was deposited on the top of the hydrogel film. The lipid and hydrogel 
film was dried in a vacuum oven for 30 minutes at 35 °C or under a gentle stream of nitrogen gas 
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which prevented lipid oxidation at room temperature (Figure 9, step 3). In the hydration step, a 
liquid chamber was made by placing a 15 mm (OD) glass O-Ring on top of the hydrogel film and 
sealed with high vacuum silicon grease. PBS (or HBS) buffer solution (400 μL) was added to the 
chamber and the film (Figure 9, step 4) was allowed to swell for 1-2 hours at room temperature 
resulting in free-floating vesicles (Figure 9, step 5). Swelling of the film was performed above the 
Tm of all lipids. For samples containing solely unsaturated lipids, this swelling was performed at 
room temperature. For mixtures containing saturated lipids, swelling was performed at 50 °C. The 
formed free floating GUVs were transferred into an eppendorf tube for further analysis. 
 
Figure 9. Procedure of the preparation of GUVs from Dex-PEG hydrogel coated glass slide. Reproduced from ref. [16]. 
The contact angle of the original, thiolated and gel-coated glass slide surfaces were measured by 
using the LBADSA plugin in ImageJ software. The osmolality of buffer solutions were determined 
from the freezing point depression using an Osmometer Roebling Type 13. The osmometer was 
calibrated using 100 mOsm/kg NaCl standard solution. The confocal imaging of the GUV growth 
was performed by a TI-Eclipse inverted microscope (Nikon, Japan) equipped with a 16-bit Cascade 
II 512 EMCCD camera (Photometrics, USA). Spinning-disc confocal microscopy was executed 
using a CSUX confocal head (Yokogawa, Japan). Illumination was provided by a 50 mW solid-
state laser at 561 nm (Coherent Inc., Germany). Fluorescence was imaged through a bandpass filter 
centered at 595 nm. Epifluorescence was measured with a 40× objective and confocal microscopy 
was carried out using a 60× NA1.43 Plan-Apo Nikon oil-immersion objective. The size and yields 
of the obtained GUVs were visualized by a Zeiss axiovert-200 inverted microscope equipped with 
a Chroma TRITC and DAPI BP 445/50 fluorescence filter sets. Images were recorded with a black 
and white CCD camera (AxioCam NRm). 
OSCILLATORY RHEOLOGY 
The mechanical properties of the Dex-PEG hydrogels were measured on a DHR-2 rheometer (TA 
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Instruments) at 25 °C using a parallel plate-plate geometry (25 mm diameter). Solutions of Dex-
Mal and PEG-SH (150 µL of each) were loaded on the bottom plate and the geometry was lowered 
to the gap distance of 600 µm. Time sweep measurements were performed to follow gelation 
process at a frequency of 1 rad s-1 with 1% strain. The linear viscoelastic regime (LVE) was 
determined for each sample using an amplitude sweep measurement at 1 rad s-1 from 0.1% to 100% 
strain. Frequency sweep measurements were conducted from 100 to 0.1 rad s-1 with 1% strain in 
the linear viscoelastic regime. 
SWELLING TEST 
Hydrogels (200 µL) were prepared in PBS buffer at room temperature (22 °C) according to the 
gelation protocol in glass vials. 2 mL PBS buffer (0.01% NaN3, pH=7.4) was added on top of each 
hydrogel at room temperature. At various time points, the buffer was removed from the top of 
hydrogels, then each swollen hydrogel was weighed and fresh buffer was put on top afterwards. 
When the weight of swollen hydrogel reached a plateau, the equilibrium mass swelling ratio (q) was 





Where Ws is the equilibrium swollen weight and Wd the dry weight of the hydrogel. Each set of 
hydrogels were measured in triplicate. 
CRYO-SCANNING ELECTRON MICROSCOPY (CRYO-SEM) 
The morphologies of the hydrogels were imaged using a JEOL 6330 Cryo Field Emission Scanning 
Electron Microscope from the General Instrumentation Facility at Radboud University (Nijmegen, 
The Netherlands). 5 μL of Dex-PEG hydrogel was injected into a hollow cylindrical sample holder 
and immediately flash frozen in liquid nitrogen. The sample was inserted in the cold-stage of the 
SEM cryo-preparation chamber and cleaved to make a horizontal fracture plane. Water was 
sublimated during 15 minutes and the fracture plane was coated with a thin gold-palladium layer 
and subsequently the sample was transferred into the SEM chamber, where it remained frozen 
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Figure S1. Equilibrium swelling ratios of hydrogel-coated glass slides prepared with various compositions of 1% (w/v) Dex-PEG. (A) 
Dex70k-Mal4, (B) Dex70k -Mal9, and (C) Dex70k -Mal13 crosslinked with thiolated PEG (□: PEG2k-2SH. ○: PEG3.4k-





Figure S2. Confocal microscopy Z-projections showing phase separated GUVs (lipid composition: 40% DPhPC : 40% DPPC : 20% 
CH, mol%) in PBS at physiological ionic strength (Scale bar: 10 µm). Images adopted from ref. [16]. 
 
 
Figure S3. Comparison of the dynamic viscosity of 0.5% (w/v) Dex70k-Mal2.5 crosslinked to PEG prepared by various thiolated 







THE EFFECT OF COILED-COIL PEPTIDE 





Dextran-peptide conjugates were prepared by grafting dextran polymers with a pair of coiled- coil 
peptides E and K. The effect of polymer conjugation on peptide conformation and coiled-coils 
interactions was investigated using circular dichroism (CD) spectroscopy, dynamic light scattering 
and fluorescence spectroscopy studies. It was found that the conformation of each peptide was 
altered upon bioconjugation to dextran. CD spectroscopy indicated homomeric coiled-coil 
formation in dextran-peptide K conjugates due to the high local concentration of peptide K. 
Dextran-peptide E and dextran-peptide K maintained the ability for coiled-coil formation with the 
complementary peptide. Upon mixing a pair of dextran-peptide E and dextran-peptide K, the 
hydrodynamic diameter increased to ~100 nm indicative of aggregate formation. Limited coiled-
coil formation between the dextran-peptide E and the dextran-peptide K in the solution was 
observed, presumably because homomeric coiled-coil formation in dextran-peptide K conjugates 


















Bioconjugation of peptides or proteins to polymers can provide multiple benefits such as improved 
water solubility, enhanced stability, increased circulation time and reduced immune response.1, 2 
Moreover, by utilizing the unique structure and function of peptides or proteins, such as enzymatic 
activity and receptor recognition, smart hybrid materials responding to certain biological and 
nonbiological stimuli can be established by designing suitable polymer-peptide and/or polymer-
protein conjugates.3 Poly(ethylene glycol) (PEG) is the most commonly applied and prominent 
polymer in the field of bioconjugation.4-6 PEGylation has been established as a powerful strategy 
to increase the serum half-life of biological molecules in vivo and many PEGylated drug candidates 
are currently in clinical trials or already on the market.7 A drawback of PEG is its potential 
immunogenicity. Although PEG alone is not immunogenic, ovalbumin and some other PEGylated 
protein agents were found to elicit antibody formation against PEG in animal studies.8, 9 Another 
drawback of the most used linear PEG is its poor loading capacity of biomolecules due to limited 
number of available functional groups for the bioconjugation. Multi-arm PEG precursors have 
been developed to introduce more functional groups. However, the number of functional groups 
is still limited to 8 for commercially available PEG polymers. In order to improve the biomolecule-
loading-capacity of bioconjugated polymers, several alternative bioconjugate systems have been 
developed. Particularly, these alternative polymeric backbones provide multiple functional groups 
by their side chains instead of by terminal end groups of the main chain. One approach is to apply 
natural or synthetic polymeric backbones bearing multiple functional sites for the bioconjugation, 
such as polysaccharides, hydroxyethyl starch, poly(vinylpyrrolidinones) and poly(glutamic acid).10, 
11 In another approach grafted polymers were synthesized directly from peptide/protein 
macroinitiators by atom transfer radical polymerization (ATRP)12-14 or reversible addition-
fragmentation chain transfer (RAFT) polymerizations.15, 16  
Dextran, a neutral polysaccharides consisting of an α-(1→6) linked D-glucose main chain, has been 
investigated as one of the potential alternatives for polymeric conjugates over last four decades due 
to its good water solubility, low toxicity, bioinertness and low immunogenicity.5, 17-19 Dextran 
possesses multiple hydroxyl groups which can be applied to conjugate numerous therapeutic 
molecules such as drugs, peptides, enzymes, proteins, fluorescent indicators and imaging agents, 
resulting hybrid mixture with increased sensitivity or activity.20-23 Typical methods for providing 
multiple functional groups on dextran polymers include direct esterification of hydroxyl group, 
periodate oxidation of dextran to produce Schiff base or its reduced form, and pre-activation of 
dextran by phosgene to produce carbonate or carbamate esters.17, 18 Recently, a more flexible 
synthetic strategy has been developed based on the thiol Michael addition reaction.20-22 By 
introducing vinyl groups (for example, maleimides, vinyl sulfones oracrylates) to dextran, 
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cysteinylated biomolecules can be coupled to the pre-functionalized dextran polymers in a 
controlled and efficient manner. The obtained multivalent biomolecule-dextran conjugates have 
shown improved biofunction compared to monomers and dimers of the corresponding 
biomolecule. For example, Morimoto reported an approximately 1000-fold increase for dextran-
peptide conjugates in affinity between FLAG peptide and anti-FLAG mouse IgG1 antibody 
relative to the monomer.21 Tang found that multivalent cationic peptides conjugated dextran led to 
achieve higher gene expression and lower cytotoxicity for gene delivery.22 Shinchi observed 
improved immunostimulatory potency and pharmacodynamics by conjugating toll-like receptors 
to dextran.24 
One of the basic folding motifs in natural proteins is the so-called coiled-coil motif. It is a left-
handed superhelix formed through the winding of two or more right-handed α-helical peptides 
around each other.25, 26 The primary amino acid sequence of coiled-coil forming peptides typically 
contains repetitions of seven amino acid residues (i.e. heptad repeats), which assemble to these 
specific noncovalent complexes in aqueous solution. Upon carefully design of the peptide sequence 
these self-assembled complexes can respond to external stimuli such as pH or temperature,27 
resulting them to function as “molecular switch” building blocks in reversible smart materials.28-35 
In previous work from our group, a heterodimeric coiled coil forming peptide pair comprised of 
peptide E (EIAALEK)3 and peptide K (KIAALKE)3 was used to form noncovalent triblock 
copolymers.36 Reversible dissociation of the coiled coil could be induced by temperature control, 
resulting in the transition of rod-like micelles into spherical micelles. Moreover, the E/K coiled-
coil motif was successfully used in other applications such as membrane fusion,37-40 surface 
patterning41 and drug delivery.42 
In the present work, we investigated whether the coiled-coils binding motif could direct the 
interaction between dextran polymers. Two pairs of dextran-peptide E and dextran-peptide K 
bioconjugates were synthesized, wherein the dextran polymer was attached at the N-terminus of 
the peptides for one pair and at the C-terminus of the peptides for the other pair. The effect of 
conjugation on peptide conformation was studied by circular dichroism spectroscopy and 
fluorescence spectroscopy. The interaction between complementary dextran-peptide conjugates 
was studied by circular dichroism spectroscopy, fluorescence resonance energy transfer and 
dynamic light scattering measurements. 
RESULTS AND DISCUSSION 
SYNTHESIS OF DEXTRAN-PEPTIDE CONJUGATES 
Firstly, the influence of dextran on the ability of equimolar E/K mixtures to form coiled-coil 
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heterodimers was studied. N-acetylated peptide E and dextran (Mw = 70 000 Da) were mixed in 
PBS (pH=7.4) to obtain a solution of 50 µM peptide E and 5 mg/mL dextran. Similarly, peptide 
K and dextran (Mw = 70 000 Da) were mixed in PBS (pH=7.4) to obtain a solution of 50 µM 
peptide K and 5 mg/mL dextran. Next, these solutions were mixed to obtain a solution of 50 µM 
peptides E and K and 5 mg/mL dextran and all solutions were analysed by circular dichroism (CD) 
spectroscopy (Figure 1B). For comparison peptide E, K and their equimolar mixture were also 
analyzed for comparison (Figure 1A). It was shown that peptide E adopted a predominantly 
random-coil conformation while peptide K exhibits a slightly more α-helical conformation.  
 
Figure 1. Circular dichroism spectra at 25 ˚C of (A) peptide E, K, and their equimolar ratio E-K mixture in PBS (pH=7.4); (B) 
peptide E, K, and their equimolar ratio E-K mixture in presence of 5 mg/mL dextran in in PBS (pH=7.4. Total peptide concentration 
was kept at 50 µM in each sample. 
When peptides E and K were mixed in an equimolar ratio a significant increase in intensity at 222 
nm was observed in the CD spectra, indicative of coiled-coil formation. In the presence of dextran 
polymers, no significant differences were observed in the CD spectra of E, K or E/K. The intensity 
at 222 nm increased upon mixing E and K in an equimolar ratio in the presence of dextran polymers, 
indicating that the formation of coiled-coils between peptide E and peptide K is not inhibited by 
the presence of this polysaccharide. However, it was noticed that the molar ellipticity at 222 nm 
varied slightly in each CD spectra in the presence of dextran. This variation may be related to 
potential hydrogen bonding between the dextran polymer and peptides E or K since unmodified 
glucose unit of the dextran polymer has three hydroxyl groups. This initial experiment revealed 
that coiled-coils formation was unaffected in presence of dextran polymers. Therefore we decided 
to conjugate these peptides to dextran in order to control its properties via coiled-coil formation. 
Four dextran-peptide conjugates were synthesized using a Michael addition reaction between a 
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vinyl sulfone group attached to the dextran and a thiol group of the peptide (Scheme 1). One pair 
of the dextran-peptide conjugates consisted of Dex-E and Dex-K, wherein the N-terminus of the 
peptides was covalently attached to the dextran polymer. The other pair of the dextran-peptide 
conjugates consisted of E-Dex and K-Dex, wherein the C-terminus of the peptides was covalently 
attached to the dextran polymer. Dextran polymers (Mw = 70 000 Da) were functionalized with 
vinyl sulfone groups by a reaction between the electrophilic double bonds of divinyl sulfone and 
alkoxide ions of the hydroxyl groups on the dextran polymers in a 0.1M NaOH solution.43 Using 
this approach, relatively stable ether linkages that can resist basic hydrolysis were formed between 
the dextran polymer backbone and vinyl sulfone groups, yielding vinyl sulfone grafted dextrans 
(Dex-VS). Both peptides E (EIAALEK)3 and K (KIAALKE)3 were synthesized with the 
previously reported amino acid sequences, and extended with a cysteine residue via a flexible oligo 
PEG linker.31, 36 To facilitate the quantification of the molar peptide concentration in the dextran-
peptide conjugates, a tyrosine (Y) was coupled to the N-terminus of peptide E and a tryptophan 
(W) was coupled to the N-terminus of peptide K. In addition, the tyrosine-tryptophan (Y-W) pair 
was used as a donor-acceptor couple to investigate interactions between dextran-peptide E and 
dextran-peptide K mixtures using fluorescence resonance energy transfer (FRET) measurements. 
Moreover, tetra(ethylene glycol), (PEG)4, was introduced as a spacer between the peptide and 
dextran backbone. This (PEG)4 spacer may increase the accessibility of the conjugated peptides 
and lower the steric hindrance of dextran influencing the formation of parallel heterodimers.44, 45 
Table 1 presents the dextran-peptide polymers used in this study, wherein the peptide sequences 
are written with the one-letter amino acid code. 
 




PROPERTIES OF DEXTRAN-PEPTIDE CONJUGATES 
In CD spectra of peptide E, Dex-E and E-Dex shown in Figure 2A, Dex-E and E-Dex 
conjugates presented rather similar CD spectra with two minima centered around 208 and 222 nm 
respectively. Compared to peptide E, the intensity of the minimum at 208 nm of Dex-E and E-
Dex conjugates was strongly decreased. In general, absorptions in the CD spectra between 240 nm 
and 190 nm relates to the peptide bonds including two types of electron transitions: an n→п* 
transition at around 222 nm and п→п* transitions at around 208 and 190 nm.46, 47 Thus the 
secondary structure of peptide E was affected after conjugated to dextran polymers. Dynamic light 
scattering (DLS) measurements revealed for both Dex-E and E-Dex assemblies of ~10 nm in the 
absence of larger aggregates (Figure 3A). 
Table 1. List of prepared peptide-dextran conjugates Dex-E, Dex-K, E-Dex and K-Dex. 





    1VS : vinylsulfone. PEG4: tetra-ethyleneglycol 
 
Figure 2. Circular dichroism spectra at 25 ˚C of (A) peptide E, Dex-E and E-Dex; (B) peptide K, Dex-K and K-Dex in PBS 





Figure 3. DLS number distribution for (A) Dex-E and E-Dex, and (B) Dex-K and K-Dex in PBS (pH=7.4). The peptide 
concentration was kept at 50 µM in each sample. 
The CD spectra of Dex-K and K-Dex conjugates presented rather similar CD spectra with two 
minima centered around 208 and 222 nm respectively (Figure 2B). The minimum at 222 nm in the 
CD spectra of both Dex-K and K-Dex conjugates was enhanced dramatically compared to peptide 
K. As the molar ellipticity at 222 nm ([θ]222) is directly proportional to the amount of α-helical 
structure, the observed enhancement of [θ]222 points to an increase in α-helix secondary structure 
upon peptide conjugation to dextran.48 The minimum at 208 nm was also enhanced for the 
polymer-peptide conjugates, resulting in an ellipticity ratio [θ]222/[θ]208 of about 1.1, indicative of 
coiled-coil formation.49, 50 DLS measurements of both Dex-K and K-Dex revealed a hydrodynamic 
diameter of ~10 nm in the absence of larger aggregates (Figure 3B). According to the CD and DLS 
results of Dex-K and K-Dex conjugates, the formation of intramolecular homo coils (i.e. K 
dimerization or oligomerization) among grafted peptides K on the dextran backbone seems to 
occur. 
This CD study revealed that the conformation of peptides in the aqueous solution varied 
significantly after conjugation to dextran polymers. When comparing this data to the CD spectra 
presented in Figure 1, the presence of dextran polymers alone has only a limited influence on 
conformation of peptides E and K. However, upon conjugation to the dextran backbone, the 
conformation of all four dextran-peptide conjugates was strongly influenced, which may due to a 
much closer distance between peptides E (or K) and the dextran backbone. This results in a 
relatively high local peptide concentration, which previously has shown to induce formation of 
homo coiled-coils.37, 51-53 
To evaluate the coiled-coil forming potential of these four dextran-peptide conjugates in more 
Chapter 6 
115 
detail, each of Dex-E, Dex-K, E-Dex and K-Dex bioconjugates was mixed with its corresponding 
partner peptide K or E in an equimolar ratio and the peptide secondary structure was determined 
by CD spectroscopy (Figure 4A-D). The CD spectra of the resulting mixtures (i.e. Dex-E/K, E-
Dex/K, Dex-K/E and K-Dex/E) indicate interactions between each dextran-peptide conjugate 
and its corresponding peptide partner resulting in coiled coil formation. To have a better 
comparison, we calculated the average CD spectra of each mixture based on the individual spectra. 
If dilution dominated the measured CD spectra, the estimated CD curve of the mixture solution 
would have a similar shape and amplitude to an average of the CD spectra of the two components. 
The estimated dilution curves were overlaid with the actual CD spectra of the Dex-E/K, E-
Dex/K, Dex- K/E and K-Dex/E mixtures respectively.  
According to the results shown in Figure 4E-H, each of the four dextran-peptide conjugates still 
maintains its potential for coiled-coil formation toward the complementary peptide probe. Using 
the Dex-E/K mixture as an example (Figure 4A/E), mixing Dex-E and K resulted in an 
amplification of [θ]222 and the ellipticity ratio [θ]222/[θ]208 increased to ~0.95. This indicates the 
formation of α-helical coiled-coils in the Dex-E/K mixture solution. Similarly, trends were 
observed for E-Dex/K, Dex-K/E and K-Dex/E. 
In summary, the conformation of both peptides E and K changed upon conjugation to dextran. 
However, all four dextran-peptide conjugates still maintained their coiled-coil formation potential 
when mixed with their complementary peptide partner. 
COILED-COIL FORMATION OF COMPLEMENTARY DEXTRAN-PEPTIDE 
CONJUGATES 
Next, we investigated whether dextran-peptide E and dextran-peptide K may generate assemblies 
via coiled-coil interactions. Initially, mixtures of dextran-peptide conjugates having the dextran 
backbone coupled to the same terminus (i.e. N-terminus or C-terminus) were studied (i.e. Dex-
E/Dex-K and E-Dex/K-Dex). The CD spectrum of Dex-E/Dex-K showed two minima around 
208 and 222 nm respectively (Figure 4A) with [θ]222/[θ]208 ~1.1. As mentioned earlier, the ellipticity 
ratio [θ]222/[θ]208 of Dex-E was ~1 and ~1.1 for Dex-K, so the ellipticity ratios [θ]222/[θ]208 did not 
change significantly. Comparison to the calculated average CD spectrum assuming no interactions 
between Dex-E and Dex-K (Figure 5B), E/K interactions in the mixture are relatively weak. 
Surprisingly, the DLS measurements revealed the presence of larger assemblies (~100 nm) in 
solution for the mixture (Figure 6A), strongly suggesting that Dex-E/Dex-K do interact. 
For the E-Dex/K-Dex mixture, similar trends in [θ]222, [θ]208 and the ellipticity ratio [θ]222/[θ]208 
were observed (Figure 5C). When compared to the calculated average CD spectrum of E-Dex and 





Figure 4. Circular dichroism spectra at 25 ˚C of (A) peptide K, Dex-E, and Dex-E/K mixture; (B) peptide K, E-Dex, 
and E-Dex/K mixture; (C) peptide E, Dex-K and E/Dex-K mixture; (D) peptide E, K-Dex and E/K-Dex mixture in 
PBS (pH=7.4). Total peptide concentration was kept at 50 µM in each sample. In each mixture the peptide segments E and K 
were mixed in an equimolar ratio. Comparisons of the CD spectrum and the estimated diluting curves of (E) the Dex-E/K 




Figure 5. Circular dichroism spectra at 25 ˚C of (A) Dex-E, Dex-K and the Dex-E/Dex-K mixture; (B) the Dex-E/Dex-K 
mixture and its estimated diluting curve; (C) E-Dex, K-Dex and the E-Dex/K-Dex mixture; (D) the E-Dex/K-Dex mixture and 
its estimated diluting curve. All experimental samples were prepared in PBS (pH=7.4) with a total peptide concentration at 50 µM. In 
each mixture the peptide segments E and K were mixed in an equimolar ratio. 
observed (Figure 5D). Moreover, DLS of the equimolar E-Dex/K-Dex mixture also revealed the 
formation of larger assemblies (>100 nm), indicating that noncovalent interactions occur (Figure 
6B). 
The interaction between the dextran-peptide E and the dextran-peptide K was further investigated 
by fluorescence spectroscopy. We utilized the tyrosine-tryptophan (Y-W) pair as a donor-acceptor 
couple to acquire structural information of dextran-peptide E/ dextran-peptide K mixtures using 
fluorescence resonance energy transfer (FRET) measurements.54, 55 The Förster distance (R0) for 
the Y/W pair is ~1.5 nm, at this distance the energy transfer efficiency between Y and W is 50%. 
When the distance between Y and W is on the order of or larger than 2R0, no energy transfer will 
occur.56 Thus if parallel E/K coiled-coils occur between dextran-peptide E and dextran-peptide K, 




Figure 6. DLS number distribution for (A) Dex-E, Dex-K and the Dex-E/Dex-K mixture, and (B) E-Dex, K-Dex and the E-
Dex/K-Dex mixture in PBS (pH=7.4). In each mixture the peptide segments E and K were mixed in an equimolar ratio and the peptide 
concentration was kept at 50 µM in each sample. 
 
Figure 7. Fluorescence emission spectra (excitation at 275 nm) of (A) peptide E (□), peptide K (Δ), and an equimolar mixture of 
peptides E and K (x); (B) Dex-E (□), Dex-K (Δ), and an equal peptide molar mixture of Dex-E and Dex-K (x); (C) E-Dex (□), K-
Dex (Δ) and an equal peptide molar mixture of E-Dex and K-Dex (x) in PBS buffer (pH=7.4) at 25 °C. Each peptide concentration 
was kept at 50 µM.  
Y and W was observed for an equimolar mixture of E and K (Figure 7A). When the mixture was 
excited with light matching the donor Y’s absorption wavelength (275 nm), the presence of the 
acceptor W quenched the donor fluorescence in the emission spectrum, proving the formation of 
parallel coiled-coils. However in both Dex-E/Dex-K and E-Dex/K- Dex mixture, no quenching 
effect of the donor Y on E-Dex was observed (Figure 7B/C). These results seem to indicate that 
the distance between Y of Dex-E (or E-Dex) and W of Dex-K (or K-Dex) is on the order of or 
larger than 2R0. Thus the conjugation of peptides to the dextran backbone seems to prevent the 
Chapter 6 
119 
close proximity of peptide E and K and concomitant prevent efficient coiled coil formation. 
Moreover, it was found from the fluorescence results that the conjugation of peptides to dextran 
backbone varies the micro-environment of the tryptophan residue (W). Comparison of the 
emission spectra of peptide K, Dex-K and K-Dex showed that the intensity of the emission of K-
Dex conjugates was lower than that of peptide K, while the intensity of the emission of Dex-K 
conjugates was even lower than that of K-Dex conjugates (Figure 7). This decrease in emission 
intensity is indicative of a change of the environment of the tryptophan residue to a more polar 
environment in Dex-K and K-Dex conjugates.57 The differences of the emission intensity between 
Dex-K and K-Dex conjugates might be explained by the position of the tryptophan residue relative 
to the dextran backbone. Considering that the tryptophan residue was coupled to the N-terminus 
of peptide K in both Dex-K and K-Dex conjugates, the tryptophan residue is in close proximity 
to the dextran backbone in Dex-K conjugates while the tryptophan residue is positioned at the far 
end of the grafting chain of K-Dex conjugates. Thus the micro-environment of the tryptophan 
residue of Dex-K conjugates seems to be more polar compared to K-Dex conjugates. The 
fluorescence results indicate changes of the micro-environment of the peptide terminus coupled 
to the dextran polymer, which may play a role in the interaction between the dextran-peptide E 
and the dextran-peptide K. 
According to the CD, DLS and fluorescence data of equimolar Dex-E/Dex-K and E-Dex/K-
Dex mixtures, each complementary dextran-peptide pair led to the formation of aggregates larger 
than 100 nm in the solution, but limited coiled-coil interactions of E/K was observed as shown by 
CD and FRET measurements. It is possible that coiled-coil formation is hampered by the micro-
environment changes after the polymer-peptide conjugation. Also, the intramolecular homo coils 
of dextran-peptide K solution may still exist in the solution of the complementary dextran-peptide 
pair thereby preventing efficient heteromeric coiled-coil formation. 
Regarding the Dex-E/Dex-K and the E-Dex/K-Dex, although the dextran backbones influence 
the grafted peptides, only a limited difference was observed. As mentioned in the introduction, 
coiled-coils formed by peptide E and K adopt a parallel orientation, thus the same-termini of 
peptide E and K are in close proximity.53 To generate E/K coiled-coils, peptides E and K associate 
at their hydrophobic face (isoleucine and leucine residues at position ‘a’ and ‘d’) and are stabilized 
by electrostatic forces (glutamate resides for peptide E and lysine residues for peptide K at position 
‘e’ and ‘g’). To enable coiled-coils formation between the grafted peptide E and K in the Dex-
E/Dex-K (or E-Dex/K-Dex) mixture, the pair of dextran-peptide conjugates need to be close 
enough to initiate the association between E and K. Considering the dextran backbones of each 
binding part are positioned at the same terminus of the conjugated peptide, the backbones of Dex-
E and Dex-K (or E-Dex/K-Dex) need to be close to each other in a similar direction toward the 
Chapter 6 
120 
peptides to facilitate the parallel coiled-coils formation (Scheme 2A), which may be spatially 
unfavorable. Presumably, such spatial hindrance between the dextran backbones prevents the 
conjugates pair Dex-E/Dex-K (or E-Dex/K-Dex) from getting close to an effective distance to 
permit the specific interaction of the grafted peptides E and K. Therefore we studied another 
mixture, wherein each bioconjugate has the dextran backbone coupled to the opposite terminus of 
peptides (i.e. Dex-E/K-Dex and E-Dex/Dex-K mixtures). Here it was assumed that the spatial 
hindrance between the dextran backbones could be reduced in this manner, see Scheme 2B. 
 
Scheme 2. Schematic diagram of the potential coiled-coil formation between dextran-peptide conjugates: (A) Dex-E and Dex-K (or E-
Dex and K-Dex); (B) Dex-E/K-Dex (or E-Dex/Dex-K). 
Figure 8A/C show the obtained CD spectra of the Dex-E/K-Dex and E-Dex/Dex-K mixtures 
respectively. Again two minima around 208 and 222 nm were observed and the calculated ellipticity 
ratios of [θ]222/[θ]208 were ~1.1 for both mixtures. Similar to the peptide-dextran conjugates 
discussed above, CD spectra for the mixture were calculated based on the CD spectra of individual 
peptide-dextran assuming no interaction occurred (Figure 8B/D). It was found that for each of the 
Dex-E/K-Dex and E-Dex/Dex-K mixtures the ellipticity at 222 nm ([θ]222) and the ellipticity at 
208 nm ([θ]208) were greater than the calculated average value, indicating that some intermolecular 
peptide-peptide interactions occurred.  
Figure 9 shows the emission spectra of the Dex-E/K-Dex and E-Dex/Dex-K mixtures 
respectively. Referring to the Dex-E/K-Dex mixture, no quenching effect of the donor Y in Dex-
E was observed in presence of K-Dex. For the E-Dex/Dex-K mixture, almost no quenching 
effect of tyrosine Y in E-Dex was observed either. These results indicate that the distance between 
Y of Dex-E (or E-Dex) and W of K-Dex (or Dex-K) is on the order of or larger than 2R0. Thus 
the relative position of the dextran backbones in the complementary dextran-peptide conjugates 
does not influence coiled-coil formation between E/K in the present system. 




Figure 8. Circular dichroism spectra at 25 ˚C of (A) Dex-E, K-Dex and the Dex-E/K-Dex mixture; (B) the Dex-E/K-Dex 
mixture and its estimated diluting curve; (C) E-Dex, Dex-K and the E-Dex/Dex-K mixture; (D) the E-Dex/Dex-K mixture and 
its estimated diluting curve. All experimental samples were prepared in PBS (pH=7.4) with a total peptide. 
formation of large aggregates in the solution. For both mixtures the peaks of individual dextran-
peptide at 10 nm disappeared and large assemblies were observed (Figure 10). The hydrodynamic 
diameter of the aggregates of Dex-E/K-Dex (~58.8 nm) and E-Dex/Dex-K (~78.8 nm) were 
smaller as compared to Dex-E/Dex-K (~190.1 nm) and E-Dex/K-Dex (~122.4 nm). Thus the 
relative position of the dextran backbones in the complementary dextran-peptide conjugates 
influences on the size of the formed aggregates. 
In summary, based on the CD, DLS and fluorescence data obtained from our four pairs of 
complementary dextran-peptide conjugates, formation of large aggregates between dextran-peptide 
E and dextran-peptide K were observed but specific coiled-coil interactions of E/K may not be 
the main driving force. It is probable that electrostatic or/and hydrophobic association contributes 
to the interaction between the peptide E-conjugated dextran and the peptide K-conjugated dextran 
and leads to the observed aggregate formation. Neither the linking direction between the peptide 
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and dextran nor the orientation of the complementary dextran-peptide pair resulted in significant 
influence on the aggregates. Based on our results and results available from literature, we will 
discuss the several factors that may play a role in the association of complementary dextran-peptide 
conjugates. 
 
Figure 9. Fluorescence emission spectra (excitation at 275 nm) of Dex-E (□), K-Dex (Δ), and an equal peptide molar mixture of 
Dex-E and K-Dex (x); (B) E-Dex (□), Dex-K (Δ) and an equal peptide molar mixture of E-Dex and Dex-K (x) in PBS buffer 
(pH=7.4) at 25 °C. The peptide concentration was kept at 50 µM. 
 
Figure 10. DLS number distribution for (A) Dex-E, K-Dex and the Dex-E/K-Dex mixture, and (B) E-Dex, Dex-K and the E-
Dex/Dex-K mixture in PBS (pH=7.4). In each mixture the peptide segments E and K were mixed in an equimolar ratio and the 




First, the conjugation of peptides K to dextran polymers induces the formation of homomeric 
coiled-coils between K peptides conjugated to the dextran backbones. Due to the formation of 
homocoils, an increase of the ellipticity at 222 nm and the ellipticity ratio [θ]222/[θ]208 was observed 
in the CD spectra of both Dex-K and K-Dex conjugates compared to the original peptide K 
(Figure 2B). These intramolecular homomeric coiled-coils seem to inhibit the dextran-peptide K 
conjugates from specific coiled-coil interactions with dextran-peptide E conjugates. Our results are 
in accordance with the finding of Gerling-Driessen et al.58 They conjugated one or two peptides K 
to polymer backbones respectively to obtain mono-peptide K polymer conjugates and divalent 
peptide K polymer conjugates. Here the oligo(amido amine) polymer backbones have well-
designed peptide K conjugation sites and two glycine resides were introduced as a linker between 
peptide K and the polymer backbone. It was shown that the divalent peptide K polymer conjugates 
formed intramolecular homocoils due to a template effect of the polymer backbone.52 The grafted 
peptides are in close proximity to each other triggering intramolecular homocoils formation due to 
the high local peptide concentration. Formation of homo coiled-coils has also been found in 
peptide K decorated liposome systems, in which multiple peptides K were anchored to the surface 
of the lipidic membrane leading to relatively high local peptide concentration at the lipidic 
membrane.37, 51 
Moreover, although homomeric coiled-coils of peptides K may transform into heteromeric coiled-
coils between E/K, the accessibility of peptides may be crucial for the transformation process. 
Upon addition of the complementary peptide E with a 1:1 stoichiometry the homomeric coiled-
coils of the grafted peptides K transformed into heteromeric coiled-coils between E/K, which is 
in accordance with the results of Gerling-Driessen et al.58 However, when the dextran-peptide E 
conjugates (Dex-E or E-Dex) were mixed as the complementary partner, heteromeric coiled-coil 
formation was inhibited. Considering the difference in the hydrodynamic volume of peptide E and 
dextran-peptide E, it is probably that the access of the grafted peptide E on the dextran backbones 
toward the complementary peptides K on the dextran backbones is hampered by steric hindrance. 
It is well accepted that even small changes on the design of peptide based molecules, such as adding 
one methyl group, can alter tertiary and quaternary structure and influence the specificity of 
biorecognition.59 The presented data further suggest that dextran polymers are not optimal 
backbones to couple α-helical (coiled-coil) peptides able to self-assemble into coiled-coil motifs. 
To our knowledge, till now poly(N-(2-hydroxypropyl) methacrylamide) (polyHPMA) is the most 
popularly applied polymeric backbones for coupling multiple α-helical (coiled-coil) peptides for 
biomedical applications.27, 28, 44, 45, 60-64 The differences between dextran and HPMA polymers may 
result in distinct effect on supramolecular interactions involved in the coiled-coil formation and 
the free energy changes upon folding. 
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The hydrophilic synthetic HPMA polymer family has been continuously developed and studied by 
Kopecek and co-workers (Scheme 3). For the coiled-coil motifs driven self-assembly systems, 
multivalent peptides grafted HPMA copolymers were prepared.64-67 Klok and co-workers reported 
another synthetic route that includes a first step of synthesis of methacrylated peptides and then 
copolymerization of HPMA monomers and the methacrylated peptides via free radical 
copolymerization (FRP) or reversible addition-fragmentation chain transfer (RAFT) 
copolymerization.60 These synthetic approaches provide straight carbon main chains with a 
majority of side chains from HPMA and a plurality of side chains terminated in desired peptides, 
resulting relatively well-defined structure of multivalent peptide-polymer conjugates. Particularly, 
the amount of peptides grafted to each polymer chain and the theoretical distribution of the 
peptides on each conjugates can be controlled in the design of the copolymerization. Successful 
formation of antiparallel and parallel heterodimeric coiled coils between a pair of peptide grafted 
HPMA copolymers was reported by Yang44, 45, 61 and Wu.62 In these studies, conjugation of the 
peptides did not alter the coiled-coil formation property. For these peptide grafted HPMA 
conjugates,44, 45, 61-63 the amide bonds and hydroxyl groups on the side chain of the HPMA polymer 
were maintained after the copolymerization with other monomers, thus a certain level of hydrogen 
bonding, both intra- and inter-molecular hydrogen bonding between the side chains of HPMA 
polymers, can be anticipated in aqueous solutions of the peptide grafted HPMA conjugates. 
 
Scheme 3. Molecular structures of (A) dextran polymers; and (B) HPMA polymers. 
Compared to HPMA, dextran consisting of an α-(1→6) linked D-glucose main chain also adopts 
a random coil conformation in dilute aqueous solution,58, 59 68, 69 but dextran exhibits much stronger 
polymer-solvent interactions. Antoniou et al.68 studied solvent effects on dextran conformation in 
various solvents and asserted that hydrogen bonding is the main interaction between dextran 
polymers and water molecules. Besides these secondary hydroxyl groups of dextran polymers, the 
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ring oxygens of the glucose unit also contribute to hydrogen bonding with neighbouring water 
molecules.68, 70 For dextran-peptide conjugates the grafted peptides are proximal to the dextran 
backbones, which may result in hydrogen bonding between the dextran backbones and the grafted 
peptides thereby altering the coiled-coil formation property. 
Additionally, the repeating unit of dextran is more compact than that of HPMA, which probably 
leads to steric hindrance. Wen et al. found that the α-(1→6) linkage of glucose units of dextran 
causes two adjacent glucose units form an arc instead of lying in a straight line.71 The α-(1→6) 
linked architecture results in one hydroxyl group of the first glucose is at the same side of the 
second glucose and the other two hydroxyl groups locates in the inner side of the arc formed by 
the adjacent glucose units. Also, these three hydroxyl groups are directly connected to each glucose 
unit of the dextran polymer, which may also be too close to the glucose unit. Such structural 
features of the dextran polymer may partially shield the grafted peptides on the dextran backbone 
by the α-(1→6) linked glucose units, reducing the accessibility of the grafted peptide for further 
coiled-coil formation. 
Last but not least, other features may also be crucial for the coiled coil formation between peptide-
grafted polymers. For example, the number of heptad repeats of the conjugated peptide segment, 
the length and flexibility of the spacer between the peptide and the polymer backbone, the amount 
of peptide conjugated to each polymer, the ratio of the length of peptide segment to the length of 
the polymeric backbone. However, the relation between each structural element and the formation 
of specific coiled-coils has not been revealed yet. In summary, the influence of the conjugation on 
coiled-coil interaction is more complicated than we initially assumed. 
CONCLUSIONS 
In this chapter, dextran-peptide conjugates were synthesized by conjugating peptide E or peptide 
K to the hydroxyl groups of dextran polymers. Dextran was attached at both the C-terminus and 
the N-terminus of each peptide to study the effect of linkage on peptide behavior of dextran-
peptide conjugates. It was found that the original conformation of peptides was altered after 
conjugated to the dextran backbone. Particularly, CD spectroscopy revealed homomeric coiled-
coil formation in dextran-peptide K (both Dex-K and K-Dex). Although the conformation of the 
dextran-peptide conjugates in solution behaves different from the peptide, each of the prepared 
dextran-peptide conjugates maintains coiled-coil formation potential toward its complementary 
peptide partner, resulting in heterodimeric coiled-coil (i.e. E/K) formation. DLS measurements 
showed a formation of large aggregates between dextran-peptide E and dextran-peptide K. 
However, no conclusion was reached on the specificity of biorecognition between the peptide E-
conjugated dextran and the peptide K-conjugated dextran. Probably, electrostatic or/and 
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hydrophobic association contributes to the interaction between the peptide E-conjugated dextran 
and the peptide K-conjugated dextran instead of the specific coiled-coil interaction. It seems that 
the coiled-coils formation between the peptide E-conjugated dextran and the peptide K-conjugated 
dextran is hampered due to structural features of the dextran backbone. 
Although the multivalent conjugation of peptides to a polymer backbone is considered to be a 
simple but efficient approach for taking the advantageous of both the peptide and the polymer, the 
multivalent peptides conjugated to one same polymer backbone may increase local concentration 
of peptides thereby yielding unexpected properties of the polymer-peptide conjugates. In addition, 
coiled-coil formation is sensitive to the variation of the surrounding environment.72 Dextran is 
generally considered as a biocompatible polymer and therefore potentially useful as a scaffold for 
peptide conjugation; however, the inherent structure of dextran, such as the multiple hydroxyl 
groups and repeating rigid glucose units, may also influence on the micro-environment of the 
peptide grafted on the dextran backbone. In order to utilize the coiled-coil motif for developing 
dextran-based assemblies, the architecture of the dextran-peptide conjugate should be designed 
more precisely and every building block need to be thoroughly investigated for a better 
understanding of the complexities of the dextran-peptide conjugates. 
EXPERIMENTAL 
MATERIALS 
Dextran (70 kDa), divinyl sulfone (DVS), sodium hydroxide, 1,2-ethanedithiol (EDT) and 
triisopropylsilane (TIS), were purchased from Sigma-Aldrich. Fmoc-protected amino acids, Rink 
Amide resin (0.55 mmol g-1) and O-(1H-6-Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HCTU) were purchased from NovaBioChem. Diisopropylethylamine 
(DIPEA), piperidine, acetic anhydride, N-methylpyrrolidine (NMP), dimethylformamide (DMF), 
acetonitrile, and trifluoroacetic acid (TFA) were obtained from Biosolve. All other reagents and 
solvents used in peptide synthesis were obtained at the highest purity available from Sigma-Aldrich. 
Phosphate buffered saline (PBS) was composed of 150 mM NaCl, 15 mM K2HPO4 and 5 mM 
KH2PO4 in H2O at pH 7.4. 
PEPTIDE SYNTHESIS 
Cys-PEG4-W(KIAALKE)3 and Cys-PEG4-Y(EIAALEK)3 were synthesized by the following 
procedure. First, peptides (KIAALKE)3 and Y(EIAALEK)3 were synthesized on a CEM-Libert 1 
Single Channel Microwave Peptide Synthesizer using standard Fmoc chemistry.73 Fmoc-protected 
Rink amide resin (0.55 mmol g-1) was used to synthesize the peptides on a 0.1 mmol scale. Fmoc 
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deprotection was performed using 20% (v/v) piperidine in DMF. 4 equivalents of a Fmoc-amino 
acid, 4 equivalents of HCTU and 8 equivalents of DIPEA in DMF were used for amino acid 
coupling. Then, 1.5 equivalents Fmoc-NH-PEG4-COOH, 4 equivalents HCTU and 6 equivalents 
DIPEA in DMF were added to the resin overnight followed by three times Fmoc deprotection. 
Next, 4 equivalents of Fmoc-cysteine, 4 equivalents HCTU and 8 equivalents DIPEA in DMF 
were added to the resin for coupling to the PEG4 spacer. After one Fmoc deprotection step, the 
N terminus of each peptide was acetylated using 5% (v/v) acetic anhydride and 6% (v/v) pyridine 
in DMF. The peptides were cleaved from the resin and side-chain deprotected using a mixture of 
TFA/water/EDT/TIS=92.5:2.5:2.5:2.5 (v/v) for 1 hour. W(KIAALKE)3-PEG4-Cys and 
Y(EIAALEK)3-PEG4-Cys were synthesized by a similar procedure as described above. Particularly, 
Fmoc-cysteine was first coupled to the resin manually followed by another manual coupling step 
of Fmoc-NH-PEG4-COOH. Then the resin was put into the Peptide Synthesizer for coupling the 
other amino acid residues.  
The cleaved peptides were precipitated in cold diethyl ether and then collected by centrifugation. 
Purification of the peptides was performed by RP-HPLC using a Shimadzu system including two 
LC-8A pumps, an SPD-10AVP UV-VIS detector and an ELSD-LTII detector. For UV detection, 
absorption was measured at 214 and 256 nm. The crude peptides were dissolved in H2O containing 
0.1 vol% TFA and eluted at a flow rate of 15 mL/min with a linear gradient from 20% to 80% of 
acetonitrile in water with 0.1% TFA (v/v) over 30 minutes. The purification was performed on an 
EVO C18 reversed phase column (00F-4633-P0-AX, 21.2 mm diameter, 150 mm length, 5 μm 
particle size). The purified peptides were lyophilized and characterized by LC-MS using a Gemini 
C18 analytical. 
VINYL SULFONE MODIFIED DEXTRAN 
Vinyl sulfone modified dextran (Dex-VS) was synthesized based on a reported procedure74 while 
the reaction temperature was kept at 0 ˚C using an ice water bath. Dextran (1 g, 6.17 mmol) was 
dissolved in 50 mL of a 0.1 M NaOH aqueous solution. The dextran solution was stirred at 1 000 
rpm and 2.324 mL of DVS (23.15 mmol) was added. After 1 minute, the reaction was quenched 
by adjusting the pH to 5 with 5 M HCl. The resulting Dex-VS was precipitated in 300 mL of cold 
isopropanol.. The precipitate was redissolved in Milli-Q water and then dialyzed against Milli-Q 
water 5 times over 3 days using a 2 000 MWCO cut-off membrane and subsequently lyophilized. 
Yield: 1.1 g (80.1%). 1H NMR spectra were recorded on a Bruker AV-400 spectrometer. 1H NMR 
(400 MHz, D2O): δ 3.4-4.1 (m, dextran glucopyranosyl ring protons), 4.9 (s, dextran anomeric 
proton), 5.1 (s, dextran anomeric proton linked to vinyl sulfone substituents), 6.3-6.5 (m, -
SO2CH=CH2), 6.9 -7 (m, -SO2CH=CH2). 
13C NMR (400 MHz, D2O): δ = 97.66, 73.37, 71.38, 




The degree of substitution of the dextran polymer (DS) is defined as the number of vinyl sulfone 
groups per 100 glucopyranose residues, calculated as 100x/y, in which x is the integral of the vinyl 
sulfone protons (δ 6.9 -7) and y is the integral of the anomeric proton of dextran (δ 4.9) from the 
1H NMR spectra. The DS of the dextran polymer (Dex-VS) synthesized and applied in this work 
was 4. 
SYNTHESIS OF DEXTRAN-PEPTIDES CONJUGATES 
The peptide was dissolved in PBS (pH=7.4) at a concentration of 200 µM under a nitrogen 
atmosphere. A Dex-VS stock solution (10 mg/mL) in PBS was added to the peptide solution 
dropwise. The final molar ratio of cysteine to vinyl sulfone in the solution was kept at 2. The 
mixture was stirred at 500 rpm at room temperature under nitrogen protection overnight. The 
resulting dextran-peptide E and dextran-peptide K conjugates were purified by Amicon Ultra 4ml 
centrifugal filters (10 kDa). During the centrifugal purification process, dextran-peptide conjugate 
stayed in the filter while unreacted peptides passed through the filter with PBS, then fresh PBS 
buffer was added into the filter for further purification until no UV absorption (280 nm) was 
detected in the elution using an Agilent Cary 300 UV-Vis spectroscopy. Then the dextran-peptide 
conjugate was diluted in Milli-Q water and purified by dialysis against Milli-Q water five times over 
three days (Dialysis float tubing, MWCO 3.5 – 5 kDa) membrane and subsequently lyophilized. 
The obtained products were stored at -20 °C.  
The peptide percentage of each dextran-peptide conjugate was quantified by the following steps 
and the results are shown in Table 2. First, a stock solution of the obtained dextran-peptide (e.g. 1 
mg/mL) was prepared. Next, the molar peptide concentration of the stock solution was determined 
by UV absorbance at 280 nm using molar extinction coefficients of ε = 1 280 M-1cm-1 per tyrosine 
residue and ε = 5 690 M-1cm-1 per tryptophan residue.75 The weight of peptides in the 
corresponding dextran-peptide solution was then calculated by multiplying the determined peptide 
molar concentration and the molecular weight of the corresponding peptide. Thus dividing the 
weight of peptides by the weight of dextran-peptide conjugates resulted in the peptide weight 
percent (wt%) of the prepared dextran-peptide conjugate. The number of peptides per dextran 
polymer was estimated by the following equation: 
[𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑝𝑒𝑝𝑡𝑖𝑑𝑒]
[𝑀𝑤 𝑜𝑓 𝑝𝑒𝑝𝑡𝑖𝑑𝑒]
[𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑒𝑥𝑡𝑟𝑎𝑛 − 𝑝𝑒𝑝𝑡𝑖𝑑𝑒] − [𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑝𝑒𝑝𝑡𝑖𝑑𝑒]





Table 2. Quantification of peptide grafted on the prepared dextran-peptide conjugates. 
Sample Peptide conc.(μM) in 1 mg/mL 
Dex-peptide solution 
Peptide wt% of the 
dextran-peptide conjugate 
Number of peptides per 
dextran polymer 
Dex-E 102.3 24% 9 
Dex-K 98.5 23% 9 
E-Dex 91.9 21% 8 
K-Dex 88.6 20% 8 
 
CIRCULAR DICHROISM SPECTROSCOPY 
CD spectra were obtained using a Jasco J-815 CD spectrometer. Wavelength scans were obtained 
from 260 to 190 nm using a quartz cuvette with 0.1 cm path length, averaging 5 scans with scanning 
speed 20 nm/s at 25 °C. The ellipticity is given as the mean residue molar ellipticity, [θ], calculated 
from [θ] = (θobs × MRW)/(10 × l ×c), where θobs is the observed ellipticity in millidegrees, MRW is 
the mean residue molecular weight (i.e. the molecular weight of the peptide divided by the number 
of amino acid residues), l is the path length of the cuvette in cm and c is the peptide concentration 
in mg mL-1. The peptide concentration was kept at 50 µM in each sample. 
FLUORESCENT SPECTROSCOPY 
Fluorescence was measured by a Tecan infinite M1000 pro plate reader with Black Greiner 96-well 
plates. The excitation wavelength was set to 275 nm, and the emission was recorded in the range 
of 300 nm to 450 nm. The bandwidth for excitation was 5 nm and the bandwidth for emission was 
10 nm. Each peptide concentration was kept at 50 µM. For each measurement, 3 scans at 25 ˚C 





1. Pelegri-O’Day E. M., Lin E.-W. and Maynard H. D., Therapeutic protein–polymer conjugates: Advancing 
beyond pegylation, Journal of the American Chemical Society, 2014, 136, 14323-14332. 
2. Klok H.-A., Peptide/protein− synthetic polymer conjugates: Quo vadis, Macromolecules, 2009, 42, 7990-8000. 
3. Cobo I., Li M., Sumerlin B. S., et al., Smart hybrid materials by conjugation of responsive polymers to 
biomacromolecules, Nature materials, 2015, 14, 143-159. 
4. Veronese F. M., Peptide and protein pegylation: A review of problems and solutions, Biomaterials, 2001, 22, 
405-417. 
5. Khandare J. and Minko T., Polymer–drug conjugates: Progress in polymeric prodrugs, Progress in Polymer Science, 
2006, 31, 359-397. 
6. Gauthier M. A. and Klok H.-A., Peptide/protein–polymer conjugates: Synthetic strategies and design 
concepts, Chemical Communications, 2008, 2591-2611. 
7. Greg T., Academic Press Inc, 2008. 
8. Garay R. P., Elgewely R., Armstrong J. K., et al., Antibodies against polyethylene glycol in healthy subjects 
and in patients treated with peg-conjugated agents, Expert Opinion on Drug Delivery, 2012, 9, 1319-1323. 
9. Schellekens H., Hennink W. E. and Brinks V., The immunogenicity of polyethylene glycol: Facts and fiction, 
Pharmaceutical Research, 2013, 30, 1729-1734. 
10. Basu A., Kunduru K. R., Abtew E., et al., Polysaccharide-based conjugates for biomedical applications, 
Bioconjugate Chemistry, 2015, 26, 1396-1412. 
11. Day E. M. P., Lin E. and Maynard H. D., Therapeutic protein-polymer conjugates: Advancing beyond 
pegylation, Journal of the American Chemical Society, 2014, 136, 14323-14332. 
12. Bontempo D. and Maynard H. D., Streptavidin as a macroinitiator for polymerization: In situ protein-polymer 
conjugate formation, Journal of the American Chemical Society, 2005, 127, 6508-6509. 
13. Heredia K. L., Bontempo D., Ly T., et al., In situ preparation of protein-“smart” polymer conjugates with 
retention of bioactivity, Journal of the American Chemical Society, 2005, 127, 16955-16960. 
14. Ten Cate M. G., Severin N. and Börner H. G., Self-assembling peptide-polymer conjugates comprising (d-
alt-l)-cyclopeptides as aggregator domains, Macromolecules, 2006, 39, 7831-7838. 
15. Boyer C., Bulmus V., Liu J., et al., Well-defined protein-polymer conjugates via in situ raft polymerization, 
Journal of the American Chemical Society, 2007, 129, 7145-7154. 
16. Liu J., Bulmus V., Herlambang D. L., et al., In situ formation of protein–polymer conjugates through reversible 
addition fragmentation chain transfer polymerization, Angewandte Chemie International Edition, 2007, 46, 3099-
3103. 
17. Larsen C., Dextran prodrugs—structure and stability in relation to therapeutic activity, Advanced Drug Delivery 
Reviews, 1989, 3, 103-154. 
18. Mehvar R., Dextrans for targeted and sustained delivery of therapeutic and imaging agents, Journal of controlled 
release, 2000, 69, 1-25. 
19. Heinze T., Liebert T., Heublein B., et al., in Polysaccharides ii, Springer, 2006, pp. 199-291. 
20. Richter M., Chakrabarti A., Ruttekolk I. R., et al., Multivalent design of apoptosis‐inducing bid‐bh3 
peptide–oligosaccharides boosts the intracellular activity at identical overall peptide concentrations, Chem-Eur 
J, 2012, 18, 16708-16715. 
21. Morimoto J., Sarkar M., Kenrick S., et al., Dextran as a generally applicable multivalent scaffold for improving 




22. Tang Q., Cao B., Lei X., et al., Dextran–peptide hybrid for efficient gene delivery, Langmuir, 2014, 30, 5202-
5208. 
23. Gaowa A., Horibe T., Kohno M., et al., Enhancement of anti-tumor activity of hybrid peptide in conjugation 
with carboxymethyl dextran via disulfide linkers, European Journal of Pharmaceutics and Biopharmaceutics, 2015, 92, 
228-236. 
24. Shinchi H., Crain B., Yao S., et al., Enhancement of the immunostimulatory activity of a tlr7 ligand by 
conjugation to polysaccharides, Bioconjugate Chemistry, 2015, 26, 1713-1723. 
25. Lupas A., Van Dyke M. and Stock J., Predicting coiled coils from protein sequences, Science, 1991, 252, 1162-
1164. 
26. Burkhard P., Stetefeld J. and Strelkov S. V., Coiled coils: A highly versatile protein folding motif, Trends in cell 
biology, 2001, 11, 82-88. 
27. Wang C., Stewart R. J. and Kopecek J., Hybrid hydrogels assembled from synthetic polymers and coiled-coil 
protein domains, Nature, 1999, 397, 417-420. 
28. Kopeček J. and Yang J., Peptide-directed self-assembly of hydrogels, Acta biomaterialia, 2009, 5, 805-816. 
29. Adams D. J. and Topham P. D., Peptide conjugate hydrogelators, Soft Matter, 2010, 6, 3707-3721. 
30. Apostolovic B., Danial M. and Klok H.-A., Coiled coils: Attractive protein folding motifs for the fabrication 
of self-assembled, responsive and bioactive materials, Chemical Society Reviews, 2010, 39, 3541-3575. 
31. Robson Marsden H. and Kros A., Self‐assembly of coiled coils in synthetic biology: Inspiration and progress, 
Angewandte Chemie International Edition, 2010, 49, 2988-3005. 
32. Boyle A. L. and Woolfson D. N., De novo designed peptides for biological applications, Chemical Society 
Reviews, 2011, 40, 4295-4306. 
33. Petkau-Milroy K. and Brunsveld L., Supramolecular chemical biology; bioactive synthetic self-assemblies, 
Organic & biomolecular chemistry, 2013, 11, 219-232. 
34. Hamley I. W., Peptide nanotubes, Angewandte Chemie International Edition, 2014, 53, 6866-6881. 
35. Kopeček J. and Yang J., Smart self‐assembled hybrid hydrogel biomaterials, Angewandte Chemie International 
Edition, 2012, 51, 7396-7417. 
36. Marsden H. R., Korobko A. V., van Leeuwen E. N., et al., Noncovalent triblock copolymers based on a 
coiled-coil peptide motif, Journal of the American Chemical Society, 2008, 130, 9386-9393. 
37. Robson Marsden H., Elbers N. A., Bomans P. H., et al., A reduced snare model for membrane fusion, 
Angewandte Chemie International Edition, 2009, 48, 2330-2333. 
38. Zheng T., Voskuhl J., Versluis F., et al., Controlling the rate of coiled coil driven membrane fusion, Chemical 
Communications, 2013, 49, 3649-3651. 
39. Zope H. R., Versluis F., Ordas A., et al., In vitro and in vivo supramolecular modification of biomembranes 
using a lipidated coiled‐coil motif, Angewandte Chemie International Edition, 2013, 52, 14247-14251. 
40. Versluis F., Voskuhl J., van Kolck B., et al., In situ modification of plain liposomes with lipidated coiled coil 
forming peptides induces membrane fusion, Journal of the American Chemical Society, 2013, 135, 8057-8062. 
41. Voskuhl J., Wendeln C., Versluis F., et al., Immobilization of liposomes and vesicles on patterned surfaces by 
a peptide coiled‐coil binding motif, Angewandte Chemie International Edition, 2012, 51, 12616-12620. 
42. Martelli G., Zope H. R., Capell M. B., et al., Coiled-coil peptide motifs as thermoresponsive valves for 
mesoporous silica nanoparticles, Chemical Communications, 2013, 49, 9932-9934. 
43. Yu Y. and Chau Y., One-step “click” method for generating vinyl sulfone groups on hydroxyl-containing 
water-soluble polymers, Biomacromolecules, 2012, 13, 937-942. 
44. Yang J. Y., Xu C. Y., Wang C., et al., Refolding hydrogels self-assembled from n-(2-




45. Yang J., Wu K., Konak C., et al., Dynamic light scattering study of self-assembly of hpma hybrid graft 
copolymers, Biomacromolecules, 2008, 9, 510-517. 
46. Kelly S. M., Jess T. J. and Price N. C., How to study proteins by circular dichroism, Biochimica et Biophysica 
Acta, 2005, 1751, 119-139. 
47. Miles A. J. and Wallace B. A., Circular dichroism spectroscopy of membrane proteins, Chemical Society Reviews, 
2016, 45, 4859-4872. 
48. Gans P. J., Lyu P., Manning M. C., et al., The helix-coil transition in heterogeneous peptides with specific 
side-chain interactions: Theory and comparison with cd spectral data, Biopolymers, 1991, 31, 1605-1614. 
49. Su J. Y., Hodges R. S. and Kay C. M., Effect of chain length on the formation and stability of 
synthetic .Alpha.-helical coiled coils, Biochemistry, 1994, 33, 15501-15510. 
50. Pandya M. J., Cerasoli E., Joseph A., et al., Sequence and structural duality: Designing peptides to adopt two 
stable conformations, Journal of the American Chemical Society, 2004, 126, 17016-17024. 
51. Marsden H. R., Korobko A. V., Zheng T., et al., Controlled liposome fusion mediated by snare protein mimics, 
Biomaterials Science, 2013, 1, 1046-1054. 
52. Mutter M., Altmann E., Altmann K., et al., The construction of new proteins. Part iii. Artificial folding units 
by assembly of amphiphilic secondary structures on a template, Helvetica Chimica Acta, 1988, 71, 835-847. 
53. Zheng T., Boyle A. L., Marsden H. R., et al., Probing coiled-coil assembly by paramagnetic nmr spectroscopy, 
Organic and Biomolecular Chemistry, 2015, 13, 1159-1168. 
54. Wu P. G. and Brand L., Resonance energy transfer: Methods and applications, Analytical Biochemistry, 1994, 
218, 1-13. 
55. Sapsford K. E., Berti L. and Medintz I. L., Materials for fluorescence resonance energy transfer analysis: 
Beyond traditional donor–acceptor combinations, Angewandte Chemie International Edition, 2006, 45, 4562-4589. 
56. Eisenhawer M., Cattarinussi S., Kuhn A., et al., Fluorescence resonance energy transfer shows a close helix-
helix distance in the transmembrane m13 procoat protein, Biochemistry, 2001, 40, 12321-12328. 
57. Eftink M. R., in Methods of biochemical analysis, John Wiley & Sons, Inc., 2006, pp. 127-205. 
58. Gerling-Driessen U. I., Mujkic-Ninnemann N., Ponader D., et al., Exploiting oligo (amido amine) backbones 
for the multivalent presentation of coiled-coil peptides, Biomacromolecules, 2015, 16, 2394-2402. 
59. Mason J. M. and Arndt K. M., Coiled coil domains: Stability, specificity, and biological implications, 
ChemBioChem, 2004, 5, 170-176. 
60. Apostolovic B., Deacon S. P. E., Duncan R., et al., Hybrid polymer therapeutics incorporating bioresponsive, 
coiled coil peptide linkers, Biomacromolecules, 2010, 11, 1187-1195. 
61. Yang J., Xu C., Kopeckova P., et al., Hybrid hydrogels self‐assembled from hpma copolymers containing 
peptide grafts, Macromolecular Bioscience, 2006, 6, 201-209. 
62. Wu K., Yang J., Koňak C., et al., Novel synthesis of hpma copolymers containing peptide grafts and their 
self‐assembly into hybrid hydrogels, Macromolecular Chemistry and Physics, 2008, 209, 467-475. 
63. Dusek K., Duskovasmrckova M., Yang J., et al., Coiled-coil hydrogels. Effect of grafted copolymer 
composition and cyclization on gelation, Macromolecules, 2009, 42, 2265-2274. 
64. Pan H., Yang J., Kopeckova P., et al., Backbone degradable multiblock n-(2-hydroxypropyl)methacrylamide 
copolymer conjugates via reversible addition fragmentation chain transfer polymerization and thiol-ene 
coupling reaction, Biomacromolecules, 2011, 12, 247-252. 
65. Luo K., Yang J., Kopeckova P., et al., Biodegradable multiblock poly[n-(2-hydroxypropyl)methacrylamide] 




66. Yang J., Luo K., Pan H., et al., Synthesis of biodegradable multiblock copolymers by click coupling of raft-
generated heterotelechelic polyhpma conjugates, Reactive & Functional Polymers, 2011, 71, 294-302. 
67. Kopecek J., Polymer-drug conjugates: Origins, progress to date and future directions, Advanced Drug Delivery 
Reviews, 2013, 65, 49-59. 
68. Antoniou E., Buitrago C. F., Tsianou M., et al., Solvent effects on polysaccharide conformation, Carbohydrate 
Polymers, 2010, 79, 380-390. 
69. Antoniou E. and Tsianou M., Solution properties of dextran in water and in formamide, Journal of Applied 
Polymer Science, 2012, 125, 1681-1692. 
70. Suzuki T. and Sota T., Improving ab initio infrared spectra of glucose-water complexes by considering explicit 
intermolecular hydrogen bonds, Journal of Chemical Physics, 2003, 119, 10133-10137. 
71. Wen H., Morris K. R. and Park K., Hydrogen bonding interactions between adsorbed polymer molecules 
and crystal surface of acetaminophen, Journal of Colloid and Interface Science, 2005, 290, 325-335. 
72. Rabe M., Aisenbrey C., Pluhackova K., et al., A coiled-coil peptide shaping lipid bilayers upon fusion, 
Biophysical Journal, 2016, 111, 2162-2175. 
73. Palasek S. A., Cox Z. J. and Collins J. M., Limiting racemization and aspartimide formation in microwave-
enhanced fmoc solid phase peptide synthesis, Journal of Peptide Science, 2007, 13, 143-148. 
74. Yu Y. and Chau Y., One-step "click" method for generating vinyl sulfone groups on hydroxyl-containing 
water-soluble polymers, Biomacromolecules, 2012, 13, 937-942. 
75. Gill S. C. and von Hippel P. H., Calculation of protein extinction coefficients from amino acid sequence data, 





SUPPORTING INFORMATION  
 


























As early as the 1950s, a variety of hydrogels have been designed, characterized and evaluated for 
biomedical applications. Commercial products based on hydrogels include contact lenses, wound 
dressings and hygiene products, due to their high water absorption, porosity and unique mechanical 
properties. In the last two decades, the focus has shifted to explore the potential of hydrogels in 
the fields of drug delivery and tissue engineering. As a result, the design of hydrogels evolved from 
relatively simple chemical or physical crosslinked networks to complex multicomponent systems 
with a high level of spatial and temporal control. The specific demand for multi-functional and 
well-controlled hydrogels resulted in the development of networks with novel synthetic 
methodologies and dynamic chemistry/assembly strategies. 
In this thesis, new crosslinked hydrogels were designed and applications of these materials in the 
field of drug delivery were explored. These hydrogels mainly consist of the neutral polysaccharide 
dextran (Dex) due to its favorable properties like its biodegradable and biocompatible nature, 
relatively low cost, good water-solubility, and ease of chemical modification.  
Inspired by natural systems, novel drug delivery platforms were established in which human serum 
albumin (HSA) acts simultaneously as an affinity-based drug carrier and crosslinker. Chapter 2 
focuses on the modification of HSA by thiolation, using it to crosslink a maleimide modified 
dextran (Dex-Mal) polymer, and the sustained delivery of low molecular drugs. To maintain the 
drug-binding capability of albumin, 2-iminothiolane was used to introduce thiols to albumin, which 
prevents denaturation by maintaining the surface charge distribution. A further extension of this 
work on affinity-based drug delivery hydrogels can be to use thiolated albumin in combination with 
other covalent polymers functionalized with Michael acceptors to gain access to hydrogel materials 
with a range of properties. 
In Chapter 3, two approaches were explored to improve the stability and mechanical properties 
of the dextran-albumin hydrogels. In the first approach, the modification of dextran with vinyl 
sulfone through an ether linkage to reduce crosslinker hydrolysis was studied. The second approach 
involved the introduction of a third macromolecular precursor, poly(ethylene glycol) end-
functionalized with thiol groups, to the dextran-albumin hydrogel system in order to tune the 
gelation kinetics and physical properties. The resulting Dex(VS)-sHSA-PEG hydrogels showed 
improved stability and increased mechanical stiffness making it more suitable for sustained drug 
delivery applications. 
Besides the use of these gels as a drug delivery tool, other applications of these hydrogels were 
explored in Chapter 4 and 5. The uptake of a low molecular weight drug in a zebrafish embryo 
toxicity assay using the dextran based crosslinked drug carriers was studied in Chapter 4. The 
model drug valproate was solubilized using -Cyclodextrins conjugated to a dextran-PEG network. 
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These Dex-CD/PEG carriers (without valproate) were taken up by 4-days post fertilization old (4-
dpf) zebrafish embryos into the gastrointestinal tract. Next, 4-dpf zebrafish embryos were exposed 
to the model drug valproate, which was encapsulated in the drug carrier. As a result, the zebrafish 
embryos became more sensitive toward valproate strongly suggesting that the Dex-CD/PEG drug 
carriers are indeed capable of improving its uptake efficiency in the zebrafish embryo toxicity assay. 
Our results indicate that the Dex-CD/PEG carriers may assist zebrafish embryo-based toxicity 
assays of any drug that is able to form an inclusion complex with -cyclodextrin. 
Giant unilamellar vesicles (GUV) are used to study membrane biophysics and membrane related 
processes in general. In Chapter 5, a new method to form GUVs using hydrogel film-assisted 
hydration of a lipid film was established. A thin layer of a hydrogel was formed by a Michael 
addition reaction between maleimide-modified dextran and dithiol terminated poly(ethylene glycol) 
on a thiolated glass slide. Covalently linking the hydrogel film to the glass slides ensures that the 
formed GUVs are not contaminated with polymer fragments. Upon hydration of the polymer film 
using a buffer of physiological ionic strength, GUVs were formed rapidly in a high yield. The yield 
and size distribution of the formed GUVs were systematically investigated by varying the hydrogel 
composition. In order to obtain GUVs with a narrow size distribution in high yield, it was essential 
that the hydrogel films had a continuous pore structure with a suitable size. Also, the interactions 
between the lipid components and hydrophilic polymers is an important factor for successful GUV 
formation. Compared to electroformation methods, this method requires no special equipment 
and is applicable to any lipid formulation in high ionic strength buffer. This hydrogel film-assisted 
hydration method generates GUVs within minutes in high yield making it an easy to use method. 
In Chapter 6, the heterodimeric coiled-coil forming peptides E and K, were conjugated to dextran 
in order to direct its self-assembly through non-covalent interactions. The peptides were 
conjugated either on their C- or N-terminus to dextran, resulting in four multivalent peptide-
dextran conjugates. It was observed that the peptide conformation was altered after conjugation to 
dextran. Formation of large aggregates between dextran-peptide E and dextran-peptide K 
conjugates was revealed by dynamic light scattering measurements. However no specific coiled-
coil interaction could be observed in fluorescence resonance energy transfer studies. This might be 
due to homomeric (K/K) coiled-coil formation in dextran-peptide K preventing heteromeric 
coiled-coil (E/K) formation. Furthermore, coiled-coil formation may be hampered by steric effects 
as a result of polymer-peptide conjugation. 
In summary, this thesis describes the development of dextran-based hydrogels which can be tuned 
within a wide range of physicochemical properties for a given application. Moreover, this thesis 
also explores emerging applications of hydrogels in fields of biophysics and toxicology. 
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Regarding the use of hydrogels for albumin drug delivery, the binding pockets of albumin were 
utilized to construct hydrogels for spatial and temporal control over the release of therapeutic 
agents. Their sustained release was proven with several different drugs in our studies, but further 
optimization is required. Drug release from these hydrogels involves two stages: the release of the 
drug from the binding cavities, and subsequent drug diffusion through the insoluble polymer 
network. Computational simulations of the release process may provide a deeper insight into the 
release mechanism. From these studies, correlation between drug-albumin binding coefficients and 
release kinetics from the hydrogel can be established and thus aid in the further design optimization 
of these materials. Co-delivery of both hydrophobic and hydrophilic therapeutic agents from the 
various parts of the hydrogel may also be an interesting direction for further investigation. 
Regarding the emerging applications of hydrogels described in this thesis, the crosslinked dextran-
PEG hydrogel films provide a facile method to prepare GUVs with and without cargo, while the 
crosslinked Dex-CD/PEG carriers improve the uptake efficiency of low molecular weight 
compounds like valproate in a zebrafish embryo toxicity assay. It is expected that this method is 
suited to enhance the uptake of any compound that is able to form host-guest complex with -
cyclodextrin. Besides establishing these new approaches, a fundamental aspect of polymer science 
is explored in this thesis: orthogonal crosslinking methods in polymer networks and examination 
of their corresponding physiochemical properties. By careful design of the hydrogel building blocks, 
defects and inhomogeneities of the polymeric network could be reduced thereby resulting in better 
performance with respect to reproducibility and application. 
Regarding the development of new biomolecule-dextran derivatives, the conjugation between the 
dextran polymer and biomolecules such as peptides, proteins and nucleic acids seems to be 
straightforward. However, it becomes apparent that the structure, conformation and functionality 
of the resulting multivalent biomolecule-dextran conjugates may be more complex than initially 
expected. Therefore it is necessary in the future to focus on the detailed interactions of 
biomolecules grafted to dextran backbones as the local environment may interfere with the 
biomolecule function. The distribution of the polymer grafts on the polymeric backbone and the 
distance between outer ends of polymer grafts as well as the polymeric backbone may also be 
important to be able to evaluate these interactions. However designing experiments that could 
reveal these parameters is not trivial. Nevertheless, a thorough understanding of the newly 
developed biomolecule-dextran derivatives can assist in their future design. 
Tremendous progress was achieved over the years in the design of hydrogels as evidenced by the 
vast body of literature. Recent developments include the design of multi-component hydrogel 
systems to meet the needs of increasingly complex scaffolds for a wide range of biomedical 
applications. To this end, novel hydrogel systems are also designed for facilitating simple and 
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controllable manipulations such as in situ forming and 3D printed hydrogels. By continuing 
investigation in this research field, new frontiers and lasting contributions to polymer and 





Al in de jaren 50 van de vorige eeuw werden verschillende hydrogelen ontworpen, gekarakteriseerd 
en geëvalueerd voor biomedische toepassingen. Commerciële producten op basis van hydrogelen 
omvatten onder anderen contactlenzen, wondverbanden en hygiëneproducten, vanwege hun hoge 
wateropname, porositeit en unieke mechanische eigenschappen. In de laatste twee decennia is de 
focus verschoven om het potentieel van hydrogelen op het gebied van medicijnafgifte en 
weefselmanipulatie te onderzoeken. Als gevolg daarvan evolueerde het ontwerp van hydrogelen 
van relatief eenvoudige chemische of fysisch verknoopte netwerken naar complexe 
multicomponent-systemen met een hoge mate van ruimtelijke en temporele controle. De specifieke 
vraag naar multifunctionele en goed gecontroleerde hydrogelen resulteerde in de ontwikkeling van 
netwerken door gebruik te maken van nieuwe synthetische methodologieën en dynamische chemie 
en assemblagestrategieën. 
In dit proefschrift werden nieuwe gecrosslinkte hydrogelen ontworpen en werden toepassingen 
van deze materialen op het gebied van drug delivery onderzocht. Deze hydrogelen bestaan 
voornamelijk uit het neutrale polysaccharide dextraan (Dex) vanwege de gunstige eigenschappen 
zoals de biologische afbreekbaarheid en biocompatibiliteit, relatief lage kosten, goede 
wateroplosbaarheid en het gemak van chemische modificatie. 
Geïnspireerd door natuurlijke systemen werden nieuwe medicijnafgifte (drug delivery) platforms 
opgezet waarin humaan serumalbumine (HSA) gelijktijdig gebruikt werd als een affinity-based drug 
carrier en crosslinker. Hoofdstuk 2 richt zich op de thiol-modificatie van HSA, om het vervolgens 
te crosslinken aan een maleïmide-gemodificeerd dextraan (Dex-Mal) polymeer, en de afgifte van 
laagmoleculaire medicijnen te bestuderen. Om het medicijn-bindend vermogen van albumine te 
behouden, werd 2-iminothiolaan gebruikt, wat denaturatie voorkomt door de verdeling van de 
oppervlaktelading te handhaven. Een verdere uitbreiding van deze studie aan hydrogelen op basis 
van affinity-based drugs kan zijn om gethioleerd albumine te gebruiken in combinatie met andere 
covalente polymeren die gefunctionaliseerd zijn met Michael-acceptoren om zo hydrogelmaterialen 
met verschillende materiaaleigenschappen te genereren. 
In Hoofdstuk 3 werden twee methoden onderzocht om de stabiliteit en mechanische 
eigenschappen van dextraan-albumine hydrogelen te verbeteren. In de eerste benadering werd de 
modificatie van dextraan met vinylsulfon bestudeerd om de hydrogel stabieler te maken. De tweede 
benadering bestond uit de toevoeging van een derde macromoleculaire precursor, 
poly(ethyleenglycol) met thiol eindgroepen, aan het dextran-albumine hydrogel systeem om 
hiermee de kinetiek van hydrogelvorming en de resulterende fysische eigenschappen beter te 
controleren. Deze Dex(VS)-sHSA-PEG-hydrogelen vertoonden een verbeterde stabiliteit en 
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verhoogde mechanische stijfheid, waardoor ze meer geschikt zijn voor langdurige afgifte van 
medicijnen. 
Naast het gebruik van deze gels als drug delivery tool, werden andere toepassingen onderzocht. De 
opname van een laagmoleculair medicijn in een zebravis-embryo met behulp van de op dextraan 
gebaseerde geconjugeerde drug carriers werd bestudeerd in Hoofdstuk 4. Het geneesmiddel 
valproaat werd met behulp van -cyclodextrines ge-encapsuleerd in een dextraan-PEG-netwerk. 
Deze Dex-CD/PEG-carriers (zonder valproaat) werden succesvol opgenomen in het 
maagdarmkanaal van 4 dagen oude zebravis-embryo's. Vervolgens werden zebravisembryo's 
blootgesteld aan valproaat, dat in deze nieuwe materialen was ge-encapsuleerd. Als gevolg hiervan 
werden de zebravisembryo's gevoeliger voor valproaat, wat laat zien dat de Dex-CD/PEG-carriers 
de opname van valproaat verbetert. Deze resultaten geven aan dat de Dex-CD/PEG-carriers 
kunnen helpen bij toxiciteitstesten met zebravis-embryo’s van geneesmiddelen die in staat zijn om 
een inclusiecomplex te vormen met -cyclodextrine. 
Grote unilamillaire vesicles (GUV) worden vaak gebruikt in de membraanbiofysica om 
membraangerelateerde processen te bestuderen. In Hoofdstuk 5 wordt een nieuwe methode voor 
het vormen van GUV's met hydrogelfilm-geassisteerde hydratatie van een lipidefilm beschreven. 
Een dunne laag van een hydrogel werd gevormd door een Michael-additiereactie tussen maleïmide 
gemodificeerd dextraan en poly(ethyleenglycol) met thiol eindgroepen op een microscoop glaasje 
dat voorbehandeld was met thiolgroepen. Het covalent koppelen van de hydrogelfilm aan de 
glasplaatjes zorgt ervoor dat de gevormde GUV's niet verontreinigd zijn met hydrogel(fragmenten). 
Na hydratatie van de polymeerfilm met behulp van een buffer van fysiologische ionsterkte werden 
GUV's snel in een hoge opbrengst gevormd. De opbrengst en grootteverdeling van de gevormde 
GUV's werden systematisch onderzocht door de hydrogel-samenstelling te variëren. Om een hoge 
opbrengst van GUV's met eenzelfde diameter te verkrijgen, was het essentieel dat de hydrogelfilms 
een continue poriestructuur met een geschikte grootte hadden. Bovendien zijn de interacties tussen 
de lipide-componenten en hydrofiele polymeren een belangrijke factor voor succesvolle GUV-
vorming. In tegenstelling tot andere methodes vereist deze methode geen speciale apparatuur en 
kan toegepast worden op elke lipide-formulering in buffers met hoge ionsterkte. Deze 
hydrogelfilm-ondersteunde hydratatiemethode genereert binnen enkele minuten GUV's in hoge 
opbrengst waardoor het een eenvoudig te gebruiken methode is. 
In Hoofdstuk 6 werden de heterodimeer coiled-coil vormende peptiden E en K gekoppeld aan 
dextraan om de zelfassemblage te controleren via niet-covalente interacties. De peptiden werden 
via de C- of N-terminus aan dextraan gekoppeld, wat resulteerde in vier verschillende multivalente 
peptide-dextraan conjugaten. Door binding aan dextraan veranderde de secundaire structuur van 
de peptides. Met behulp van dynamische lichtverstrooiingsmetingen werd duidelijk dat er grote 
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aggregaten tussen dextraan-peptide E en dextraan-peptide K-conjugaten gevormd werden. Er kon 
echter geen specifieke coiled-coil interactie worden waargenomen met fluorescentieresonantie-
energieoverdracht (FRET). Een mogelijke verklaring is de vorming van homocoil (K/K) 
complexen in dextraan-peptide K waardoor heteromeer coiled-coil (E/K)-vorming niet meer 
mogelijk is. Verder kan coiled-coil vorming belemmerd worden door sterische hindering als gevolg 
van polymeer-peptide-koppeling. 
Samengevat beschrijft dit proefschrift de ontwikkeling van dextraan-gebaseerde hydrogelen 
waarvan de fysisch-chemische eigenschappen kunnen worden afgestemd voor iedere gewenste 
toepassing. Bovendien wordt in dit proefschrift ook nieuwe toepassingen van hydrogelen op het 
gebied van biofysica en toxicologie onderzocht en beschreven. 
Met betrekking tot het gebruik van hydrogelen voor medicijnafgifte, werden de bindingspockets 
van albumine gebruikt om hydrogelen te ontwerpen voor ruimtelijke en temporele controle over 
de afgifte van therapeutische middelen. Langdurige afgifte werd aangetoond voor verschillende 
medicijnen in deze studie, maar verdere optimalisatie is vereist. Geneesmiddelafgifte van deze 
hydrogelen omvat twee stadia: de afgifte van het medicijn uit de bindingsholtes en daaropvolgende 
geneesmiddeldiffusie door het onoplosbare polymeernetwerk. Computersimulaties van het afgifte-
proces kan een dieper inzicht verschaffen in het afgifte-mechanisme. Uit deze studies kan de 
correlatie tussen geneesmiddel-albuminebindingscoëfficiënten en afgiftekinetiek van de hydrogel 
worden bepaald en bijdragen aan de verdere optimalisatie van deze materialen. Gelijktijdige afgifte 
van zowel hydrofobe als hydrofiele therapeutische middelen uit de verschillende delen van de 
hydrogel kan ook een interessante richting zijn voor verder onderzoek. 
Met betrekking tot de nieuwe toepassingen van hydrogelen die in dit proefschrift worden 
beschreven, bieden de gecrosslinkte dextraan-PEG-hydrogelfilms een gemakkelijke methode om 
GUV's met en zonder lading te bereiden, terwijl de gecrosslinkte Dex-CD/PEG-dragers de 
opname-efficiëntie van medicijnen met een laag molecuulgewicht zoals valproaat verbeteren in een 
toxiciteit test. Naar verwachting is deze methode geschikt om de opname van elke verbinding die 
in staat is om een inclusiecomplex te vormen met -cyclodextrine te verhogen. Naast het vaststellen 
van deze nieuwe benaderingen, werd in dit proefschrift een fundamenteel aspect van de 
polymeerwetenschap onderzocht: orthogonale methoden voor het crosslinken van 
polymeernetwerken en onderzoek van de resulterende fysisch-chemische eigenschappen. Door het 
zorgvuldig ontwerpen van de hydrogelbouwstenen kunnen defecten en inhomogeniteiten van het 
polymeer netwerk verminderd worden, resulterend in betere prestaties met betrekking tot 
reproduceerbaarheid en daadwerkelijke toepassing van deze materialen. 
Met betrekking tot de ontwikkeling van nieuwe biomolecuul-dextraanderivaten is de conjugatie 
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tussen dextraan en biomoleculen zoals peptiden, eiwitten en nucleïnezuren eenvoudig. Dit 
proefschrift laat echter zien dat de structuur, conformatie en functionaliteit van de resulterende 
multivalente biomolecuul-dextraan conjugaten complexer kunnen zijn dan aanvankelijk werd 
verwacht. Daarom is het in de toekomst noodzakelijk om de interacties van biomoleculen 
gekoppeld aan dextraan te bestuderen, aangezien de lokale omgeving invloed heeft op de 
functionaliteit van de biomoleculen.. Het ontwerpen van experimenten die deze interacties 
onthullen, is echter niet triviaal. Niettemin kan een grondig begrip van de nieuw ontwikkelde 
biomolecuul-dextraan-conjugaten helpen bij hun toekomstige ontwerp. 
Door de jaren heen is er enorme vooruitgang geboekt in het ontwerp van hydrogelen, zoals blijkt 
uit de enorme hoeveelheid literatuur. Recente ontwikkelingen omvatten het ontwerp van 
multicomponent hydrogel-systemen om te voldoen aan de behoeften van steeds complexere 
materialen voor een breed scala van biomedische toepassingen. Voor dit doel zijn nieuwe 
hydrogelsystemen ontworpen voor het vergemakkelijken van eenvoudige en regelbare manipulaties 
zoals in situ vormende en 3D-geprinte hydrogelen. Door voortzetting van het onderzoek op dit 
gebied, liggen nieuwe grenzen en duurzame bijdragen aan polymeer- en biomedische 






LIST OF ABBREVIATIONS 
2-IT 2-iminothiolane 
3D three-dimensional 
ATRP atom transfer radical polymerization 
CD circular dichroism 
CDI 1,1’-carbonyldiimidazole 
CH cholesterol 
Cryo-SEM Cryo-scanning electron microscopy 
dex-RhoB rhodamine B labelled dextrans 
DIC N,N'-diisopropylcarbodiimide 
DIPEA diisopropylethylamine 
DLS dynamic light scattering 
DMAP dimethylaminopyridine 
DMF dimethylformamide 





DPTS 4-(dimethylamino)pyridinium 4-toluenesulfonate 
DT degrees of thiolation 
DTNB 5,5’-dithiobis(2-nitrobenzoic acid) 
DVS divinyl sulfone 
DXM dexamethasone 
EDT 1,2-ethanedithiol 
ESR equilibrium swelling ratio 
FACS fluorescence activated cell sorting 
FRET fluorescence resonance energy transfer 
G' storage modulus 
G” loss modulus 
GUVs giant unilamellar vesicles 
HCTU O-(1H-6-Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 




MSCD mono-thiolated β-cyclodextrins 
NMP N-methylpyrrolidine 
PBS phosphate buffered saline 
PEG polyethylene glycol 
PEG-DT poly(ethylene glycol) dithiol 
POPC 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
POPG 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol)  




PVA poly(vinyl alcohol) 
RAFT reversible addition-fragmentation chain transfer 
RP-HPLC reversed-phase high performance liquid chromatography 
sHSA thiolated human serum albumin 
TFA trifluoroacetic acid 
TIS triisopropylsilane 
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